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Abstract 
 
Histamine is central in sleep-wake regulation. First, I mapped the distribution of 
histamine producing neurons in the adult brain using genetic approaches. 
Second, to further explore the histaminergic system, I found that a local 
circadian clock regulates the expression of histidine decarboxylase (HDC), the 
enzyme producing histamine in hypothalamic neurons. The level of this enzyme 
varies with time of day and is up-regulated by sleep deprivation. I disrupted this 
local clock by using HDC-Cre recombinase by deleting BMAL1, the 
transciption factor central to circadian rhythms, selectively in histaminergic 
neurons, generating HDC-Bmal1 mice. Hdc gene expression in HDC-Bmal1 
mice showed a disrupted 24-hour rhythm. This greatly affected natural sleep 
and reduced recovery sleep after sleep deprivation.  
Third, the HDC-neurons contain GABA. To understand the role of this GABA, I 
used different AAVs carrying shRNAs to deliver into the brain to knock down 
vesicular GABA transporter (vGAT) in histaminergic neurons. Reducing vGAT 
in HDC-neurons increased general activity and wakefulness in mice; moreover, 
these GABA in HDC-neurons contributed to recovery sleep after sleep 
deprivation. To further investigate the mechanism, we conducted an optogenetic 
method by delivering Channelrhodopsins (ChR2) into the HDC-neurons. We 
found that photostimulating tuberomamillary nucleus (TMN) fibers in neocortex 
and striatum triggered GABA release. Thus the decrease of ambient GABA 
might contribute to the phenotype that we observed in HDC-vGAT knock down 
mice. 
In summary, I identified a local “histaminergic clock” that regulates HDC 
levels, and is necessary for maintaining appropriate sleep-wake cycle 
architecture as well as sleep homeostasis. I also found GABA produced by 
HDC-neurons is necessary for regulating the normal behavioral state. 
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1 Introduction 
1.1 Hypothalamic neurotransmitters: histamine and sleep 
 
The hypothalamus plays an important action in integrating signals from the 
body and other parts of the central nervous system (CNS). Lesioning or 
inactivation of the posterior hypothalamus causes hypersomnia, whereas 
damage to the anterior hypothalamus has the opposite effect: profound insomnia 
(Haas and Panula, 2003). The hypothalamus has been identified as a key 
regulator of sleep and wakefulness (Mignot et al., 2002; Saper et al., 2005; 
2010). My PhD thesis is concerned with the role of hypothalamic histamine 
neurons in mice. As one of the most important excitatory neurotransmitters, 
histamine was first described in 1910 by the British scientists Sir Henry H. Dale 
and P.P. Laidlaw (Dale and Laidlaw et al., 1910) and in 1936, the Nobel Prize in 
Physiology or Medicine was awarded jointly to Sir Henry Dale and Otto Loewi 
"for their discoveries relating to chemical transmission of nerve impulses" 
(http://www.nobelprize.org/nobel_prizes/medicine/laureates/1936/). 
 
Histamine (HA) acts at four receptors (H1-4) that couple to G-proteins. H1, H2 
and H3 receptors are expressed in the brain. H1 and H2 receptors are expressed 
in neuronal and glial cells, whereas H3 receptors are only found in neurons 
(Panula and Nuutinen, 2013). H1 and H2 receptors are expressed in all parts of 
the brain: in cerebral, cortex, striatum, hippocampus and hypothalamus, those 
receptors play important roles; however, in most brain regions, the types of 
neurons expressing H1 and H2 receptors have not been identified. Originally, 
H3 receptors were thought to be autoreceptors in histaminergic cells to regulate 
histamine release, whereas later studies revealed that H3 receptors can regulate 
the release of the neurotransmitters in non-histaminergic cells acting as 
heteroreceptors (Schlicker et al., 1994). H4 receptor was found to be expressed 
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on hematopoietic cell types (Fung-Leung et al., 2004). H1R knock out mice 
have normal sleep-wakefulness, but show an increase in non-rapid eye 
movement (NREM) sleep; Mice without H3R exhibit reduction in locomotor 
activity with enhanced HA transmission. Those mice show higher  
electroencephalography (EEG) theta power; with reduced wakefulness in the 
night. Histamine receptors have been widely studied genetically and 
pharmacologically. H1, H2 or H3 receptors knock-out animals have been 
generated, and their phenotypes exhibit differential effects (Dai et al., 2007, 
Takashashi et al., 2002).  Histamine receptor antagonists have been used for the 
treatment of diseases such as allergic rhinitis, asthma and sleep disorders 
(Thurmond et al., 2008).  
 
Histamine plays diverse functions to regulate the nervous and immune system: 
from influencing hematopoiesis and allergic inflammation to controlling basic 
body functions like the sleep-wake cycle and temperature homeostasis (Haas 
and Panula, 2003). H1 antihistamines remain among the most commonly used 
medications in the world, specifically in the treatment of allergic disorders 
(Thurmond et al., 2008). There is also evidence that histamine signalling is 
involved in higher cognitive processes such as learning and memory. However, 
several lines of evidence indicate that histamine is also required for arousal. For 
example, H1-receptor antagonists increase slow-wave sleep (Solomon et al., 
1989; Huang et al., 2006). H3-receptor knockout mice exhibit reduced 
wakefulness in the waking state (Gondard et al., 2013). Mice that lack histamine 
have been generated by disrupting the histidine decarboxylase (hdc) gene, and 
these mice show a deficit in waking, attention and interest in a new environment. 
They show impaired wakefulness such as increased sleepiness and have 
abnormal EEG patterns during slow wave sleep (Ohtsu et al., 2001; Parmentier 
et al., 2002). The mice without histamine awake much slower when entering 
into the waking state. Although the amount of wake and NREM sleep did not 
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change in the light period, the episode duration was shortened, in other words, 
sleep was fragmented without histamine release (Parmentier et al., 2002). In 
other standard behavioural testing, the disruption of histamine production 
improved performance in the water-maze test but decreased their performance 
in object discrimination tests (Dere et al., 2003; Sakai et al., 2010). Thus much 
evidence shows histamine is responsible for arousal; however the mechanism is 
poorly understood. Since histaminergic cells project to the entire brain (Panula 
et al., 1989; Wilcox et al., 1982), the effects of histamine on controlling the 
sleep-wake cycle in different brain areas might not be the same. Deleting the 
HDC gene shows obvious phenotypes; however, we are more concerned about 
what factors can regulate the homeostatic states of histaminergic cells in vivo, 
and to a further extent, influence behavior like sleep and wakefulness.  
 
During early postnatal development, significant parts of the brain’s histamine is 
generated by mast cells (Johnson and Erdö 1973; Ferrer at al., 1979). However, 
in the adult rat brain, significant numbers of mast cells are only found in the 
dorsal thalamus (Panula and Nuutinen, 2013). First evidence based on in situ 
hybridization for hdc expression suggested a developmental function for 
histamine in the mouse brain at E14 (olfactory neurons) and in the TMN 
neurons at E19 (Karlstedt et al., 2001). The sites of enzyme expression in the 
brains of mouse and rat are conserved and illustrate the histamine production 
within the central nervous system (CNS) (Karlstedt et al., 2001). It has been 
demonstrated that the tuberomamillary nucleus (TMN) in the hypothalamus is 
the only origin of histaminergic neuronal projections (Panula et al., 1984). They 
reach to large target fields, such as the ventrolateral preoptic nucleus (VLPO); 
the noradrenaline (NE) neurons in the locus coeruleus (LC) and the serotonergic 
neurons in the dorsal raphe nucleus and the neocortex (Fig 1.1) (Schwartz et al., 
1991; Wada et al., 1991; Haas and Panula, 2003; Panula and Nuutinen 2013). 
Mapping TMN neuronal projections had been started a long time ago; however, 
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the previous methods that used to identify the projections were mainly based on 
tracing or immunocytochemistry, and those methods have limitations on 
sensitivity and non-specificity. New approaches are required to map the 
projections of histaminergic cells. In my thesis, I used different methods to map 
histaminergic neurons, including traditional in situ hybridization and genetic 
manipulations to label the neurons. The genetic method provides an effective, 
sensitive way to mark the cells, particularly for tracing the projections of 
neuronal cells.   
 
 
 
 
Fig 1.1 The histaminergic system in the human brain: origin and projections. About 
64,000 histamine-producing neurons, located in the tuberomamillary nucleus of the human 
brain, innervate all of the major parts of the cerebrum, cerebellum, posterior pituitary and the 
spinal cord (Reproduced from Haas and Panula, 2003). 
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1.2 Histamine metabolism 
 
The L-amino-acid-transporter takes histidine into the histaminegric neurons and 
histamine is synthesized by a specific enzyme HDC by decarboxylating 
histidine. After production, histamine is transported into vesicles by the 
vesicular monoamine-transporter (VMAT-2). After release, histamine is 
methylated by histaminemethyltransferase (HNMT) (Fig 1.2). Besides a high 
affinity system for up taking the histamine, this methylation is the principal 
inactivation mechanism. The turnover rate for neuronal histamine is high, and 
its half-life, about 30 minutes, can change quickly depending on neuronal 
activity (Haas and Panula 2003). Hdc mRNA and histamine level varies in 
different brain regions during the day (Orr and Quay 1975; Rozov et al., 2014; 
Shan et al., 2012), but what drives the change of histamine release has not really 
been investigated. In some reports, at the cellular level, hdc gene expression has 
been found to be regulated by some transcriptional factors in vitro (Ku et al., 
2014; McLaughlin et al., 2004; Kuramasu et al., 1998); however, what happens 
in vivo is unknown. In my study, I investigated how circadian transcriptional 
factors regulate hdc gene expression both in vivo and in vitro. 
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Fig 1.2 Histamine transport and metabolism in neurons (Reproduced from Haas and 
Panula 2003). 
 
 
1.3 Sleep and arousal promoting system: the Flip-Flop model 
 
The arousal-promoting and sleep-promoting system has been studied for a long 
time. The commonly recognized “flip-flop” model (Saper et al., 2001; Saper et 
al., 2010) is shown in Fig 1.3 which highlights the various nucleus that control 
the sleep and wake state. In the waking state (top), tuberomammillary nucleus 
(TMN), locus coeruleus (LC) and perifornical area (Pef) are all active, which 
release excitatory neurotransmitters, like histamine and noradrenaline to excite 
the forebrain and neocortex. Orexinergic neurons in the Pef release orexin onto 
the TMN neurons thus reinforcing firing, as well as releasing dynorphin at the 
TMN, which blocks inhibitory GABAergic input from The ventrolateral 
preoptic nucle (VLPO) (Eriksson et al., 2001; Sakurai, 2005). There may also 
be reciprocal connections from the TMN to Pef (Eriksson et al., 2001), so that 
these nuclei will act in synergy to promote arousal, although this has yet to be 
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directly demonstrated. In contrast, during sleep (bottom), when VLPO and 
medial preoptic nucleus (MnPO) neurons are active, inhibitory input is provided 
to the arousal-promoting nuclei whose reciprocal pathways disinhibit and thus 
reinforce ventrolateral preoptic area (VLPO) (and probably MnPO) firing. As 
indicated above, one of the most remarkable features of sleep and arousal 
promoting neurons is mutual inhibition (Saper et al., 2010). Although the 
mutual inhibition is considered to be relatively rapid, the changes in behavioral 
state are not instantaneous and usually take a few seconds in rodents or a few 
minutes in humans. For example, neurons in the VLPO, LC and TMN of 
rodents change their firing rates over less than a second when transitioning from 
wake to NREM or from NREM to wake (Fig 1.4) (Saper et al., 2010).   
 
 
 
Fig 1.3 Circuits involved in modulating the histamine arousal pathway. MnPo, 
median preoptic nucleus (GABA), Pef, perifornicular area (orexin), TMN, 
tuberomammillary nucleus (histamine), VLPO, ventrolateral preoptic area (GABA), LC, 
locus coeruleus (noradrenaline) (Reproduced from Franks, Brickley, Maze and Wisden, 
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MRC grant application, 2008). 
 
 
Fig 1.4 Reciprocol firing patterns between sleep-promoting neurons in the preoptic area 
and wake-promoting neurons in the LC, TMN, and basal forebrain. Changes in ﬁring 
rate during the transition from NREM sleep to wake (top) and (bottom) ﬁring rates during the 
transition from wake into light NREM sleep. The ﬁring rates of some cell groups, such as the 
LC, begin to increase or decrease 1–2 s in advance of awakening or falling asleep. In 
contrast, neurons in the TMN begin to ﬁre only after the transition to wake (Saper et al., 
2010; the original data are from Takahashi et al., 2010). 
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Recently, a review described the networks that support sleep and wakefulness 
(Fig 1.5) (Saper et al., 2010): the wake-promoting networks, NREM sleep-
promoting networks and REM sleep-promoting networks. In the wake-
promoting networks, many cholinergic neurons in the pedunculopontine and 
laterodorsal tegmental nuclei (PPT and LDT) and monoaminergic cell groups 
including noradrenergic cells in the locus coeruleus (LC) and histaminergic 
neurons in the tuberomammillary nucleus (TMN) ﬁre most rapidly during 
wakefulness, and decreased their activity during NREM sleep; however, 
cholinergic neurons fire during REM sleep, and monoaminergic systems are 
silent during REM sleep (Saper et al., 2010; Steriade et al., 1993).  
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Fig 1.5 The Wake-Sleep Switch. Many wake-promoting projections arise from neurons in 
the upper brainstem (A). Cholinergic neurons (aqua) provide the major input to the thalamus, 
whereas monoaminergic and (presumably) glutamatergic neurons (dark green) provide direct 
innervation of the hypothalamus, basal forebrain, and cerebral cortex. The orexinergic 
neurons in the lateral hypothalamus (blue) reinforce activity in these brainstem arousal 
pathways and also directly excite the cerebral cortex and BF. The main sleep-promoting 
pathways (B) from the ventrolateral (VLPO) and median (MnPO) preoptic nuclei inhibit the 
components of the ascending arousal pathways in both the hypothalamus and the brainstem 
(pathways that are inhibited are shown as open circles and dashed lines). However, the 
ascending arousal systems are also capable of inhibiting the VLPO (C). This mutually 
inhibitory relationship of the arousal and sleep-promoting pathways produces the conditions 
for a ﬂip-ﬂop switch, which can generate rapid and complete transitions between waking and 
sleeping states. DR, dorsal raphe nucleus (serotonin); LC, locus coeruleus (norepinephrine); 
LDT, laterodorsal tegmental nucleus (acetylcholine); PB, parabrachial nucleus (glutamate); 
PC, precoeruleus area (glutamate); PPT, pedunculopontine tegmental nucleus (acetylcholine); 
TMN, tuberomammillary nucleus (histamine); vPAG, ventral periaqueductal gray (dopamine) 
(Reproduced from Saper et al., 2010). 
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Cholinergic neurons in the PPT and LDT and the monoaminergic cell groups in 
LC, the serotoninergic dorsal, median raphe nuclei and histaminergic neurons 
predominantly project to the forebrain, thalamus, lateral hypothalamus and 
cerebral cortex (Fig 1.5a) (Aston-Jones and Bloom, 1981; Dahlstroem and Fuxe 
1964; Kocsis et al., 2006; Panula et al., 1989; Steininger et al., 1999).  
 
As another source that influences arousal, glutamatergic neurons in the 
parabrachial nucleus and the adjacent precoeruleus area (PC) show that c-Fos 
expression predominantly in wake- and REM-sleep in cats (Chu and Bloom 
1973; Lu et al., 2006b; Saito et al., 1977). Nevertheless, the activity pattern of 
those neurons has not been well-established. These neurons also send major 
projections to the lateral hypothalamus, basal forebrain, and cerebral cortex 
(Hur and Zaborszky 2005; Lu et al., 2006a; Saper and Loewy 1980).  
 
The forebrain arousal systems in the posterior half of the lateral hypothalamus 
also contribute to arousal. The lateral hypothalamus (perifornical area) contains 
neurons producing the orexin neuropeptides which are thought to sustain 
wakefulness. They target to the entire cerebral cortex, brainstem and basal 
forebrain, with particularly intense input to the TMN and the LC (Peyron et al., 
1998). Orexinergic neurons receive projection from the ascending arousal 
systems. Like neurons in the PPT and LDT, histaminergic neurons in the TMN, 
orexin neurons ﬁre predominantly during wakefulness. Orexinergic neurons also 
receive inhibitory GABA input. Deletion of GABA subreceptor B in orexinergic 
neurons causes fragmented NREM and REM sleep (Matsuki et al., 2009). 
Overall, the orexinergic neurons are thought to sustain wakefulness and 
suppress REM sleep. Although the arousal-producing neurons have been widely 
studied, it is meaningful to explore other nuclei that contribute to the arousal 
system (Fig 1.3).  
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In the NREM sleep-promoting system (Fig 1.5b), a population of neurons in the 
ventrolateral preoptic area (VLPO) was identified to express c-Fos protein 
during sleep but not wake. VLPO neurons contain inhibitory neurotransmitters 
GABA and galanin and they send dense projections to arousal systems. A key 
feature of VLPO neurons is that they receive reciprocal inputs from many 
regions which implicate in arousal, including the TMN, dorsal raphe nucleus 
and adjacent ventral periaqueductal gray matter (vlPAG), parabrachial nucleus, 
and LC (Chou et al., 2002; Lu et al., 2006a). Notably, a more diffuse group of 
cells also show c-Fos expression during sleep which is named as extended 
VLPO. In fact the extended VLPO area is much larger than the VLPO which 
also contribute to sleep. The population of neurons in the median preoptic 
nucleus (MnPO) exhibit Fos activity during sleep, moreover they contain 
GABA as well. However, MnPO neurons receive only sparse inputs from the 
LC and periaqueductal gray matter and little if any from the dorsal or median 
raphe nuclei or from the TMN (Saper and Levisohn, 1983).  
 
In the REM sleep-promoting state (Fig 1.5c), studies have examined Fos 
expression during periods of augmented REM sleep to identify REM-promoting 
neurons (Boissard et al., 2002; Lu et al., 2006a). Fos expression was elevated in 
some cell groups: PPT or LDT; the sublaterodorsal nucleus (SLD); the 
precoeruleus region (PC), and the medial parabrachial nucleus (MPB). Lesions 
of the SLD in rats reduced the amount of REM sleep (Lu et al., 2006b). This 
region receives inputs from the extended VLPO and the orexin neurons in the 
lateral hypothalamus (Lu et al., 2006b). The neurons in vlPAG-LPT are 
GABAergic which project to the SLD. Inhibition of the vlPAG and LPT with 
GABA agonists increases REM sleep (Crochet et al., 2006; Sapin et al., 2009; 
Sastre et al., 1996), and lesions increase REM sleep (Lu et al., 2006b), 
suggesting the vlPAG-LPT area can prevent REM sleep. A recent paper 
underlined the neurochemical circuitries to promote and maintain REM sleep by 
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the brainstem is under hypothalamic control (Luppi et al., 2013). 
 
As indicated above, the histaminergic TMN neurons in the hypothalamus are a 
key coordinator in the flip-flop theory. In my research, I mainly concentrated on 
how histaminergic neurons regulate the sleep-wake cycle. A recent study 
indicates that histamine directly excites NA (noradrenaline)-excited VLPO 
neurons (Liu et al., 2010). As shown in Fig 1.6, they proposed that the NA-
excited VLPO neurons are GABA-containing neurons and the NA-inhibited 
VLPO neurons are known to contain GABA (Szymusiak, 1995; Sherin et al., 
1998; Szymusiak et al., 1998). When excited, these NA-inhibited VLPO 
neurons release GABA into the TMN, thus inhibiting the activity of this 
arousal-producing nucleus and reducing the release of histamine to induce the 
onset of sleep. However, when awake, the NA-inhibited VLPO neurons are 
probably normally under the inhibitory control of the NA-excited neurons. 
Histamine may excite these NA-excited VLPO neurons by acting on the H1 and 
H2 receptors in the cells, leading to the inhibition of the NA-inhibited VLPO 
neurons.  
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Fig 1.6 Working model on how histamine in the VLPO contributes to the maintenance 
of wakefulness. Histamine excites NA-excited (NA(+)) neurons and increases their 
probability of releasing GABA onto the NA-inhibited (NA(−)) neurons, thus inhibiting the 
activity of these sleep-promoting neurons. This will result in disinhibition of the TMN 
neurons, and maintain the wakefulness of the animal (Reproduced from Liu et al., 2010). 
 
 
Previous studies that identify sleep or arousal nuclei mainly used lesions or 
examined c-Fos expression. Lu and his colleagues found lesions of the preoptic-
basal forebrain reduced sleep in cats and rats (Lu et al., 2000); after that, VLPO 
was found to contain GABAergic neurons and show c-Fos expression in sleep 
(Nelson et al., 2003). A study identified that lesions of VLPO decreased NREM, 
REM and total sleep to 50%; and lesions of the extended VLPO were suggested 
to contribute to REM sleep (Lu et al., 2000). Interestingly, lesion of arousal 
nuclei, like cholinergic or monoaminergic cells does not make profound effects 
on the amount of sleep (Webster and Jones, 1988; Gerashchenko et al., 2004). 
However, lesioning has limitations on cell type specificity and it is hard to 
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control the brain area for small nuclei. For example, the VLPO contains 
GABAergic and galaninergic neurons, and some neurons are both positive for 
GABA and galanin. These neurons send projections to different brain regions. 
Lesioning VLPO destroys two types of neurons, and it is not clear if the effect is 
caused by GABA or galanin. Moreover, as lesioning VLPO only decreased 
sleep up to 50%, there must be other nuclei that are involved in sleep regulation. 
New approaches are needed to investigate the sleep-wake nuclei. Recent studies 
using both lesion and genetic methods identified a sleep-active cell group in the 
rostral medullary brainstem, which has many GABAergic cells. Lesion of the 
brain area or knockout of vGAT by delivering AAV-Cre into the vgat lox/lox 
mice increased wakefulness in the light period (Anaclet et al., 2012). In my 
studies, I used different genetic strategies to investigate the sleep-wake cycle. 
Firstly, to test the ‘‘flip-flop’’ model that GABA from VLPO switches off TMN 
neurons, we inhibited GABA input onto the HDC-cells by crossing HDC-Cre 
mice with mice containing GABAA floxed 2 subunit gene or GABAB R1 
subunit floxed gene. Nevertheless, removing GABAA 2 subunit or GABAB R1 
subunits from histaminergic neurons did not affect sleep-wake cycle (Zecharia 
et al., 2012). There might be several reasons and we will discuss all the 
possibilities later. The GABA input into TMN did not affect the sleep-wake, 
which suggested to us there could be other mechanisms that in histaminergic 
neurons contributing to sleep regulation.  
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1.4 Circadian clocks and sleep 
 
Not only why, but how we sleep, are vital issues underpinning health (Kyriacou 
and Hastings, 2010; Vassalli and Dijk, 2009). The sleep drive is usually 
conceived as a summation of two independent drives: circadian and homeostatic 
(Franken, 2013). 
 
The homeostatic drive, tracks the “wear and tear” of being awake. Homeostatic 
sleep drive is reflected in sleep rebound, which means that when an animal is 
sleep deprived (SD), there is a recovery of sleep debt, marked by higher power 
delta rhythms in the initial parts of the EEG and longer sleep times (Dijk, 
2009 ). The mechanism(s) of the rebound sleep drive is poorly understood, but 
involves both global and local regulation (Saper et al 2010; Krueger et 
2008Porkka-Heiskanen, 2013). 
 
For the circadian drive, the mammalian suprachiasmatic nucleus (SCN), which 
is situated bilaterally in the hypothalamus, contains the “master” clock 
mechanism and determines when during the 24-hour period an animal is active 
or, conversely, asleep (Mohawk et al., 2012). Lesions of the SCN result in 
fragmentation of wakefulness and sleep. But the animal still exhibited a strong 
delta power rebound after sleep deprivation (Edgar et al., 1993). The 
environmental light-dark cycle provides the principal entraining signal to the 
SCN, which in turn produces rhythms within both extra-SCN neurons and 
peripheral tissues (Huang et al., 2011). This enables the animal to match its 
ecological niche, anticipating and thereby maximising opportunities and 
minimising threats. At the molecular level, mammalian circadian rhythms are 
maintained by controlling of the transcription of period genes, cryptochrome 
genes and the Clock and Bmal1 genes (Reppert and Weaver, 2001). BMAL1 
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together with its partner CLOCK, drives the expression of the BMAL1-CLOCK 
inhibitor proteins, PER and CRY, which provide delayed negative feedback (Fig 
1.7) (Mohawk et al., 2012). This mechanism forms a cell autonomous clock, 
which together with other interlocked transcriptional feedback loops, 
determines how animal physiology alters with time of day (Fig 1.7). Deletion or 
mutation of core circadian clock genes in mice induced unexpected alternations 
in sleep (Wisor et al., 2002; Shiromani et al., 2004; Hasan et al., 2014; Naylor et 
al., 2000). However, deletion of the Bmal1 gene leads to profound differences in 
the amount of sleep and sleep architecture, in terms of a notably attenuated 
diurnal distribution of sleep stages and NREM delta power under entrained 
conditions, and in terms of significant increases in 24 hours NREM and REM 
baseline sleep amounts (Laposky et al., 2005). Accumulated evidence showed 
the critical role of mammalian circadian clock genes in sleep-wake regulation. 
For example, in global Clock mutant mice, NREM sleep is reduced by 1 to 2 
hours per day under both light-dark and dark-dark conditions (Naylor et al., 
2000). Global Cry1 and Cry2 double-knockout mice have a severely attenuated 
sleep-wake rhythm and increased NREM baseline sleep time and NREM delta 
power (Wisor et al., 2004). Similarly, the clock mutation and global PER3 
deletions influence sleep homeostasis (Naylor et al., 2000; Archer et al., 2010), 
and polymorphisms in PER3 correlate with how humans respond to sleep 
deprivation (Archer et al., 2010). These results suggest that circadian clock 
genes might regulate how the circadian neurons input into sleep-wake 
pathways. An alternative possibility is that circadian clock genes directly 
influence cellular processes within neurons involved in sleep-wake regulation 
either through circadian molecular machinery in these cells or through non 
circadian cellular events. A recent study found that the synaptic adhesion 
molecular Neuroligin-1 (NLG1) can influence the sleep-wake cycle and sleep 
homeostasis. They further identified that the transcriptional factors BMAL1 and 
CLOCK can drive the expression of NLG1, which underlines that the sleep-
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wake changes involve circadian transcriptional factors (EI Helou at al., 2013). 
Circadian and clock genes are expressed in a variety of brain regions, including 
some that are involved in sleep regulation. This raises the interesting possibility 
that changes in circadian clock-gene expression (Abe et al., 2002), independent 
of SCN-timing functions, may underlie their wide-ranging effects on sleep 
architecture.  
 
 
 
Fig 1.7 The molecular circadian oscillator. Positive elements: BMAL1 and CLOCK (red), 
negative elements: PER and CRY (yellow) and components that stabilize the loop are shown 
in (blue).  In the circadian clock transcriptional–translational negative feedback loop, the 
basic-helix–loop–helix-PAS domain-containing transcription factors BMAL1 and CLOCK or 
NPAS2 (neuronal PAS domain-containing protein 2) activate the transcription of genes that 
have E-box elements in the promoter. The BMAL1/CLOCK complex activates the expression 
of Per and Cry genes which represent negative elements of the loop. PER and CRY form 
complexes and inhibit the activity of BMAL1/CLOCK. An additional loop involves Rev-
Erbα and retinoic orphan receptors (RORs). Rev-Erbα negatively regulates the expression of 
31 
 
BMAL1, whereas RORs positively regulate the expression of BMAL1. Finally, the 
BMAL1/CLOCK complex provides a circadian output in physiology by regulating the 
expression of circadian-clock-controlled genes (CCGs) (Adapted from Kondratova and 
Kondratov, 2012).  
 
 
1.5 Histamine and circadian rhythms 
 
Histamine was suggested to be involved in the regulation of the mammalian 
circadian rhythms. Application of histamine induced phase-shifts in the 
circadian rhythm of rat’s locomotor activity (Itowi et al., 1990; Itowi et al., 
1991) and of neuronal activity in the SCN. Morphologically, the SCN receives 
rich histaminergic innervations from the TMN (Watanabe et al., 1984). These 
aspects of the histaminergic system raise the hypothesis that histamine is 
involved in the feedback pathway from behavior to the circadian pacemaker. 
Abe et al. demonstrated several phenotypes of HDC knockout mice in behavior 
and clock gene expressions in the brain: low physical activity under light-dark 
(LD) and dark-dark (DD), a lengthening of free-running period under DD, and 
damped circadian rhythms in Per1 and Per2 expressions in brain areas outside 
the SCN (Abe et al., 2004). On one hand, these findings suggest that histamine 
is involved in the expression of circadian behavioral rhythms in mice. On the 
other, these results demonstrated that histaminergic cells are involved in the 
output pathway or feedback from activity to the circadian system. A previous 
study using an in vivo microdialysis technique coupled with HPLC-fluorometry 
in rats revealed that histamine release exhibits a ‘‘circadian rhythm’’: histamine 
release gradually increased in the second half of the light period and the average 
histamine release during the dark period was significantly higher than that 
during the light period, which suggests that the central histaminergic system is 
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related to the circadian rhythm of rats (Mochizuki et al., 1992); although this 
has not been tested in constant darkness (D:D) conditions. 
 
As discussed above, the circadian clock outside the SCN might contribute to 
sleep architecture. A recent report found a significant rhythm in Fos expression 
in the ventral tuberomammillary nucleus (VTM) (a subregion of TMN). Not so 
many Fos cells were found in the VTM of A. niloticus (diurnal rodent) taken at 
ZT 17 than at any other time point. A. niloticus are most likely to be sleeping in 
the middle of the night (Novak et al., 2000), when VTM Fos expression is 
lowest. Novak et al. also found there is no rhythm in Fos expression in the rat 
TMN, although the circadian modulation of Fos expression in the grass rat 
VTM may represent a species difference in the mechanism through which the 
circadian clock controls the activity cycle (Novak et al., 2000). The reduction in 
Fos expression in the VTM in A. niloticus seen during the middle of the night 
may reflect a circadian signal to the TMN in A. niloticus that is weak or absent 
in rats. The importance of histamine in the peaks of locomotor activity in grass 
rats is supported by data from this experiment showing that Fos expression in 
histaminergic cells within the VTM peaks at ZT 1 and ZT 13. Therefore, 
histaminergic cells are most active at the times of the day when this species 
shows the strongest activity, at the light-dark transitions.  
 
Our findings and theirs suggest that the circadian clock might regulate HDC 
cells activity.  Dr. Anna Zecharia in our lab patched histaminergic cells in acute 
slice of TMN at different times of the day. However, we found the cell 
excitability appears to be the same when mice are in dark period or light period, 
which demonstrates the local circadian rhythms in HDC-cells has no effect on 
histamine cells electrophysiological properties. We assume the circadian 
rhythms might drive the rhythmic expression of other factors in TMN neurons. 
In particular, HDC enzyme activity in rat brain hypothalamic extracts varies 
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with time of day; and HDC mRNA levels in post-mortem human hypothalamus 
are 2-fold higher if death occurred during the day (Orr and Quay, 1975; Rozov 
et al., 2014; Shan et al., 2012). We found that HDC protein expression is much 
higher when mice are in their active phase compared to their sleep phase. All of 
this evidence remains us that the circadian rhythms might contribute to the 
variations of HDC expression during the day. 
In our work, we genetically removed the circadian driver Bmal1 selectively 
from histaminergic neurons and found that this strongly affected the sleep-wake 
cycle and sleep rebound after sleep deprivation (Chapter 4). We suggest that the 
sleep-wake cycle is partially governed by hdc gene expression levels, which in 
turn are, directly or indirectly, under intrinsic Bmal1 transcriptional control in 
the histaminergic neurons themselves. 
 
 
1.6 Roles of GABA in histaminergic neurons 
 
In addition to histamine, TMN projection neurons contain several other 
neurotransmitters and modulators. The GABA (-aminobutyric acid)-
synthesizing enzyme, glutamic acid decarboxylase (GAD), and GABA itself are 
found in most TMN neurons. TMN neurons also can contain galanin, 
proenkephalin A-derived peptides and thyrotropin -releasing hormone, but this 
varies in different species, including rats, guinea pigs, zebrafish and humans 
(Kukko-Lukjanov and Panula 2003; Sherin et al., 1998; Ko et al., 2003).  
 
Originally, before they were identified as histaminergic cells, the TMN was 
described as a GABAergic projection from hypothalamus to neocortex (Vincent 
et al., 1983). However, the role of GABA released from histamine cells has 
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never been studied, and in the first place, whether GABA can be transported 
into other brain areas from the TMN has not been investigated. TMN neurons 
contain small granular deposits of GABA immunoreactivity which are distinct 
from those having histamine, suggesting that GABA and histamine might be 
released differently. It has been reported that vesicular monoamine transporter-2 
(vMAT2) can package GABA into the synaptic vesicles in dopaminergic cells 
(Tritsch et al., 2012). However, in the TMN, vMAT2 localizes with histamine 
but not GABA, suggesting that vMAT2 in TMN is not responsible for 
transporting GABA (Peter et al., 1995). In my studies, I found HDC-neurons are 
positive for GAD67 and GAD65 (Chapter 5); of note, those neurons also 
contain vesicular GABA transporter (vGAT). It is likely vGAT is the 
transporter for GABA in TMN. We are also using optogenetics to 
photostimulate TMN neurons to investigate neurotransmitter release including 
histamine and GABA from TMN and to identify their targeting areas.  
 
As an inhibitory neurotransmitter, GABA influences behaviour, including the 
sleep-wake cycle (Winsky-Sommerer et al., 2009). Inhibition of GABA inhibits 
NREM and REM sleep (Lu et al., 2000; 2006a). For example, GABA inputs to 
the locus coeruleus and dorsal raphe nucleus from the dorsal paragigantocellular 
nucleus, substantia nigra pars reticulata, and local interneurons could be 
responsible for shutting down REM-off serotonergic and noradrenergic cells, 
thereby disinhibiting pontine cholinergic REM-on networks (Gervasoni et al., 
2000; Nitz et al., 1997), probably through both GABAA and GABAB receptors 
(Varga et al., 2002). Although it was shown in Fig 1.3 and Fig 1.4 that TMN 
nuclei project histamine to anterior ventrolateral preoptic area, there is no direct 
evidence reporting the function of GABA that is produced by the TMN.  
 
The flip-flop model hypothesized that GABA projections from histamine cells 
can inhibit VLPO GABAergic cells, as a result, VLPO GABAergic cells put 
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less inhibition into the TMN (Saper et al., 2001; 2011). Histamine neurons 
widely project within the brain, but GABA might be differently packaged into a 
subset of TMN neurons that possibly do not project to VLPO. On the other hand, 
we found that removing GABA input onto TMN neurons does not affect sleep-
wake switch, so GABA release from TMN neurons is unlikely to affect the 
TMN neurons themselves via inhibiting VLPO. In our studies, we reduced 
GABA release from TMN neurons using different methods. I generated 
different AAV-shRNAs to target GABA transport and production in specific 
HDC-cells. We found removing GABA from TMN neurons increased mice 
locomotion activity, and wakefulness in the dark period (Chapter 5). To 
understand the mechanisms, we are conducting optogenetics and focusing on 
different brain regions, which receive histaminergic projections, like neocortex 
and striatum (Chapter 5). 
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2 Materials and Methods 
2.1 Mouse genetics 
 
HDC-Cre mice (129SVJ and C57BL/6J) and HDC-GFP knock-in mice 
(129SVJ) were generated by Dr. Thomas Goetz in our lab (Zecharia et al., 
2012). The Rosa26-loxP-Stop-loxP-YFP mice (C57BL/6J) were generated by 
Prof. Frank Costantini’s group (Srinivas et al., 2001) and provided by Prof. 
Michael Hastings (MRC LMB, Cambridge). Bmal1 lox/lox mice (C57BL/6J) 
were generated by Prof. Charles J. Weitz’s group (Storch et al., 2007) and 
provided by Prof. Michael Hastings. Vgat lox/lox mice (C57BL/6J and 129S4) 
were generated by Prof. Bradford B Lowell’s group (Tong et al., 2008) and 
purchased from JAX lab (stock NO. 012897; 
http://www.jax.org/search/Main.jsp?qt=vgat+FLOX&x=0&y=0). To generate 
the HDC-Bmal1 and HDC-Rosa-YFP mice, HDC-Cre mice were crossed with 
the Bmal1 lox/lox mice or Rosa26-lox-Stop-lox-YFP mice. Specifically 
heterozygous HDC-Cre/Bmal1 +/lox mice were crossed with Bmal1 lox/lox 
mice to generate HDC-Bmal1 mice. Experiments were performed on male 
mice homozygous for the conditional Bmal1 allele (HDC-Cre/Bmal1 lox/lox) 
and HDC-Cre-negative littermate controls or homozygous for the conditional 
vgat (vgat lox/lox) allele. 
 
2.2 Genotyping assay by PCR 
 
For the experimental breedings, all the offspring were genotyped by PCR 
analysis using mouse ear clip DNA. The protocol for extraction of genomic 
DNA was: 50 l Buffer A (25mM NaOH, 0.2mM EDTA, pH = 12) to which 
was added the ear clip in a 1.5ml tube; the tube was placed at 95ºC for 40 min 
and then 50l Buffer B (40mM, Tris, pH = 5) was added. An aliquot was added 
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directly in a PCR reaction. Specific primers for genotyping were: iCre: forward: 
5’-GTGTGGCTGCCCCTTCTGCC -3’, reverse: 5’-
AGCCTCACCATGGCCCCAGT-3’ (250 bp product) (Zecharia et al., 2012); 
GFP forward: 5’-CATTGTATGGGATCTGATCTG-3’, reverse: 5’-
TGAACTTGTGGCCGTTTA-3’ (224 bp) (Zecharia et al., 2012); RosaYFP 
forward: 5’- GGC 
GCTACCGGTCGCCACCATGGTGAGCAAGGGCGAGGAGC-3’, reverse: 
5’-GCGCGCGTTAACTTACTTGTACAGCTCGTCCATGCC-3’ (980 bp) (Fig 
2.1A); BMAL1 forward: 5’-ACTGGAAGTAACTTTATCAAACTG-3’, reverse: 
5’-CTGACCAACTTGCTAACAATTA-3’ (327 bp wild-type; 431 bp floxed 
allele) (Storch et al., 2007) (Fig 2.1B). PCR conditions were:  
iCre: 1, 95 ºC, 5 min; 2, 95 ºC, 30 s; 3, 67 ºC, 30 s; 4, 72 ºC, 30 s; 5, repeat 2-4 
for 35 cycles; 6, 72 ºC, 5 min. 
GFP: 1, 95 ºC, 5 min; 2, 95 ºC, 30 s; 3, 55 ºC, 30 s; 4, 72 ºC, 30 s; 5, repeat 2-4 
for 35 cycles; 6, 72 ºC, 5 min. 
RosaYFP: 1, 95 ºC, 5 min; 2, 95 ºC, 30 s; 3, 58 ºC, 30 s; 4, 72 ºC, 1 min; 5, 
repeat 2-4 for 35 cycles; 6, 72 ºC, 5 min. 
BMAL1: 1, 95 ºC, 5 min; 2, 95 ºC, 30 s; 3, 55 ºC, 30 s; 4, 72 ºC, 45 s; 5, repeat 
2-4 for 35 cycles; 6, 72 ºC, 5 min. 
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Fig 2.1 Genotyping of HDC-Rosa26-YFP and HDC-mal1 mice. ko, knock-out; wt, 
wild-type. Arrowhead in Fig A indicates YFP positive band. Arrowhead in C indicates Cre 
positive band. Lanes 1-5 are ear clip DNA samples from individual mice. 
 
 
2.3 Immunocytochemistry 
 
Mice were transcardially perfused with 4% paraformaldehyde (Thermo 
scientific) in phosphate buffered saline (PBS) (Sigma). Brains were removed 
and 35-μm-thick or 60-μm-thick coronal sections were cut using a Leica 
VT1000S vibratome. Free-floating sections were washed in PBS three times for 
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5 min, permeabilized in PBS plus 0.4% Triton X-100 for 30 min, blocked by 
incubation in PBS plus 5% normal goat serum (NGS) (Vector), 0.2% Triton X-
100 for 1 hour (all at room temperature) and subsequently incubated with 
primary antibody which diluted in PBS plus 2% NGS for 24 hours (48 hours for 
HDC) at 4°C in a shaker. Incubated slices were washed three times in PBS for 
10 min at room temperature, and then incubated for 2 hours at room temperature 
with a 1:1000 dilution of a secondary antibody (Molecular Probes) in PBS plus 
1% NGS, and subsequently washed there times in PBS for 10 min at room 
temperature. For cell cultures, medium was removed and cells were washed in 
PBS three times for 5 min, and then fixed in PFA for 10 min, after that, cells 
were permeabilized in PBS plus 0.4% Triton X-100 for 10 min; blocked by 
incubation in PBS plus 5% normal goat serum (NGS) (Vector), 0.2% Triton X-
100 for 10 min (all at room temperature) and subsequently incubated with 
primary antibody which diluted in PBS plus 2% NGS overnight at 4°C in a 
shaker. Incubated cells were washed three times in PBS for 10 min at room 
temperature, and then incubated for 2 hours at room temperature with a 1:1000 
dilution of a secondary antibody (Molecular Probes) in PBS plus 1% NGS, and 
subsequently washed there times in PBS for 10 min at room temperature. 
Primary antibodies used were rabbit polyclonal EGFP, (Invitrogen Molecular 
Probes, Eugene, OR), 1:1000; guinea pig polyclonal HDC, (American Research 
Products, Belmont, MA), 1:300; rabbit polyclonal BMAL1, 1:1000; rabbit 
polyclonal PER2, 1:1000, (BMAL1 and PER2 antibodies were kindly donated 
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by Prof. Michael Hastings, MRC, LMB, Cambridge). Mouse monoclonal TH, 
(Chemicon, UK), 1:2000, mouse monoclonal Gad67, (Millipore, UK), 1:1000; 
mouse monoclonal Gad65, (Millipore, UK), 1:1000; rabbit polyclonal vGAT, 
(Millipore, UK), 1:1000. Secondary antibodies were Alexa Fluor 488 goat anti-
rabbit IgG, 1:1000, Alexa Fluor 488 goat anti-mouse IgG, 1:1000; Alexa Fluor 
488 goat anti-guinea pig IgG, 1:1000, Alexa Fluor 594 goat anti-rabbit IgG, 
1:1000, Alexa Fluor 594 goat anti-mouse IgG, 1:1000; Alexa Fluor 594 goat 
anti-guinea pig IgG, 1:1000, (Invitrogen Molecular Probes);Slices were 
mounted on slides, embedded in Mowiol (DAPI or without DAPI), cover-
slipped, and analyzed using an upright fluorescent microscope (Nikon eclipase 
80i, Nikon Corporation, JAPAN) or a Zeiss LSM 510 confocal microscope or a 
Zeiss LSM 510 inverted confocal microscope (Facility for Imaging by Light 
Microscopy, FILM, Imperial College). Images were acquired using single track 
scanning or Z-scan. Fluorescence intensity was quantified using ImageJ (NIH, 
USA). 
 
 
2.4 In Situ Hybridization 
 
In situ hybridizations were carried out as described (Wisden and Morris 1994; 
2002) with a little modification. Nonperfused brains were removed and frozen 
on dry ice embed with OCT (CellPath). Sections (14 m) were cut on a cryostat 
(Leica CM3050), mounted onto poly-L-lysine-coated slides, and dried at room 
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temperature. Sections were fixed in 4% paraformaldehyde, washed in DEPC-
treated phosphate-buffered saline, and dehydrated into 95% ethanol (prepared 
with DEPC-treated water) for storage at 4°C until required. Before 
hybridization, sections were removed from ethanol and allowed to air dry. 
Probes (0.3 pmol/l) were 3’ end labeled using a 100: 3 molar ratio of 33P-dATP 
(250 Ci /l; Perkin Elmer) to oligonucleotide, and terminal deoxynucleotidyl 
transferase (Roche Diagnostics, Germany). To assess non-specific labeling of 
the sections, each labeled oligonucleotide was hybridized to brain sections with 
a 100-fold excess of unlabeled oligonucleotide. Unincorporated nucleotides 
were removed by Sephadex G-25 spin column (GE Healthcare). Labeled probe 
dissolved in hybridization buffer was then applied to sections. Hybridization 
buffer contained 50% formamide/ 4 x SSC (1 x SSC: 0.15 M Nacl, 0.015 M Na-
citrate)/l0% dextran sulfate. Hybridization was performed at 42°C overnight in 
an incubator (Techne hybridiser). Sections were washed with 1 x SSC (prepared 
with DEPC-treated water) at room temperature for 5 min, 1 x SSC at 65°C for 
40 min, 0.1 x SSC for 1 min at room temperature, 70% ethanol for 1 min at 
room temperature before 95% ethanol dehydration and exposure to Kodak film 
(Eastman Kodak, Rochester, NY). The oligonucleotide sequence used was: 
HDC: 5′-
GCTGTCGGGTTCCTCGGGAGCACTCGCAGGTAGCTGGGCTCGCAG-3′, 
Images were generated from 1 to 4 week exposures to Biomax MR X-ray film.  
 
2.5 Generation of vGAT, Gad65 and Gad67 expression vectors  
 
To construct the vGAT expression vector, the mouse vGAT coding sequence 
and 3’-UTR were PCR amplified with primers (forward: 5’-ATATAT-
GCTAGC-CCCAGACCCTTCTGTCCTTTTCTC-3’; reverse: 5’-ATATAT-
AAGCTT-CGCCTTTGTTTCTTCTTTATTTGCGG-3’) with HindIII and NheI 
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sites from a mouse vGAT cDNA clone (clonetech, CA). PCR conditions were: 
1, 95 ºC, 5 min; 2, 95 ºC, 30 s; 3, 60 ºC, 30 s; 4, 72 ºC, 3 min; 5, repeat 2-4 for 
35 cycles; 6, 72 ºC, 5 min. PCR products (2.1 kb) and pcDNA3.1(+) vector 
(Invitrogen, UK) were digested by HindIII and NheI. The digested PCR insert 
was purified and cloned into the pcDNA3.1 vector. The mouse Gad65 cDNA 
clone and mouse Gad67 cDNA clone were purchased from Origene 
Technologies (Rockville, MD) in a pCMV6-Kan/Neo vector.  
 
2.6 Construction of AAV-shRNAs vectors 
 
The pPRIME system, which generates miR30-based shRNAs, ensures correct 
processing of the pre-miRNA to the mature siRNA (Stegmeier et al., 2005); it 
allows siRNA to be produced from an RNA polII transcript, allowing 
expression of a protein such as dsRed or GFP from the same transcript. Three 
hairpin oligonucleotides against vGAT, three against Gad65 and three against 
Gad67 mRNA were designed 
(http://katahdin.cshl.org:9331/siRNA/RNAi.cgi?type=shRNA). The 
oligonucleotides sh hairpins were: 
 
Scramble oligonucleotide: 
TGCTGTTGACAGTGAGCGGCCGCGATTAGGCTGTTATAATAGTGAAGC
CACAGATGTATTATAACAGCCTAATCGCGGCTGCCTACTGCCTCGGA 
vGAT sholigo1: 
TGCTGTTGACAGTGAGCGAAGCCATTCAGTGCTTGGAATCTAGTGAC
CACAGATGTAGATTCCAAGCACTGAATGGCTGTGCCTACTGCCTCGGA 
vGAT sholigo2: 
TGCTGTTGACAGTGAGCGCACTCATCTTGTGCAATGTATCTAGTGAAG
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CCACAGATGTAGATACATTGCACAAGATGAGTTTGCCTACTGCCTCGG
A 
vGAT sholigo3: 
TGCTGTTGACAGTGAGCGCGGTGTGCTCGTGGTGAATAAGTAGTGAA
GCCACAGATGTACTTATTCACCACGAGCACACCATGCCTACTGCCTCG
GA 
Gad65 sholigo1: 
TGCTGTTGACAGTGAGCGCACAGACAGTGTGATTCTGATTTAGTGAA
GCCACAGATGTAAATCAGAATCACACTGTCTGTTTGCCTACTGCCTCG
GA 
Gad65 sholigo2: 
TGCTGTTGACAGTGAGCGATGCCAGCGTGTGATGGAGAAATAGTGAA
GCCACAGATGTATTTCTCCATCACACGCTGGCAGTGCCTACTGCCTCG
GA 
Gad65 sholigo3: 
TGCTGTTGACAGTGAGCGCTGATTCCATCTGATCTTGAAATAGTGAAG
CCACAGATGTATTTCAAGATCAGATGGAATCATTGCCTACTGCCTCGG
A 
Gad67 sholigo1: 
TGCTGTTGACAGTGAGCGCTCACATAAGCTTGTTTGTTAGTAGTGAA
GCCACAGATGTACTAACAAACAAGCTTATGTGAATGCCTACTGCCTC
GGA 
Gad67 sholigo2: 
TGCTGTTGACAGTGAGCGAAGTCACTATTCCATAAAGAAATAGTGAA
GCCACAGATGTATTTCTTTATGGAATAGTGACTGTGCCTACTGCCTCGG
A 
Gad67 sholigo3: 
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TGCTGTTGACAGTGAGCGCCTCGCTTAGCTGAAACCTAAGTAGTGAA
GCCACAGATGTACTTAGGTTTCAGCTAAGCGAGTTGCCTACTGCCTC
GGA 
 
The hairpin oligonucleotides were PCR amplified by VENT polymerase (NEB, 
UK) using the pPRIME forward and reverse oligonucleotides with added XhoI 
and EcoRI sites underlined (forward: 5’-GATGGCTG-CTCGAG-
AAGGTATAT-TGCTGTTGACAGTGAGCG-3’; reverse: 5’-GTCTAGAG-
GAATTC-CGAGGCAGTAGGCA-3’). PCR conditions were: 1, 94 ºC, 5 min; 
2, 94 ºC, 30 s; 3, 54 ºC, 30 s; 4, 75 ºC, 30 s; 5, repeat 2-4 for 12 cycles; 6, 75 ºC, 
2 min. After XhoI and EcoRI digestion, products were cloned into the pPRIME 
vector (Stegmeier et al., 2005) (Fig 2.2A). The PCR products and pPRIME 
vector were digested with XhoI and EcoRI and the purified products were 
cloned into the pPRIME-dsRed or pPRIME-GFP vector to generate pPRIME-
dsRed-shScr, pPRIME-dsRed-shvGAT, the pPRIME-GFP-shScr, pPRIME-
GFP-shGad65 and pPRIME-GFP-shGad67 (Fig 2.2B). To further generate 
AAV-dsRed-shScr and AAV-dsRed-shvGAT, pPRIME-dsRed-shScr and 
pPRIME-dsRed-shvGAT vectors were PCR amplified using the primers 
(forward: 5’-AGTGAACCGTCGGCGCGCCTAGCGCTACC-3’; reverse: 5’-
CGTGTTTAAACGCGCTAGCCTTCCAATTG-3’) with an AscI site 
(underlined) in the forward primer and a NheI site (underlined) in the reverse 
primer. PCR products and AAV vector (pAAV-hSyn-DIO-hM4D(Gi)-mCherry 
(Add gene plasmid #44362)) were digested with AscI and NheI, and the insert 
was cloned into the vector (Fig 2.2C). To construct AAV-FLEX-dsRed-shScr 
and AAV-FLEX-dsRed-shvGAT plasmids, pPRIME-dsRed-shScr and pPRIME-
dsRed-shvGAT were PCR amplified using primers (forward: 5’-
GAACCGTCAGATCCGCTAGCGCTACCG-3’; reverse: 5’-
GAACGCGTCGGCGCGCCTTTAAACGCAT-3’) with a NheI site in the 
forward primer and an AcsI sites in the reverse primer. PCR products and AAV 
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vector were digested with AscI and NheI, and then purified inserts were cloned 
into the vector (Fig 2.2D). To generate AAV-GFP-shScr, AAV-GFP-shGad65 
and AAV-GFP-shGad67, pPRIME-GFP-shScr, pPRIME-GFP-shGad65, 
pPRIME-GFP-shGad67 were PCR amplified using primers (forward: 5’-
AGTGAACCGTCGGCGCGCCTAGCGCTACC-3’; reverse: 5’-
CATTATGGTGAAAGTTGCTAGCTCTTACGTGCCGATCA-3’) with an AscI 
site in the forward primer and a NheI site in the reverse primer. PCR products 
and AAV vector were digested with NheI and AscI, and the inserts were cloned 
into the AAV vector (Fig 2.2C). To construct AAV-FLEX-GFP-shScr, AAV-
FLEX-GFP-shGad65 and AAV-FLEX-GFP-shGad67 plasmids, pPRIME-GFP-
shScr, pPRIME-GFP-shGad65 and pPRIME-GFP-shGad67 were PCR 
amplified by primers (forward: 5’-
GAACCGTCAGATCCGCTAGCGCTACCG-3’; reverse: 5’- 
GTTGGAACCTATGGCGCGCCGATCAACGTCTC-3’) with a NheI site in the 
forward primer and an AscI site in the reverse primer. PCR products and AAV 
vector were digested with NheI and AcsI, and then purified inserts were cloned 
into the AAV vector (Fig 2.2D). The PCR conditions to generate all AAV-
shRNAs were: 1, 95 ºC, 2 min; 2, 95 ºC, 1 min; 3, 60 ºC, 1 min; 4, 72 ºC, 1.5 
min; 5, repeat 2-4 for 30 cycles; 6, 75 ºC, 10 min. 
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Fig 2.2 Diagram of strategy to generate AAV-shRNA vectors. (A) Oligo targeting vGAT, 
Gad67 and Gad65. (B) Oligonucleotides were PCR amplified and cloned into the pPRIME-
dsRed or pPRIME-GFP vectors to generate: pPRIME-dsRed-shvGAT, pPRIME-GFP-
shGad67 and pPRIME-GFP-shGad65. (C) To generate AAV-shRNAs, dsRed-miR30-
shvGAT, GFP-miR30-shGad67 and GFP-miR30-shGad65 vectors were PCR amplified with 
primers carrying AscI and NheI sites and cloned into the AAV vector. (D) To generate AAV-
FLEX-shRNAs, dsRed-miR30-shvGAT, GFP-miR30-shGad67 and GFP-miR30-shGad65 
vectors were PCR amplified with primers carrying NheI and AscI sites (labelled with red IN 
b) and cloned into the AAV vector. CMV, Cytomegalovirus ehancer/promoter; dsRed, red 
fluorescent protein; GFP, green fluorescent protein; miR30, microRNA30; ITR, inverted 
terminal repeats; hSyn, human synapsin promoter; WPRE, woodchuck postregulatory 
regulatory element. 
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2.7 Generation of AAV-HDC-iCre-Venus vector 
 
The AAV-iCre-Venus plasmid was provided by Prof. Tomas Kuner (Abraham et 
al., 2010). To generate AAV-HDC-iCre-Venus plasmid, a mouse hdc gene 
promoter fragment was PCR amplified using mouse brain genomic DNA with 
primers (forward:     5’- 
ATATATGAATTCCTTGGATTGCTCCTCCTGGCAGACAG-3’; reverse:        
5’-ATATATGGTACCGACCACCCCCCATGAAGTCTGTTGTG-3’). PCR 
products and AAV-iCre-Venus plasmid were digested with EcoRI and KpnI. 
After purification, the PCR products were cloned into the AAV-iCre-Venus 
vector to generate the AAV-HDC-iCre-Venus plasmid.  
 
 
2.8 AAV-FLEX-ChR2-EYFP vector 
 
AAV-FLEX-ChR2-EYFP vector was purchased from Addgene (20298). This 
vector is Cre-activated AAV expression of humanized ChR2 with H134R 
mutation fused to EYFP for optogenetic activation with an EF1 promoter 
(http://www.optogenetics.org). 
 
 
2.9 RNA extraction and real-time PCR 
 
For tissue analysis, brains were collected at the selected ZT0, ZT4, ZT8, ZT12, 
ZT16, ZT20, ZT24 points and tissue was punched and collected into the tube 
and stored at -80 ºC until use. Total RNA from TMN punches and LC punches 
was extracted using Trizol reagent (Invitrogen). Reverse transcription and real-
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time PCR were performed using TaqMan RNA-to-Ct 1-Step Kit (Life 
technologies, 4392653) with a real-time PCR device (Applied Biosystems, UK). 
The TaqMan assay probes for real-time PCR were designed and purchased from 
Invitrogen (UK). mHdc: Mm00456104_m1; mBmal1: Mm00500226_m1; 
mPer1: Mm00501813_m1; mCry1: Mm00514392_m1; mHnmt: 
Mm00475563_m1; m18s rRNA: Mm03928990_g1  
 
2.10 Luciferase assays 
 
To clone the hdc gene promoter (Kuramasu et al., 1998; McLaughlin et al, 
2004; Suzuki-Ishigaki et al., 2000; Zecharia et al., 2012) into the pGL3-basic 
luciferase vector (Promega), primers (forward: 5’- 
CTACGTAGCCATGCTCTAGGTACCGACCAC-3’; reverse: 5’-
GACAAGCTTCGACGCGTGCTCTGAATTCCTTG-3’) were used to amplify 
the promoter fragment from the HDC-Cre-2A-Venus plasmid. The PCR 
conditions were: 1, 95 ºC, 2 min; 2, 95 ºC, 1 min; 3, 60 ºC, 1 min; 4, 72 ºC, 1 
min; 5, repeat 2-4 for 30 cycles; 6, 72 ºC, 10 min. The E box was mutated in the 
HDC luciferase vector by Quick Change mutagenesis (Strategy, UK) using the 
primers (forward: 5’-
GATGCACTGGCTGCCAGGGAGTGggCAGCACAGACAAAGG-3’ reverse: 
5’-CCTTTGTCTGTGCTGccCACTCCCTGGCAGCCAGTGCATC-3’). Hdc 
promoter (500ng) or mutant promoter luciferase vectors (500ng) and control 
pRL-sv40 Renilla luciferase (5ng) (Promega #E2231) were transiently 
transfected into the HEK293 cells using the calcium phosphate method, along 
with combinations of expression vectors for BMAL1 (50ng or 100ng), CLOCK 
(50ng or 100ng), CRY1 (100ng or 200ng) and PER2 (100ng or 200ng) (All 
provided by Prof. Michael Hastings, MRC LMB, Cambridge). PcDNA3.1 
plasmids were added to each group to make the same amount of DNA before 
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transfection. Luciferase activity was measured using the Dual-luciferase 
reporter assay system (Promega, Cat.#1910) using a Lumat3 (LB 9508, 
Berthold technologies).  
 
2.11 Adeno-associated virus (AAV) preparation: serotype 1/2 
 
HEK293 cells were plated out 24 hours before transfection. The transfection 
mixture used was: 62.5µg AAV transgene plasmid, 125µg pFdelta6 helper 
plasmid, 31.25µg pRVI helper plasmid, 31.25µg pH21 helper plasmid 
(Klugmann at al., 2005; Murray et al., 2011), 1650µl 2.5 M CaCl2, 12ml H2O. 
16 hours after transfection, the medium was removed and replaced with 50ml of 
fresh DMEM. 60-65 hours after transfection, media were removed and 
discarded, cells were washed in 1xPBS, and after washing, cells were collected 
in 50ml Nunc tissue culture tubes, and cells were pelleted at 800g for 5-10 min, 
supernatants were discarded and cell pellets were resuspended in 150mM NaCl, 
20mM Tris pH 8.0. Sodium deoxycholate (Sigma #D5670) and benzonase 
endonuclease (Sigma #E1014) were added to a final concentration of 50U/ml. 
Cells were incubated in a 37oC waterbath for 1hr. After incubating, cell debris 
were removed by centrifugation at 3000g for 15 min. The supernatant were 
purificated by a heparin column. The column was pre-equilibrated (1ml HiTrap 
Heparin columns, Sigma #5-4836) with 10ml 150mM NaCl, 20mM Tris, pH 
8.0. The pump was set at 25mm diameter, 200ul/min flow rate; the 50 ml 
sample was loaded onto the 60ml syringe. The column was washed with 20ml 
100mM NaCl, 20mM Tris pH 8.0 and virus was eluted off the column as 
follows: 1ml 200mM NaCl, 20mM Tris, pH 8.0 (discarded), 1 ml 300mM NaCl, 
20mM Tris, pH 8.0 (discarded), 1.5ml 400mM NaCl, 20mM Tris, pH 8.0 
(collected), 3ml 450mM NaCl, 20mM Tris, pH 8.0 (collected), 1.5ml 500mM 
NaCl, 20mM Tris, pH 8.0 (collected). After purification, AAV particles were 
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concentrated using AMICON ULTRA-4 (100000MWCO; Millipore; CatNo. 
UFC810024) at 2000g for 10 min. The concentrator was refilled with 3.5ml of 
0.9% NaCl to wash for two times. Elutions were removed to a sterile tube, 
250l of 0.9% NaCl was added into the tube. AAV was aliquated and stored at  -
80 ºC until use. 
 
2.12 Stereotaxic injections 
 
To deliver the AAV into the brain, stereotaxic injections were performed using 
an Angle Two apparatus (Leica) that linked to a computational mouse atlas 
(www.brain-map.org). Before injection, 1 l AAV virus was mixed with 1 l 
20% mannitol (MERCK K93152782 111). The virus and mannitol mixture were 
injected into a pulled-glass pipette (Warner Instruments; OD=1.00 mm, ID=0.78 
mm, Length=7.5 cm). Virus was injected by an airpressure system at a speed of 
25 nl/min. 1 l virus was bilaterally injected into the brain, 0.5 l for each side. 
The coordinates for injections were:  
LC: ML (-0.86 mm), AP (-5.40 mm), DV (-3.78 mm); ML (0.7 mm), AP (-5.40 
mm), DV (-3.67 mm).  
VLPO: ML (-0.74 mm), AP (-0.1 mm), DV (-5.71 mm); ML (0.73 mm), AP (-
0.1 mm), DV (-5.69 mm). 
TMN: ML (-0.92 mm), AP (-2.7 mm), DV (-5.34 mm); ML (0.92 mm), AP (-
2.70 mm), DV (-5.34 mm). 
For unilateral injections: Str: ML (-2.10 mm), AP (0.50 mm), DV (-3.66 mm). 
 
2.13 Locomotor activity experiment in a novel environment 
 
Mice were placedinto an open box (45 x 45 x 35 cm) to let them explore it. All 
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experiments were performed at ‘‘lights off’’ (active phase). The locomotion 
activity was detected in an activity test chamber with infrared around the box 
(Med associates, inc). To detect the EEG theta power, mock Neurologgers were 
attached two days before the experiment. Five minutes before the experiments, 
Neurologgers were attached to the mice. For mouse turning experiments, a 
camera was attached to the open field, and mice were put into the open box for 
30 min. Data were collected by counting the video for the first 1 min or 5 min.  
 
2.14 Sleep experiments and EEG analysis  
 
Sleep experiments and EEG analysis were performed as described before (Pang 
et al., 2009; Zecharia et al., 2012). All surgery was carried out under halothane 
(1.5–2.5% in oxygen) anesthesia. Three gold-plated EEG electrodes 
(Decolletage AG) were inserted through the skull onto the dura mater, the 
coordinates for the three electrodes were: frontal bone (+1.5 mm to Bregma, -
1.5 mm from midline), parietal bone (+1.5 mm to Bregma, +1.5 mm from 
midline), interparietal bone (+2.0 mm from Lambda, 0.0 mm from midline). For 
EMG recording, three lengths of Teflon-insulated stainless steel wire were 
inserted in the neck muscle. After all of the electrodes and EMG wires were in 
place, they were covered with dental cement (Orthoresin; DeguDent GmbH). 
The animals were allowed at least 14 days to recover from surgery.  For sleep 
experiments, the EEG and EMG signals were recorded using Neurologgers 
(Vyssotski et al., 2009; Pang et al., 2009; Zecharia et al., 2012) 
(http://www.vyssotski.ch/neurologger2). Two days before the sleep experiment, 
mice were attached with mock neurologgers. Sleep experiments were performed 
2 to 3 hours before ‘‘lights off’’ and 1-2 hours after ‘‘lights off’’ the following 
day, a total 27 to 29 hours activity was recorded. Two EEG and two EMG 
channels for each mouse were recorded onto the Neurologger. Spike2 (version 
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7.10) was used to analysis the sleep (EEG/EMG) data. The sampling rate was 
set up to 200 Hz. EMG was filtered by band pass between 5 and 45 Hz. EEG 
frequency below 0.5 Hz was filtered. The sleep state (wake, W; nonrapid-eye-
movement, NREM; rapid-eye-movement, REM; doubt, D) was scored 
automatically as before (Pang et al., 2009; Zecharia et al., 2012). To classify the 
behaviour state, the general criteria were:  
Wake = high EMG and intermediate theta/delta ratio; 
NREM sleep = low EMG, low theta/delta ratio and high delta; 
REM sleep = low EMG and high theta/delta ratio. 
Firstly, the delta and theta oscillations were used to generate the sleep score 
from filtered EEG signals. Second, new data channels were created for delta, 
theta and the theta/delta ratios. Along with the EMG channel, consecutive 5 
second epochs of data were used as an initial score for wake, NREM, REM or 
‘‘doubt’’. The last step was to group the four consecutive 5 second epochs to 
create a 20 second epoch from the predominant state. The final percentage of 
doubt scores was below 10% for every mouse scored. The percentage of wake, 
NREM and REM was exported as a text file. EEG power was analysed using 
FFT (Fast Fourier transforms of the autocorrelation function) power spectra 
(FFT size: 1024) (Pang et al., 2009; Zecharia et al., 2012) or Morlet Wavelet 
analysis using software written for Matlab by Torrence and Compo (1998) 
(Pang et al., 2009).  
 
 
2.15 Sleep deprivation  
 
Sleep deprivation experiments were performed as described before 
(Gerashchenko et al., 2008; Halassa et al., 2008) with modifications. Mice were 
attached with mock Neurologgers two days before sleep deprivation. Before 
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sleep deprivation, mice were attached with Neurologgers. Mice were sleep 
deprived for 5 hours after ‘‘lights off’’. In the first hour of the sleep deprivation 
(at the beginning of sleep deprivation), mice were put into novel cages with new 
objects. At each hour, objects were changed with new objects. During the last 
two hours, mice were gently handled for some seconds when they tended to 
sleep. Most of the time during the last two hours, mice were very active and in a 
total of two hours, the mice only needed to be handled one or two times. After 
sleep deprivation, the mice were put back into their home cage to recover.  
 
2.16 Memory experiment: novel object recognition 
 
The novel object recognition experiment was performed as described 
before (Halassa et al., 2008). An open box (45 x 45 x 35 cm) was used to 
conduct the experiment. A camera was mounted above the open field. Before 
the experiment, mice were handled every day for one week. Two days before 
the experiment, they were allowed to explore the open box for 10 minutes to get 
familiar with the apparatus. Each test contained three sessions. In the first 
session, mice were placed into the empty open field without objects for 10 
minutes. In the second session, two identical objects were added. Mice were 
then placed into the open field for another 10 minutes to explore the objects. In 
the third session, the object presented was a duplicate of the sample presented in 
second session in order to avoid olfactory trails, and a different object was 
introduced in the third session. In the control experiment (normal 24 hour 
natural sleep), the interval between the second and third session was 24 hours. 
In the sleep deprivation (SD) experiment, after the second session, the mice 
were sleep deprived for five hours and allowed to recover for 19 hours in their 
home cages and after recovery sleep, a third session was performed.  
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2.17 Animal ethics 
 
All animal work was licensed under the UK animals (Scientific Procedures) Act 
of 1986 with local ethical approval and all animal work was conducted under 
Home Office project license PPL70/7273. I obtained a permitted licence 
(Modules 1-4).  
 
2.18 Statistical analyses 
Values are expressed as mean ± s.e.m. Data were analyzed using GraphPad 
Prism 5.0. Data were analyzed using unpaired two-tailed t-test or one-way 
ANOVA and post hoc Bonferroni or two-way ANOVA and post hoc Bonferroni, 
as stated in the figure legends, *p<0.05, **p<0.01, ***P <0.001.  
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3 Mapping the histaminergic system in the adult mouse brain using 
genetic tagging 
 
3.1 Summary 
 
In this chapter, I used in situ hybridization to detect hdc mRNA expression in 
the whole adult brain; moreover, Thomas Goetz, a previous PhD student in the 
Wisden lab, knocked GFP into the hdc gene, and I am going to examine the 
GFP expression in HDC-neurons of these mice. In addition, I used a lox-stop-
lox-YFP reporter mouse line to label the histaminergic cells, which provides 
visible primary fluorescence. Using this method, not only HDC-neurons but 
also some other brain regions were labelled with fluorescent protein (YFP); 
however, those brain regions might be involved in histamine development. The 
most significant aspect of using reporter mice is that we can clearly show all the 
histamine fibers within the whole brain. At the end of this chapter, I will show 
some brain regions that receive massive histaminergic cell projections.  
 
3.2 Using in situ hybridization to map histidine decarboxylase mRNA        
distribution in the adult mouse brain 
 
In the adult mouse brain, others have reported that the hdc gene’s main 
expression sites are the tuberomammillary nuclei and the ependyma lining the 
ventricles/choroid plexus (Karlstedt et al., 2001). To examine the expression of 
the hdc gene in wild-type mouse brain (C57BL/6J), I used in situ hybridization 
to hybridize the entire coronal atlas of adult mouse brain sections with a 
33
P-
labelled antisense probe for HDC. Signals could only be detected in particular 
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brain sections (Bregma -1.46 mm to -2.92 mm) at the level of TMN nuclei (Fig 
3.1) (Zecharia et al., 2012). No hdc mRNA signal was found in other areas.  
 
 
 
Fig 3.1 Examining hdc gene expression in adult wild-type mice. HDC in situ hybridization 
with a 
33
P-labelled probe specific for the hdc mRNA and X ray film autoradiographs 
corresponding of brain sections (NISSL stained). The histidine decarboxylase (hdc) gene is 
only expressed in the tuberomammillary nucleus (TMN) in the adult brain. No expression 
could be detected in other areas. This is a series of fourteen coronal sections, moving from 
rostral (section A; Bregma -1.22) through to caudal (section N; Bregma -2.92). Ctx, Cortex, 
Hi, Hippocampus, Th, Thalamus, VMH, ventral medial hypothalamus, Arc, arcuate 
hypothalamus nucleus, 3V, 3rd ventricle, MM, medial mammillary nucleus. Scale bar, 2 mm 
(Zecharia et al., 2012). 
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3.3 Using GFP knock-in mice to map the HDC-neurons in the adult mouse 
brain 
 
3.3.1 Generation of HDC-EGFP knock-in mouse 
 
The HDC-EGFP mouse line was generated by Dr. Thomas Goetz (Zecharia et 
al., 2012). Briefly, a GFP and Cre reading frame was driven under the HDC 
promoter (Fig 3.2). The construct, carrying a tandem double ‘‘internal ribosome 
entry site’’ (IRES) element, was designed to express both GFP and Cre 
recombinase (Fig 3.2). However, it was subsequently found that the second 
IRES-Cre element did not allow sufficient translation of the Cre protein, and the 
knock-in allele effectively only expressed GFP. 
 
 
 
Fig 3.2 Gene targeting strategy to produce the HDC-EGFP knock-in mouse line. The 
IRES-EGFP-IRES-Cre cassette was placed into exon 12 of the hdc gene, between the stop 
codon (TAG) and the polyadenylation signal. An frt-flanked neomycin resistance gene was 
inserted downstream for positive selection in ES cells. For negative selection, T. Goetz used a 
GFP-expressing gene, which flanked the 3’ homology arm, and analyzed nonfluorescent 
colonies. After successful targeting, the neomycin cassette (neo) was removed by Flp 
recombinase to give the final targeted allele (T. Goetz; see Zecharia et al., 2012). 
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3.3.2 Assaying GFP expression in the HDC-EGFP knock-in mice  
 
Thomas Goetz had left the Wisden lab before I started and he had not analysed 
the HDC-GFP mouse line. One of my first tasks when I started my PhD was to 
map the GFP expression in this mouse line. The first thing I discovered was that 
histaminergic neurons in the HDC-EGFP knock-in mice did not provide strong 
primary fluorescence to visualize directly. Therefore, to test the GFP expression 
in the HDC-GFP mice, those knock-in mice and littermate controls were 
examined by staining for GFP with an EGFP antibody. Given that HDC mRNA 
had a specific location in the brain (see Fig 3.1), some particular coronal 
sections were firstly selected. GFP immunoreactivity could be detected in the 
HDC-EGFP knock-in mice but not in the littermate control mice (Fig 3.3A). As 
expected, the GFP-positive cells only exist in particular coronal sections, 
between section “a” and section “b” (Fig 3.3B), as shown in Fig 3.3C, D, the 
medial (MTM), ventral (VTM) and diffuse (DTM) groups and dorsal 
ependyma. 
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Fig 3.3 Distribution of GFP in HDC-EGFP knock-in mice. (A) Coronal sections of HDC-
EGFP knock in mice and wild-type (WT) mice were incubated with EGFP antibody, and 
stained black by the immunoperoxidase method with diaminobenzidine/nickel reaction 
(DAB/Ni). GFP-positive staining could only be seen in HDC-GFP mice, but not wild-type 
mice. All the brain sections were stained with EGFP antibody. (B) Using a fluorescent 
secondary antibody, GFP-positive cells were found between section “a (Bregma -2.06 mm)” 
and section “b (Bregma 3.16 mm)”. (C, D) Two examples of GFP-positive sections. 
Histaminergic neurons were restricted to the medial (MTM), ventral (VTM) and diffuse 
(DTM) groups and dorsal ependymal. Scale bar, A, 0.2 mm; C, 0.5 mm (Zecharia et al., 
2012). 
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3.3.3 Characterizing that GFP-positive cells as histamine neurons in HDC-
EGFP knock-in mice 
 
Although GFP was detectable in the posterior hypothalamus of the HDC-EGFP 
knock-in mice, it was not possible to ascertain whether GFP-positive cells were 
actually histaminergic neurons. Here, an HDC antibody was used to identify the 
GFP-positive cells. Brain sections were incubated with both EGFP and HDC 
antibodies. By visualizing the fluorescence, GFP-positive cells were also found 
to be HDC-positive in the medial (MTM) and ventral (VTM) groups of the 
TMN (Fig 3.4A). A diffuse group (DTM) was examined as well; interestingly, 
the signal of HDC in the DTM was not as strong as those in the medial (MTM) 
and ventral (VTM) (Fig 3.4B, C). There was also an intense EGFP staining in 
the dorsal ependyma lining the roof of the 3rd ventricle, which was not 
positively stained with the HDC-antibody (Fig 3.4C). No other brain areas had 
EGFP immunoreactivity.  
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Fig 3.4 Confirmation of GFP-positive cells in the TMN were histaminergic neurons. 
Coronal sections of HDC-GFP mice were double stained with GFP and HDC antibodies. 
GFP-positive cells could be found in VTM (A), MTM (B) and DTM (C). GFP cells were 
HDC positive in TMN (A, B), but showed less HDC signal in MTM and DTM. The bottom 
panels of Fig A are magnifications of boxed areas in upper panels of Fig A. VTM, ventral 
tuberomammillary; MTM, medial tuberomammillary; DTM, diffuse tuberomammillary. Scale 
bar, 40m (Zecharia et al., 2012). 
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3.3.4 Further mapping the histamine neurons in the HDC-EGFP knock-in 
mouse brain 
 
In the adult mouse brain, others have reported that the histamine containing 
cells are mainly found in the tubermammillary nuclei (Panula et al., 1984; 
Parmentier et al., 2002). Next, a broader range of coronal atlas of the sections 
from HDC-GFP mice was examined. Coronal sections from the anterior through 
to the posterior were produced, and all the sections were incubated with EGFP 
antibody followed by the secondary fluorescence antibody. HDC-GFP neurons 
were scattered throughout the TMN area. The GFP-positive cells still could only 
be detected in particular coronal sections, between Begma -2.06 mm and Begma 
3.16 mm. The coronal brain sections outlining the representative GFP-positive 
neurons were drawn in Fig 3.5. Drawings of coronal sections show the 
distribution of histaminergic neurons bilaterally distributed in DTM, VTM and 
MTM.  
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Fig 3.5 Distribution of EGFP-immunoreactive neurons in the HDC-EGFP knock-in 
mouse. Coronal sections of the whole brain of an HDC-EGFP mouse were stained with 
EGFP antibody. Histaminergic neurons (EGFP-positive cells) were classified into three 
subgroups along the mediolateral axis, beginning with the most rostral and progressing 
caudally (A-D). I mapped the location of each EGFP-positive neuron: their positions are 
illustrated as triangles. The illustration shows these groups as the medial, diffuse and 
ventrolateral tuberomammillary nucleus (MTM, DTM and VTM respectively). EGFP 
immunoreactivity was also in ependymal cells capping the mammillary recess (arrowhead). 
mt, mammillothalamic tract; f, fornix; 3V, 3rd ventricle. DM, dorsomed hypothalamus 
nucleus; VTM, ventral tuberomammillary; MTM, medial tuberomammillary; DTM, diffuse 
tuberomammillary. 
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3.4 Using the Cre-LoxP/Rosa reporter system to map HDC-neurons in the 
adult mouse brain 
 
Dr. T. Goetz in our lab developed HDC-Cre mice so that histaminergic neurons 
could be specifically manipulated (Zecharia et al., 2012) (Fig 3.6). Because the 
GFP knock-in mice were not able to provide visible primary fluorescence, we 
realized that, another method, by using the Cre-LoxP system, might give a 
stronger primary fluorescence. A mouse line was generated before, in which Cre 
was knocked into the histaminergic neurons, similar to the HDC-EGFP knock-
in line, but only containing iresCre after the hdc gene stop code (Zecharia et al., 
2012) (Fig 3.6).  
 
 
 
 
Fig 3.6 Gene targeting strategy to produce the HDC-Cre knock-in mouse line. The IRES-
Cre cassette was placed into exon 12 of the HDC gene, between the stop codon (TAG) and 
the polyadenylation signal. The strategy was identical to that for the HDC-EGFP mice line 
described in Fig 3.2. (T. Goetz; Zecharia et al., 2012) 
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Another mouse line was introduced here, the Rosa26-LoxP-Stop-LoxP-YFP 
mouse line, which has been used to map different group of neurons in brain 
areas before (Zhuang et al., 2004; Rivers et al., 2008). I crossed this mouse line 
with the HDC-Cre mouse line; as a consequence, Cre activation would delete 
the stop sequence, and YFP would be expressed in Cre-containing cells (Fig 
3.7A). Firstly, primary fluorescence was checked in the whole brain sections of 
the offspring (Fig 3.7B). A visible primary fluorescent was seen directly in only 
the TMN area, including VTM, DTM and MTM (Fig 3.7B). To amplify the 
primary YFP signal, GFP antibody was used. With antibody staining, the 
Rosa26-YFP mice provide a high resolution to outline the HDC-neurons’ 
distributions (Fig 3.7C). To further confirm those YFP-positive cells, brain 
sections were double stained with both GFP and HDC antibodies. Fig 3.7D 
shows all the cells with YFP fluorescence are HDC-neurons in VTM.  
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Fig 3.7 HDC-Cre mice crossed with Rosa26-STOP-YFP mice. Fig A shows the ROSA26 
locus carries an insertion of EYFP, preceded by loxP-flanked stop sequences. R26-Stop-YFP 
mice were crossed with HDC-Cre mice, in which Cre excises a loxP-flanked transcriptional 
"stop" sequence. Primary fluorescence is visible directly without antibody staining (B). 
Immunostainning of GFP shows the distribution of GFP-positive cells in VTM, DTM and 
MTM (C). YFP-positive cells were further stained with HDC antobody, which shows all GFP 
cells are HDC-neurons (D). VTM, ventral tuberomammillary; MTM, medial 
tuberomammillary; DTM, diffuse tuberomammillary. Scale bar, B, C, 500 m; D, 50 m 
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The Rosa26-YFP mice have great value for mapping the histaminergic system. 
Low magnification images display the YFP-positive areas of the brain (Fig 3.8); 
however, the YFP-positive areas are restricted to TMN and DLG, while primary 
fluorescence is undetectable in DLG.  
 
 
 
Fig 3.8 Distribution of YFP-positive cells of HDC-Cre/Rosa26-YFP mice. (A) Coronal 
sections of Rosa26-YFP/HDC-Cre mice were incubated with GFP antibody and stained with 
DAPI. Lower magnification of those sections shows that GFP-staining can be found in TMN 
and DLG brain sites, and also a few GFP-expressing cells are distributed randomly in other 
brain areas. GFP-positive cells in TMN were found between section ‘‘a’’ (Bregma -1.58 mm) 
and section ‘‘e’’ (Bregma 3.16 mm).  In the TMN, GFP-positive cells were restricted to the 
medial (MTM), ventral (VTM) and diffuse (DTM) groups and dorsal ependyma. 3V, 3rd 
ventricle; DLG, dorsal lateral geniculate nucleus; D3V, dorsal 3rd   ventricle. Ependyma are 
indicated with arrowhead. Scale bar, 0.5 mm 
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Further looking at the TMN site, higher magnification images clearly show the 
histaminergic neurons scattered at VTM, DTM and MTM (Fig 3.9). Compared 
with the HDC-EGFP knock-in mouse, more HDC populations can be found in 
VTM and DTM in the HDC-Cre/Rosa26-YFP mouse. However, YFP-positive 
cells did not present only in TMN neurons, but in some other brain regions as 
well: DLG thalamic nucleus (Fig 3.10A), cerebellar Purkinje cell layer (Fig 
3.10B, C), SCN (Fig 3.10D), and also a few microglial cells distributed in the 
neocortex (Fig 3.10E).  GFP in the extra TMN neuronal areas might be caused 
by hdc gene expression during development. 
 
Fig 3.9 Distribution of YFP-immunoreactive neurons in the HDC-Cre/Rosa26-YFP 
mouse. Coronal sections of the whole brain of a Rosa26-YFP mouse were stained with GFP 
antibody. YFP-positive cells (histaminergic neurons) were found to localise in VTM, DTM 
and MTM from section ‘‘a’’ (Bregma -1.58 mm) to section ‘‘h’’ (Bregma 3.16 mm). YFP 
immunoreactivity was also in ependymal cells capping the mammillary recess. Some 
microglial cells also show YFP expression in some brain sections, especially in MM. 3V, 3rd 
ventricle; VTM, ventral tuberomammillary; MTM, medial tuberomammillary; DTM, diffuse 
tuberomammillary; MRe, mammillary recess 3V; MM, medial mammillary nucleus. Scale 
bar, 0.2 mm  
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Fig 3.10 YFP expression in other brain regions in HDC-Cre/Rosa26-YFP mice.  Coronal 
sections of the whole brain of HDC-Cre/Rosa26-YFP mice were stained with GFP antibody 
(green) and DAPI (blue). YFP-positive cells can be found in DLG (A), cerebellar Purkinje 
cell layer (B, C), SCN (D) and microglial cells in neocortex (E). DLG, dorsal lateral 
geniculate nucleus; Pur, purkinje cell; SCN, suprachiasmatic nucleus; Ctx, cortex. Scale bars: 
A, B, D, E, 60 m; C, 40 m. 
 
3.5 Identifying fibers in HDC-Cre/Rosa26-YFP mice  
 
The Cre-LoxP system provides a sensitive way to label the histaminergic cells 
in TMN, and another advantage of this method is that it can clearly show the 
projections of HDC-cells in brain regions. Because histamine fibers were shown 
in lots of brain regions before (Panula et al., 1989), we mapped the GFP 
immunoreactivity in whole brain of HDC-Cre/Rosa-YFP mice. GFP-positive 
fibers could be detected in nearly the whole brain, but distributed differently. 
The highest density area was the posterior hypothalamus, including ventral 
tuberomammillary (VTM); medial tuberomammillary (MTM); diffuse 
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tuberomammillary (DTM); medial mammillary nucleus (MM) (Fig 3.9). TMN 
fibers can be seen from posterior hypothalamus to neocortex. Fig 3.11 shows the 
brain regions that have the massive distribution of the fibers: Layer IV and V of 
the visual cortex (A); Layer IV and V of the sensory cortex (A); cingulate cortex 
(A); striatum (B). Beyond those regions, fibers could also be detected in 
primary and secondary motor cortex; ventral tenia tecta; median preoptic 
nucleus (MnPO); ventral median preoptic nucleus (VMPO); ventral lateral 
preoptic nucleus (VLPO); medial preoptic area (MPA); medial preoptic nuclear 
(MPO); magnocell preoptic nucleus (MCPO); lateroanterior hypothalamus 
nucleus (LA); central anterior hypothalamus area (AHC), Hippocampus (Hi).  
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Fig 3.11 Distribution of YFP-positive fibers in different brain regions in HDC-
Cre/Rosa26-YFP mice neocortex and striatum. Coronal sections of the whole brain of 
HDC-Cre/Rosa26-YFP mice were stained with GFP antibody (green) and DAPI (blue). 
Massive number of YFP-fibers were found in layer 4 and 5 of the visual cortex (A), sensory 
cortex (A), cingulate and motor cortex (A), striatum (B). Arrowhead in sensory cortex 
indicates a microglia cell.  Arrowheads in striatum indicate YFP-positive fibers. Scale bars: 
40 m. IV: layer 4 of the cortex; V: layer 5 of the cortex; WM, white matter. 
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3.6 Discussion 
 
3.6.1 Mapping of HDC-neurons with genetic approaches. 
 
TMN neurons and their projections were identified 30 years ago (Panula et al., 
1984; Panula et al., 1989; Inagaki et al., 1988). Most of the approaches used 
traditional histamine immunoreactivity, HDC immunoreactivity and tracer. 
Although these methods can illustrate the cells, the sensitivity is quite limited.  
For example, HDC protein is mainly present in the cytoplasm of TMN neurons, 
so, it is difficult to identify the fibers in other brain regions. Furthermore, the 
HDC antibody can not detect all the histaminergic cells. Our staining results 
show positive HDC signal in VTM area; however, few cells were detected in the 
DTM region, but in fact, there is a large population of HDC cells that distribute 
in the DTM region. For the tracing method, injecting particular dyes into the 
TMN area can clearly show the TMN cells, nevertheless, the cells are not HDC-
neuron specific, because there are other populations in the TMN region in 
addition to histaminergic neurons. In our study, firstly, we used traditional in 
situ hybridization to confirm the hdc mRNA expressions that are restricted to 
TMN region (Zecharia et al., 2012).  Moreover, in order to label the HDC cells, 
we knocked GFP into the hdc gene; we had anticipated that the GFP can provide 
strong primary fluorescence, but when we checked the GFP expression, we 
could not see the primary fluorescence. In the HDC-GFP mouse line, GFP is 
driven by an IRES element, and the translation of the GFP reading frame is not 
efficient enough. Even though, when we used antibody to amplify the GFP 
signal in HDC-GFP mice, we were able to illustrate all the histaminergic cells in 
TMN region, but we still could not label the histaminergic fibers. Instead, we 
used the Cre-LoxP system by crossing the HDC-Cre mose line with a Rosa26-
loxP-Stop-loxP-YFP mouse line (Srinivas et al., 2001). Indeed, the offspring 
show nice primary fluorescent of GFP in only the TMN area, which provides us 
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with a simple way to identify and patch the histaminergic neurons in our future 
electrophysiological experiments. In addition, using GFP antibody, the fibers 
were clearly shown in the whole brain. After sectioning the whole brain, we can 
map the distribution of the histamine fibers within the brain. We obtained the 
useful information about the fibers, in terms of the location and density. The 
most projected regions were shown in Fig 3.11, and we will focus on those brain 
regions in our future experiments. Although the genetic method is sensitive and 
specific, it has drawbacks.  For example, in some brain areas, additional cells 
are also labelled as GFP-positive. In particular the DLG thalamic region, most 
of the cells in there are GFP-positive, and the DLG sends projections to cortex 
V1 region. Although we found dense fibers in V1, the fibers are mixed with 
TMN neurons and V1 cells. Nevertheless, the fibers in other brain regions are 
restricted to TMN projection. The patterns in sensory cortex and motor cortex 
are similar as V1 area, presumably, most of the fibers in V1 are histamine 
projections.  
 
3.6.2 HDC expression during brain development 
 
Our mapping results with the HDC-Cre/Rosa-YFP and also HDC-Cre/ROSA-
lacZ (Zecharia et al., 2012) shows that GFP is not only found in TMN neurons 
but is also present in the DLG, VTM, cerebellar Purkinje cells and randomly 
expressed in some other brain regions. However, the previous traditional 
mapping all show HDC gene expression is confined to the TMN and ependyma, 
and indeed, in adult mice, for neurons, we found hdc mRNA only in TMN. The 
expression of GFP in the genetic mice indicates a probable transient expression 
of hdc gene during the development. We searched the hdc gene expression in 
on-line database, and in Brain Gene Expression Map (BGEM) (unannotated), 
which is a database that uses oligonucleotide probes to detect gene expression in 
embryonic (E11 & E15) and postnatal (P7 & adult) mouse brain (Magdelano et 
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al., 2006), we found an expression of hdc gene in a subset of thalamic nuclei at 
P7, yet not in the adult brain. In addition, the BGEM images from P7 also seem 
to have a weak positive signal in the Purkinje cell layer which was also absent 
in adult. This evidence suggests histamine might be synthesized transiently in 
some brain regions additional to TMN during development. In early 
developmental stages, mast cells are said to be the main source of histamine, but 
in adult mice, there are only a few mast cells in the brain. In my mapping, I 
found lots of GFP-positive microglial cells in the neocortex. A study of those 
cells might be of great interest. Moreover, in addition to thalamus and Purkinje 
cell layer, I found that the suprachiasmatic nucleus was also GFP-positive, 
suggesting the central clock pacemaker in the mice brain are involved in the 
histamine development. This result matches the previous report that SCN 
neurons contain histamine (Michelsen et al., 2005). However, our results with 
GFP mapping contradict the Pannula’s group developmental expression pattern. 
They found hdc mRNA in serotonin neurons (Eriksson et al., 1998), but we do 
not see that. The dorsal raphe is not GFP-positive. In future, the study of 
histaminergic development is of great importance, and our genetic mouse line 
would provide a powerful way to study it.     
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4 Circadian clock factor BMAL1 in histaminergic neurons regulates 
sleep-wake cycle and sleep homeostasis 
 
4.1 Summary 
 
Our previous results demonstrated that an inhibitory GABAergic input onto 
TMN does not affect the natural sleep-wake cycle, and also there might be other 
mechanisms that are involved in the regulation of sleep (Zecharia et al., 2012). 
Considering there are different types of nuclei in the brain, the mechanisms 
could be complex and diverse. However, several lines of evidence showed a 
circadian-like mechanism in histaminergic cells (Mochizuki et al., 1992; Rozov 
et al., 2014) (see Introduction). Indeed, in this chapter, I found circadian clock 
protein BMAL1 is expressed in histaminergic neurons, and the hdc gene 
exhibits a ‘‘circadian’’ expression. We genetically deleted BMAL1 in specific 
histaminergic neurons (HDC-Bmal1); interestingly, the circadian-like 
expression of the hdc gene was disturbed. HDC-Bmal1 mice exhibit several 
behavioural phenotypes: increased locomotor activity; increased wakefulness in 
wake phase; impaired sleep homeostasis. In further experiments, I explored the 
mechanism of regulation between BMAL1 and HDC. 
 
 
4.2 HDC protein has a dynamic expression that varies with time of the day 
 
This study began with a chance observation: immunocytochemical staining for 
HDC protein in TMN neurons of the posterior hypothalamus was visibly 
stronger in animals killed at ZT18 (lights off, the period when the animals are in 
dark period) than ZT6 (lights on, the period when the animals are in light 
period) (Fig 4.1A). Considering histamine as an excitatory neurotransmitter, 
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released during the dark period, our findings make reasonable sense; moreover, 
this daily three fold variation (the relative fluorescence intensity is shown in Fig 
4.1B) in HDC protein level could indicate a clock-like mechanism in 
histaminergic neurons.  
 
 
 
 
 
Fig 4.1 Different expression of HDC in the tuberomamillary nucleus at ZT6 and ZT18. 
Expression of histidine decarboxylase in the mouse tuberomamillary nucleus varies with time 
of day (ZT6 and ZT18). Immunocytochemical staining intensity of neurons with histidine 
decarboxylase (HDC) antibody was significantly higher at ZT18 than ZT6. Boxed regions are 
shown at higher power on the right panels. Scale bars, 40 m. The graph (B) was obtained by 
counting the fluorescence intensity of individual HDC neurons at each time point. The 
relative fluorescence intensity was much higher at ZT18 (n=3 mice; n=18 cells) compared to 
ZT6 (n=3 mice; n=17 cells). Error bars represent SEM. Unpaired two-tailed t-test, p<0.001. 
 
4.3 Histaminergic neurons are positive for the circadian marker: BMAL1 
 
As one of the circadian master molecular drivers, BMAL1, was identified to be 
widely expressed throughout the brain (Mieda et al., 2011), and its expression in 
different brain areas was further confirmed by myself. Fig 4.2 shows BMAL1 
77 
 
expressed in central clock pacemaker SCN, cortex, hippocampus and 
hypothalamus, but distributed differently. For example, many neurons in layer 
II, layer III and layer IV of the neocortex contain nuclear BMAL1 (Fig 4.2B); 
similarly, the dentate gyrus in hippocampus (Fig 4.2C), VTM and DTM areas of 
hypothalamus (Fig 4.2D). See also Fig 4.5 for expression of BMAL1 in 
thalamus, lateral medial hypothalamic area and cerebellum purkinje cells and 
granule cells. Although BMAL1 is widely located, its expression in the 
histaminergic cells has never been investigated. Experiment using double-
staining revealed that all histaminergic neurons in the TMN were positive for 
BMAL1 at both ZT6 and ZT18 (Fig 4.3A). HDC expression was much higher at 
ZT18, as we showed before (Fig 4.1), and the expression of BMAL1 displayed 
no difference between ZT6 and ZT18 (Fig 4.3A). Higher magnification images 
showed the BMAL1 staining (green) was present in both the cytoplasm and the 
nucleus of HDC-positive neurons (red) (Fig 4.3B). To test the specificity of the 
BMAL1 antibody, SCN brain sections from BMAL1+/+ or BMAL1-/- mice 
(loxBmal1 x Nestin-Cre) were incubated with the BMAL1 antisera. BMAL1 
was detected in control mouse SCN cells but not in BMAL1-/- sections (data 
not shown). 
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Fig 4.2 BMAL1-positive cells are found in most brain areas. Immunocytochemistry using 
BMAL1 antibody shows BMAL1 expressed in the SCN (A), neocortex (B), hippocampus 
(C), and tuberomammillary nucleus (D). I: layer I; II: layer II; IV: layer IV; VTM: ventral 
tuberomammillary nucleus; DTM: diffuse tuberomammillary nucleus. Scale bars, 0.5 mm. 
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Fig 4.3 Histaminergic neurons are positive for BMAL1. In the most tuberomamillary area, 
identified by immunocytochemistry with HDC and BMAL1 antibodies, HDC-neurons (red) 
are positive for BMAL1 (green) at both ZT6 and ZT18. HDC expression was much higher at 
ZT18 (A). (B) Higher magnification shows BMAL1 (green) present in both nucleus (stained 
with DAPI, blue) and cytoplasm of the HDC-neurons (red). Scale bar, 40 m.  
 
4.4 Immnocytochemical characterization of HDC-Bmal1 mice 
 
To investigate if circadian rhythms in specific HDC-neurons affect neuronal 
function, an HDC-neuron-specific BMAL1 knock-out mouse line (HDC-
Bmal1) was generated by crossing the HDC-Cre mice (Zecharia et al., 2012) 
with mice containing a floxed Bmal1 gene (Storch et al., 2007) (Fig 4.4A). To 
check the knock out efficiency, immunostaining against BMAL1 was performed 
using both HDC-Bmal1 mice (homozygotes with Cre) and littermate controls 
(hemozygotes with Cre or homozygotes without Cre). Fig 4.4B shows BMAL1 
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is expressed in the HDC-neurons in control mice; by contrast, in HDC-Bmal1 
mice, there is loss of BMAL1 signal in HDC-neurons (Fig 4.4C), which 
confirms BMAL1 was removed in HDC-neurons in the knock outs. Because the 
hdc gene is transiently expressed in some other brain areas, like SCN, DLG, 
VMH and cerebellum (Zecharia et al., 2012), BMAL1 expression was also 
assessed in these brain sites. Fig 4.5 shows BMAL1 exist in the DLG (A), VMH 
(B) and cerebellum (C) in both control and knock out animals. Because YFP 
was positive in SCN in HDC-Cre/Rosa-YFP mice (Fig 4.6A), so, to examine 
whether deletion of BMAL1 affects the circadian clock protein expression in the 
central clock pacemaker SCN, BMAL1 and PER2 expression were assessed in 
SCN at ZT6 and ZT18. No differences were observed in either BMAL1 or 
PER2 expression between the controls and the knock outs (Fig 4.6B); notably, 
PER2 expression shows a remarkable increase at ZT18 in both control 
littermates and HDC-Bmal1 mice (Fig 4.6C). This result reveals that removing 
BMAL1 in HDC-neurons does not affect circadian protein expression in SCN. 
Indeed, HDC-Bmal1 mice had a normal circadian rhythm (Fig 4.6D, E). 
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Fig 4.4 Generation and immunocytochemical characterization of HDC-Bmal1 mice. To 
produce HDC-Bmal1 mice, HDC-Cre mice were crossed with BMAL1-flox mice, in which 
two loxP sites were flanked between exon that encodes the basic helix-loop-helix domain 
(Storch et al., 2007) (A). Offspring were characterized using immunocytochemistry to stain 
HDC and BMAL1 in brain sections. BMAL1 (green) stained positive in HDC-cells (red) in 
control mice (homozygous or heterozygous with out Cre) (B); however, BMAL1 does not 
exist in HDC-cells in HDC-Bmal1 mice (C). Scale bars, 40 m. 
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Fig 4.5 No loss of BMAL1 in dorsal lateral geniculate (DLG), ventral medial 
hypothalamus (VMH) and cerebellum of HDC-Bmal1 mice. Brain sections were stained 
with BMAL1 and DAPI. In DLG (A), VMH (B) and cerebellum (C), BMAL1 stained the 
same pattern in HDC-Bmal1 mouse compared to the control mouse. There was no loss of 
BMAL1 in those areas in HDC-Bmal1 mice and BMAL1 located in the nucleus of the cells 
in both control and HDC-Bmal1 mice. Higher magnification images of the boxed areas 
were shown in the bottom panels. DLG: dorsal lateral geniculate nucleus; VMH: ventral 
tuberomammillary nucleus. Scale bar, 0.5 mm (upper panel); 40 m (lower panel). 
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Fig 4.6 BMAL1 and PER2 staining was unchanged in SCN of control and HDC-Bmal1 
mice. (A) Brain section stained with GFP showed that SCN were GFP-positive in HDC-
Cre/Rosa-YFP mice. Brain sections of SCN were stained with BMAL1 and DAPI (B) or 
PER2 and DAPI (C). BMAL1 or PER2 staining shows the same pattern in SCN in control 
and HDC-Bmal1 mouse at ZT6 or ZT18: the number of BMAL1 or PER2-positive cells 
stains the same; BMAL1 or PER2, are located in the nucleus of the cells, as merged with 
DAPI (B, C). There was no significant change of BMAL1 expression in either control or 
HDC-Bmal1 mice at ZT6 compared with ZT18 (B).  However, PER2 stained much stronger 
at ZT18 compared with ZT6 in both control and HDC-Bmal1 mice (C). Higher 
magnification images of the boxed areas are shown in the bottom panels. Scale bar, 0.5 mm 
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(up panel of A and B); 20 m (bottom panel of A and B). (D) Representative wheel-running 
actograms from Bmal1 lox/lox mice and HDC-Bmal1 mice. Mice were initially entrained to 
12h white light, 12h dim red light (LD) and then transferred to continuous dim red light 
(DD). (E) HDC-Bmal1 mice (n=4) and littermate controls (n=4) did not have differing 
circadian periods. Error bars represent SEM. Unpaired two-tailed t-test, p>0.05. 
 
 
4.5 HDC-Bmal1 mouse present normal histaminergic cell morphology 
 
To assess whether loss of BMAL1 in HDC-neurons affected neuronal number 
and morphology, histaminergic cell populations were examined in control 
littermates and HDC-Bmal1 mice. First, from Nissl staining that outlines the 
TMN area in brain sections in both control and knock-out mice, there was no 
difference of overall cell numbers in TMN area between two genotypes (Fig 
4.7). In order to get better visualization of HDC-neurons, HDC-Cre mice were 
crossed with Rosa26-Stop-YFP mice (see Chapter 3), in which YFP could be 
turned on in HDC-neurons in triallelic mice: heterozygous HDC-Cre, lox/lox 
Bmal1 homozygous, Rosa26 heterozygous. YFP staining reveals that 
histaminergic neurons in HDC-Bmal1 mice were present in normal numbers 
and their crude morphology did not differ from littermate control mice (Fig 
4 .7C, D). 
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Fig 4.7 HDC-Bmal1 mouse present normal crude histaminergic cell morphology. Nissl 
staining shows the distribution of HDC-cells in TMN area in control (A) and HDC-Bmal1 
mouse (B). Higher magnification images of the boxed area reveal HDC-Bmal1 mouse (B) 
had similar neuronal distribution and neuronal number compared to the control mouse (A). 
(C, D) HDC-Cre mice were crossed with ROSA26-STOP-YFP mice to generate mouse 
carrying YFP in HDC-neurons. YFP staining displays that HDC-Bmal1 mouse (D) had the 
same crude morphology in VTM and DTM compared with the control mouse (C). VTM: 
ventral tuberomammillary; DTM: diffuse tuberomammillary. Scale bars, A, 0.5 mm; C, 40 
m. 
 
 
4.6 Histaminergic cells in HDC-Bmal1 mice have normal histaminergic 
cell electrical parameters  
 
The above data showed that deleting BMAL1 in HDC-neurons did not affect 
cell crude morphology; however, it might influence the electrophysiological 
properties of those cells. To see whether the intrinsic excitability of HDC-
containing neurons was related to time of day (LD) or Bmal1 expression, Dr. 
Anna Zecharia made whole-cell current clamp recordings from HDC neurons in 
acute TMN slices from littermate and HDC-Bmal1 mice in both the sleep (L) 
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period and the active (D) period. Resting membrane potential, input 
conductance and the membrane time constant were not affected by time of day 
or the absence of BMAL1 (table 4.1).  
 
 
 
Table 4.1 Whole cell current-clamp recordings of VTM histaminergic neurons from 
littermate control and HDC-Bmal1 mice in acute brain slices taken from animals in 
the sleep (light) period and the active (dark) period. Measures of excitability (membrane 
potential, input conductance and the membrane time constant) were unaffected by either time 
of day or absence of BMAL1. ± represent SEM. One-way ANOVA and post hoc Bonferroni, 
p>0.05. (Data kindly provided by Dr. Anna Zecharia). 
 
 
4.7 Deletion of BMAL1 in HDC-neurons disrupted hdc and circadian gene 
expression 
 
We examined by Q-PCR how levels of transcripts encoding BMAL1, CRY1 and 
PER1 and HDC varied over the 24 hour in the posterior hypothalamus (TMN 
punch), and if these levels were altered in HDC-Bmal1 mice. In littermate 
control mice, BMAL1 transcript levels in the TMN punch had a weak rhythm, 
with levels peaking at around ZT0. In HDC-Bmal1 mice, BMAL1 expression 
was still detectable, but the LD rhythm was flattened (Fig 4.8). Presumably, 
BMAL1 transcripts still remain in the posterior hypothalamus of HDC-Bmal1 
mice as the HDC-positive cells contribute only a certain percentage to the total 
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number of cells in the posterior hypothalamus, and the Bmal1 gene seems 
widely expressed in many neuronal cell types (Fig 4.2). In littermate control 
mice, Per1 and Cry1 mRNA levels peaked around the beginning of “lights off”; 
In HDC-Bmal1 mice, the LD rhythm was flattened. In agreement with the 
immunocytochemical data (Fig 4.1), Hdc gene expression in the posterior 
hypothalamus also varied over the LD period. In littermate control mice, there 
was a two-fold variation in HDC transcript levels: Hdc mRNA was highest at 
the start of “lights off”, declined during the “lights off” period and increased 
during the “lights on” period.  In HDC-Bmal1 mice, this rhythm was 
disrupted, with reduced amplitude and advanced phase peaking at ZT08, and 
with hdc transcript levels overall higher, compared with littermate controls (Fig 
4.8). However, the gene (hnmt) that encodes enzyme which degrades histamine 
was unchanged. 
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Fig 4.8 Circadian gene and hdc expression in control (n=6) and HDC-Bmal1 mice 
(n=6). Q-PCR analysis shows on RNA from TMN punches reveals that transcripts encoding 
Bmal1, Per1, Cry1 and Hdc vary with time of day; in knockout mice (red traces), these 
rhythms are either flattened (Bmal1, Per1 and Cry1) and/or have elevated transcript levels 
(Per1, Cry1, Hdc) at some time points of the day; Histamine N-methyltransferase (Hnmt) 
transcript levels were unchanged from littermate controls. Two-way ANOVA and post hoc 
Bonferroni, *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
4.8 Circadian proteins can regulate hdc gene promoter activity in vitro 
 
Is there a direct regulation of hdc gene expression by BMAL1? The mouse 
HDC gene contains an E-box (BMAL1 and CLOCK binding site) element in the 
5’ region. We tested the functional significance of the E-box element with HDC 
gene promoter-luciferase reporter constructs (Fig 4.9A), and transient 
expression assays in an HEK cell line. BMAL1 and CLOCK protein could 
increase HDC-luciferase activity in a dose-dependent manner (Fig 4.9B), but 
not when the E-box was mutated (Fig. 4.9B). This was actually the opposite 
result of what happens in vivo, when HDC transcript levels increase after 
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BMAL1 deletion, so it is likely that a repressor complex could be recruited by 
BMAL1 in histaminergic neurons. However, given that cry and per gene 
expression increases in HDC-Bmal1 mice (Fig 4.8), we tested how CRY and 
PER regulate the HDC promoter as well. CRY stimulated HDC-luciferase 
activity and even without BMAL1 and CLOCK in transiently transfected HEK 
cells (Fig 4.9C), and even when the E box was mutated (Fig 4.9C). However, 
transfecting PER2 expression plasmids had no effect on HDC-luciferase activity 
in both WT and E-box mutation HDC-luciferase constructs (Fig 4.9D). Given 
CRY and PER are repressors, we then co-transfected BMAL1, CLOCK, PER or 
(and) CRY. BMAL1, CLOCK and CRY are able to co-active HDC-luciferase 
activity (Fig 4.9E), whereas, PER can suppress BMAL1 and CLOCK’s 
activation (Fig 4.9E); notably, by adding CRY into the BMAL1, CLOCK and 
PER mixture (Fig 4.9E), CRY can finally restore PER’s suppression (Fig 4.9E).   
So, based on this result in cell lines, it could be that the elevated CRY 
expression in HDC-Bmal1 mice drives increased HDC expression, directly or 
indirectly. This clearly points to a complex situation in vivo. 
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Fig 4.9 Circadian protein can regulate hdc promoter activity. (A) Two luciferase 
constructs were generated: HDC-wt: HDC promoter with a normal E-box (CACGTG) cloned 
into pGL3-basic luciferase plasmid; HDC-mt: HDC promoter with mutant E-box (CACCTG) 
cloned into PGL3-basic luciferase plasmid. (B) BMAL1 and CLOCK component can dosely 
activate HDC promoter activity; however an E-box mutation abolished this activation. (C) 
CRY1 alone can significantly activate HDC promoter in a dose-dependent manner, even 
without a functional E-box. (D) Low dose of PER2 did not affect HDC promoter activity, 
where a high dose of PER2 slightly increased HDC promoter activity, in HDC-mt luciferase 
constructs, both low and high dose of PER2 had no effect on its activity. (E) BMAL1, 
CLOCK and CRY1 can co-activate HDC promoter activity; PER2 can supress BMAL1 and 
CLOCK’s activation of the HDC promoter. High dose of CRY remarkably attenuated PER2’s 
repression. Error bars represent SEM. One-way ANOVA and post hoc Bonferroni, *p<0.05, 
**p<0.01, ***p<0.001. 
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4.9 Behavioural analysis of HDC-Bmal1 mice: Deletion of BMAL1 in 
HDC-neurons increases locomotor activity 
 
We examined the behaviour of the HDC-Bmal1 mice and littermate controls 
using non-tethered EEG recordings with or without Neurologgers in an open 
field (Fig 4.10). During a 30 minute recording segment in the “lights off” period 
(dark period), HDC-Bmal1 mice travelled significantly further (Fig 4.10A) 
and at significantly higher speeds (Fig 4.10B) than littermate controls.  The 
power spectrum of the EEG in these awake HDC-Bmal1 animals was strongly 
enriched in the theta frequency range (peak at 9 Hz) compared with littermate 
controls (peak at 8 Hz) (Fig 4.10C, D), correlating with the increased activity of 
HDC-Bmal1 knockout mice. Looking at how this frequency changed over 30 s 
intervals of wake, Morlet wavelet analysis shows that in HDC-Bmal1 mice, 
the 8 Hz theta power was strong, persistent and sustained (Fig 4.10D), whereas 
in littermate controls there was weaker theta and flickering in and out of the 
theta band frequency.   
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Fig 4.10 HDC-Bmal1 mice had higher locomotion activity. (A, B) HDC-Bmal1 mice 
(n=10) (red trace) travel further (A) and faster (B) than littermate control mice (n=10) in a 30 
minute period when placed in the activity monitor. (C) EEG power spectra of mice that 
travelled in 30 minute period; HDC-Bmal1 mice had much higher theta power; (D) The 30 
second Morlet wavelet power spectrum taken from 30 minutes travelling showed in HDC-
Bmal1 mice, there was a persistent but elevated theta frequency compared with littermate 
controls. Error bars represent SEM. Two-way ANOVA and post hoc Bonferroni, *p<0.05.  
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4.10 HDC-Bmal1 mice have disturbed sleep-wake patterns 
 
To investigate the natural sleep behaviour of HDC-Bmal1 mice, Neurologgers 
were attached to those mice to record the 24 hours EEG and EMG signals. At 
the start of lights off, and for the first three hours of dark period, HDC-Bmal1 
mice were strikingly and significantly more active as enhanced by EMG activity 
and theta frequency than littermate controls (Fig 4.11A), although as the 12 hour 
lights off period progressed, the activity of the mice became similar to littermate 
controls (Fig 4.11A). The total wake time, however, of HDC-Bmal1 mice 
averaged over 24 hours was unchanged (Fig 4.11B), but averaged the whole 
‘‘light off’’ period they spent slightly more time awake than littermate control 
mice and slightly less time awake during the “lights on” rest period (Fig 4.11A). 
When the HDC-Bmal1 mice were awake, the theta range of frequencies in the 
EEG, averaged over the full 24 hour period, was significantly enhanced (Fig 
4.11C), but the lower frequencies ranging from 2 to 4 Hz, were remarkably 
diminished. Over the entire 24 hour period the amount and intensity of NREM 
sleep was similar between HDC-Bmal1 and control mice (Fig 4.11D, E); 
however, there was a decrease of NREM delta power in HDC-Bmal1 mice 
(Fig 4.11F), suggesting the sleep quality was poorer in HDC-Bmal mice; the 
amount of REM sleep in HDC-Bmal1 mice compared with littermate controls 
was slightly higher in the lights-on “light period’’ (Fig 4.11G, H), and averaged 
over the 24 hour period, HDC-Bmal1 mice had significantly deeper REM 
sleep (theta range of frequencies) as measured by power (Fig 4.11I). 
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Fig 4.11 24 hour natural sleep-wake cycle of control (n=10) and HDC-Bmal1 mice 
(n=12). (A, D, G) show the percentages of wake (A), NREM (D) or REM (G) during the 24 
hours at each 1 hour interval. (B, E, H), illustrate the time of wake (B), NREM (E) or REM 
(H) at light period, dark period or total 24 hours. (C, F, I) show the EEG wake (C), NREM 
(F) or REM (I) power across the entire 24 hours. HDC-Bmal1 mice were more active than 
littermate controls at the start of lights off (dark period) (A), and less active during lights on 
(light period) (A, B). HDC-Bmal1 mice spent less time in wake during light period, but 
spent more time in REM sleep,  but their total wake, NREM or REM time was unaffected (B, 
E, H). (C) EEG wake power during the 24 hours, HDC-Bmal1 mice had more theta power 
which peaks at 8 Hz, but less delta power compared with the control littermates. (F) shows 
the NREM power during the 24 hours, HDC-Bmal1 mice had a reduced delta power 
peaking at 4 Hz. (I), REM power during the 24 hours shows that HDC-Bmal1 mice had an 
increase of REM theta power peaking at 8 Hz. Error bars represent SEM. (B, E, H) Unpaired 
two-tailed t-test, *p<0.05. (C, F, I) Two-way ANOVA and post hoc Bonferroni, *p<0.05. 
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4.11 Deletion of BMAL1 in HDC-neurons increases sleep fragmentation  
 
I next looked more closely at the sleep-wake architecture of the HDC-Bmal1 
mice. Selective Bmal1 deletion from histaminergic neurons caused the natural 
sleep pattern to become more fragmented in the lights on “light period” (Fig 
4.12). HDC-Bmal1 mice had significantly more NREM sleep episode numbers 
compared with littermate control mice (Fig 4.12A), although the length of each 
NREM episode was significantly shorter (Fig 4.12C, E). During the lights off 
“dark period”, the number of NREM sleep episodes did not differ, but their 
duration was shorter in HDC-Bmal1 mice, especially during the first four 
hours, following on from the difference in the “lights on” period (Fig 4.12C). 
Furthermore, the number of REM sleep episodes was elevated in HDC-Bmal1 
mice in the lights on period (Fig 4.12B), but this difference was not as large as 
that seen for the NREM episodes (Fig 4.12A). REM episode duration did not 
differ between genotypes, except at the start of lights off, where again the 
duration was significantly shorter in the HDC-Bmal1 mice (Fig 4.12D, F). 
Morlet wavelet power spectra (Fig 4.12G, H) show representative examples of 
the two genotypes, where a continuous 400 seconds delta oscillation could be 
seen in the control mice (Fig 4.12G); however, in the knock-out mice, the delta 
oscillation was fragmented, lasting only about 100 seconds (Fig 4.12H). I found 
that HDC-Bmal1 mice had many more NREM to REM and REM to NREM 
transitions (about double for each type of transition compared with littermate 
controls) (Fig 4.12I, J) during the lights on “light period”. This phenotypic 
difference was specific for the lights on light period (Fig 4.12I); during the dark 
period, there was no significant difference between genotypes in the number of 
NREM to REM transitions (Fig 4.12J), but there were more transitions between 
NREM and wake in HDC-Bmal1 mice (Fig 4.12J). 
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Fig 4.12 HDC-Bmal1 mice have more fragmented sleep. (A, B) Episode numbers of 
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control littermates (n=10) and HDC-Bmal1 mice (n=12) during the 24 hours natural sleep. 
HDC-Bmal1 mice had much more NREM (A) and REM (B) episode numbers during 
“lights on”, but less episode numbers at the first 5 hours after “lights off”. (C, D) Episode 
duration of control littermates and HDC-Bmal1 mice during the 24 hours natural sleep-
wake cycle. HDC-Bmal1 mice had shorter NREM episode duration during the entire 24 
hours; There was no difference of REM episode duration during “lights on”, however, the 
REM episode duration of HDC-Bmal1 mice was shortened during “lights off”. (E, F) shows 
the NREM and REM episode duration in light period, dark period and total 24 hours. The 
NREM episode duration significantly decreased in the light period, dark period and total 24 
hours. No changes of REM episode duration were found in the light period, dark period or 
total 24 hours. (G, H) show wavelet transforms of a 10 minute segment of sleep; control 
littermate shows a continuous 400 seconds NREM wavelet (G), while the NREM wavelet in 
HDC-Bmal1 mice was fragmented (H). (I, J) number of transitions between wake (W), 
NREM (NR) and REM (R) sleep in the ‘‘lights on’’ light period and “lights off” dark period. 
Significant differences are shown with red arrows. HDC-BMAL1 mice had significantly 
more NREM to REM transitions than littermate control mice during the “lights on” light 
period (I), and had significantly fewer wake to NREM transitions in the active “lights off” 
period (J). Error bars represent SEM. Unpaired two-tailed t-test, *p<0.05. 
 
 
4.12 HDC-Bmal1 mice have strongly reduced recovery sleep after sleep 
deprivation 
 
Sleep deprivation (SD) experiments were performed to investigate if deletion of 
BMAL1 in HDC-neurons affects sleep homeostasis in recovery sleep (RS). 
Control littermates and HDC-Bmal1 mice were sleep deprived for 5 hours 
using novel objects (see method) and they were put back into their home cages 
to recover.  Fig 4.13A and B illustrate the trace of EEG, EMG and epochs 
during sleep deprivation experiments in both control and HDC-Bmal1 mice. 
During the 5 hour sleep deprivation, there was a strong EMG signal and EEG 
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signal with low magnitude but high frequency EEG in both genotypes; whereas 
in the recovery sleep stage, both control and HDC-Bmal1 mice presented a 
very low EMG signal but a high magnitude EEG signal with low frequency 
(NREM, 4 Hz). Fig 4.13C and D show the percentage of NREM sleep during 
the 5 hour sleep deprivation and following with 13 hours recovery sleep. 
Compared with the baseline NREM sleep (normal sleep-wake cycle), during 
sleep deprivation, there was a significant reduction of NREM sleep in both 
control and HDC-Bmal1 mice, while during recovery sleep, both control and 
HDC-Bmal1 mice exhibited a strong rebound in the first 5 hours, then, the 
HDC-Bmal1 mice quickly fall back to the baseline level; however, the control 
mice still maintained NREM rebound and gradually reached the baseline level 
after 13 hours. The REM profile in Fig4.13E and F shows that there were no 
REM sleep during 5 hours sleep deprivation in either genotype, however, during 
recovery sleep, both control and HDC-Bmal1 mice gained a REM rebound, 
which lasted for about 4 hours. Looking at the total time of NREM sleep or 
REM sleep in sleep deprivation (SD) and recovery sleep (RS), HDC-Bmal1 
mice had a significant increase in NREM and REM loss during 5 hours sleep 
deprivation, but the NREM gain during recovery sleep was remarkably reduced 
in the HDC-Bmal1 mice, whereas there was no difference of REM gain 
between the two genotypes. Using the criteria of length of NREM sleep and 
delta power, HDC-Bmal1 mice recovered from 5 hours sleep deprivation 
about 6 hours more quickly than sleep-deprived control littermates (Fig 4.14 
and 4.15). The episode duration was longer in recovery sleep in control 
littermates (Fig 4.14) and average 1 to 4 Hz EEG delta power rebound in 
control mice lasted about 10 hours; however, the rebound of delta power only 
existed for 3 hours in HDC-Bmal1 mice (Fig 4.15A, B). The EEG profiles 
between the genotypes were quite different during sleep deprivation (Fig 
4.15C): littermate control mice had a broad range of frequencies in the low delta 
99 
 
to theta range (2-10 Hz), with two peaks at 2 and 8 Hz, but the HDC-Baml1 
mice had a single broad peak of enhanced power relative to controls, centred in 
the theta range (Fig 4.15C). This prominent single peak during sleep deprivation 
was similar to that seen when HDC-Bmal1 mice are normally awake (Fig 
4.11C). During the recovery light period, not only did the HDC-Bmal1 sleep 
substantially less, but their overall NREM delta power in the EEG was reduced 
and shifted up to higher frequencies. 
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Fig 4.13 HDC-Bmal1 mice had reduced rebound sleep after sleep deprivation. Mice 
were sleep deprived (SD) for 5 hours, and then allowed to take a recovery sleep in their home 
cage. The upper panels (A and B) show the EEG, EMG and sleep score (blue, wake; green, 
NREM; red, doubt) of control littermate (left) and HDC-Bmal1 mouse (right). (C, D) After 
5 hours of SD during the lights on (natural light period), littermate control mice (n=5) had 
sustained bouts of recovery sleep (NREM sleep) lasting almost 12 hours; in contrast, after 5 
hours SD, HDC-Bmal1 mice (n=5), the recovery sleep time of the mice was strongly 
reduced. (E, F) After 5 hours of SD during the lights on (natural light period), littermate 
control and HDC-Bmal1 mice had remarkable reductions of REM sleep; after 5 hours SD, 
both littermate control and HDC-BMAL1 mice had the recovery REM sleep. (G) Total time 
of NREM or REM sleep loss during 5 hours sleep deprivation and NREM or REM sleep gain 
during 13 hours recovery sleep. HDC-Bmal1 mice had more NREM and REM loss 
compared with the littermate controls, but had significant less NREM gain in recovery sleep. 
Error bars represent SEM. Unpaired two-tailed t-test, *p<0.05 
 
 
 
 
Fig 4.14 HDC-Bmal1 mice had shorter NREM episode duration in recovery sleep. 
Episode duration in recovery sleep of control littermates and HDC-Bmal1 mice. The overall 
NREM episode duration during the 13 hours recovery sleep was reduced in HDC-Bmal1 
mice (n=5) compared with the littermate controls (n=5), especially at ZT11 and ZT13, which 
showed significant difference. Error bars represent SEM. Unpaired two-tailed t-test, *p<0.05 
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Fig 4.15 HDC-Bmal1 mice had less delta power during recovery sleep. (A, B) show 
average delta (1-4 Hz) power of control littermates (n=5) (A) and HDC-Bmal1 mice (n=5) 
(B) during 18 hours natural sleep (baseline) or 5 hours sleep deprivation and 13 hours 
recovery sleep. Five hours sleep deprivation remarkably reduced delta power in control 
littermates and HDC-Bmal1 mice. The recovery sleep drove the delta power up, which lasts 
for about 11 hours in control mice; however, the delta rebound only existed 4 hours in HDC-
Bmal1 mice. (C) shows the total wake power during the 5 hour sleep deprivation. Control 
mice had two peaks at 2 Hz and 8 Hz; the HDC-Bmal1 mice had more theta power peaking 
at 8 Hz than the control littermates. (D) shows the total NREM power during the recovery 
sleep, control littermates had 2-4 Hz NREM power, but NREM power of HDC-Bmal1 mice 
was shifted to higher frequencies. Error bars represent SEM. 
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4.13 HDC expression is reversibly elevated by sleep deprivation in normal 
mice but remains constantly higher in HDC-Bmal1 mice 
 
We examined HDC expression in TMN histaminergic neurons by 
immunocytochemistry at the end of the sleep deprivation period (ZT5, five 
hours of sleep deprivation). At the end of the sleep deprivation period, HDC 
expression was strong in both littermate controls and HDC-Bmal1 mice (Fig 
4.16A, B). However, at four hours into the recovery light period, HDC 
expression had decreased (roughly halved) to typical ZT6 levels (Fig 4.16A, B; 
see also Fig 4.1). However, in HDC-Bmal1 mice, HDC expression remained at 
the same elevated level as during sleep deprivation (Fig 4.16A, B). 
 
 
 
 
Fig 4.16 HDC expression during sleep deprivation and recovery sleep in control and 
HDC-Bmal1 mice. (A) shows HDC expression at the end of SD (ZT5) and recovered for 4 
hours (ZT9) in control littermate and HDC-Bmal1 mice. Both genotypes had high HDC 
expression at the end of the sleep deprivation. After sleep recovery for 4 hours, the HDC 
expression of control mice was remarkably reduced, closing to the ZT6 baseline level (Fig 
4.1). HDC-Bmal1 mice still maintained a high level of expression of HDC. Scale bar: 50 
m. Relative fluorescence intensity is shown in Fig B; each dot represents an HDC-positive 
neuron. Error bars represent SEM. One-way ANOVA and post hoc Bonferroni, *** p<0.001. 
104 
 
4.14 HDC-Bmal1 mice have impaired working memory after sleep 
deprivation and recovery sleep. 
 
The depletion of recovery sleep after sleep deprivation in HDC-Bmal1 mice 
gave us the opportunity to see if this affected a cognitive memory task: novel 
object recognition. This task is sensitive to sleep deprivation in normal mice 
(Palchykova et al., 2006). We performed novel object recognition under normal 
sleep-wake cycle or after sleep deprivation and recovery sleep using control 
littermates and HDC-Bmal1 mice (Fig 4.17A). All the mice were trained for 
10 minutes in the open field with the same objects, 1 and 2 and both control 
littermates and HDC-Bmal1 mice spent the same time exploring the objects 
(Fig 4.17B). In normal sleep-wake cycle conditions, control littermates and 
HDC-Bmal1 mice had the same performance of novel object recognition (Fig 
4.17C). However, in control littermates, SD+RS impaired the performance of 
novel object recognition (Fig 4.17C); strikingly, HDC-Bmal1 mice had an 
even worse performance of novel object recognition compared with the control 
littermates (Fig 4.17C). This result reveals that: SD can impair working memory 
even if there is a recovery sleep; HDC-Bmal1 mice had much less sleep 
rebound than the control littermates (Fig 4.13), which consequently may have 
damaged the ability of recognition.  
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Fig 4.17 HDC-Bmal1 mice have impaired performance of novel object recognition. 
Diagram A shows the novel object recognition experiment which were performed under 
normal sleep-wake cycle or SD+RS conditions. Control littermates and HDC-Bmal1 mice 
were trained for 10 minutes to explore the same object (1 and 2), and then the mice were 
under condition of 22 hours normal sleep or 5 hours sleep deprivation (SD) and 17 hours 
recovery sleep (RS), after that, object 1 were changed with a new object: 3, and the mice 
were tested for 10 minutes. In the 10 minutes training experiment, control littermates and 
HDC-Bmal1 mice spent the same time to explore the objects (B). In the test experiment, 
both two genotypes spent significant more time to explore the novel object (object 3) under 
normal sleep-wake cycle conditions, however, control and HDC-Bmal1 mice spent the same 
time to explore the object 2 and 3 after SD and RS. (C) Percentage of novel object 
performance shows that both control littermates and HDC-Bmal1 mice performed worse 
after SD+RS compared to the normal sleep-wake, nevertheless, but HDC-Bmal1 mice had 
much less performance than the control littermates. Error bars represent SEM. One-way 
ANOVA and post hoc Bonferroni, *p<0.05, **p<0.01, ***p<0.001. 
 
 
4.15 Deletion of BMAL1 from the Locus coeruleus (LC) did not affect the 
sleep-wake cycle 
 
Beyond histaminergic neurons, there are various other neurotransmitter systems 
that regulate the sleep-wake cycle. I found that BMAL1 in histaminergic 
neurons can affect sleep-wake cycle and sleep homeostasis, yet we do not know 
whether this effect is unique or tissue-specific. So, another neurotransmitter 
system was chosen to investigate whether circadian clock factors can affect the 
sleep-wake cycle. A brain site, the locus coeruleus, which releases an excitatory 
neurotransmitter, noradrenaline, is located bilaterally at the lower edge of the 4th 
ventricle of the cerebellum. Adeno-associated virus expressing Cre was used to 
deliver exogenous Cre into the LC of Bmal1 lox/lox mice to knock out BMAL1 
(LC-Bmal1). Fig 4.18A shows AAV-iCre-2A-Venus was bilaterally injected 
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into the LC. Fig 4.18B shows GFP (Venus is a variant of GFP) expression in 
tyrosine hydroxylase-positive cells, indicating that virus carrying Cre was 
expressed in the LC. By slicing the brain and mapping, most of the LC area was 
infected by virus; however, given that the promoter in the AAV is not tissue-
specific, there were some GFP-positive cells that beyond the LC, but the 
number was quite limited: about 5 to 10 cells. To check the knock out efficiency 
of Bmal1 in those injected animals, I used qRT-PCR to detect the Bmal1 mRNA 
level in LC tissue punches in both virus-injected wild-type and virus-injected 
homozygotes mice (Bmal1 lox/lox). Bmal1 mRNA levels were decreased to 
approximately one third in Bmal1 lox/lox mice with Cre virus injection 
compared to the virus injected control group, which indicates that virus-
mediated Cre expression effectively knocked out BMAL1 in the LC (Fig 
4.18C). Next, we assessed the behaviour of those mice. Locomotion 
experiments were used to test their activity in an open field. There was no 
difference in distance travelled or travelling speed between two groups, 
indicating that removal of BMAL1 in LC did not affect the locomotion activity 
(Fig 4.18D).  
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Fig 4.18 LC-Bmal1: Deletion of BMAL1 in locus coeruleus. (A) AAV-Cre-2A-Venus 
was bilaterally delivered into the locus coeruleus of BMAL1 lox/lox mice. (B) shows GFP 
expression (green) cells in locus coeruleus and co-localized with tyrosine hydroxylase-
positive cells (red). Scale bar: 40 m. (C) Q-PCR assay to assess the Bmal1 mRNA level in 
LC punches in AAV-Cre injected wild type mice (n=4) and AAV-Cre injected lox mice (n=4). 
The Bmal1 mRNA level significantly decreased in virus-injected lox/lox mice. (D) 
Locomotor activity of virus injected control (AAV-Cre wt) and virus injected flox (AAV-Cre 
lox/lox) mice. There was no difference in distance travelled in an open field for 30 minutes 
between control and LC-Bmal1 mice. ITR, inverted terminal repeat; CBA, chicken beta 
actin promoter. 4V,4th ventricle. Error bars represent SEM, Unpaired student t-test, ** p<0.01. 
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4.16 Deletion of BMAL1 in the LC did not affect sleep-wake parameters 
 
Sleep experiments were performed to examine the sleep-wake cycle of LC-
Bmal1 mice, which was similar to what I had done before using the HDC-
Bmal1 mice. Interestingly, LC-Bmal1 mice showed normal sleep-wake 
behaviour: the percentage of wake, NREM sleep and REM sleep displayed the 
same pattern between the two groups in both sleep and dark periods (Fig 4.19A, 
D, G). AAV-injected Bmal1 lox/lox mice did not differ in wake, NREM sleep 
or REM sleep time compared to the control mice (Fig 4.19B, E, H). EEG power 
analysis showed that the two groups had the same theta and delta oscillations. 
During the 24 hours, average total wake power, NREM power and REM power 
were the same between the two groups: wake and REM power peaked at 8 Hz; 
NREM power peaking at 4 Hz in both groups (Fig 4.19C, F, I). Further looking 
at the episodes of NREM sleep and REM sleep, in both the sleep and dark 
periods, NREM and REM episode number (Fig 4.20A, B, E) and episode 
duration did not differ between LC-Bmal1  mice and control mice (Fig 4.20C, 
D, F).  Error bars represent SEM.  
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Fig 4.19 24 hour sleep-wake cycle of control and LC-Bmal1 mice showed no difference. 
(A, D, G) show the percentages of wake (A), NREM (D) or REM (G) during the 24 hours. 
(B, E, H) shows the time of wake (B), NREM (E) or REM (H) at light period, dark period or 
the total 24 hours. (C, F, I) show the EEG wake (C), NREM (F) or REM (I) power across the 
entire 24 hours. LC-Bmal1 mice did not differ compared with the controls in light period or 
dark period. (A, D, G) LC-Bmal1 mice spent the same time in wake, NREM sleep or REM 
sleep during light period, dark period or total 24 hours. (C, F, I) EEG power analysis 
demonstrate LC-Bmal1 mice and control mice had the same EEG power pattern, both 
peaking at 8 Hz in wake (C) and REM power (I) during the entire 24 hours,  and NREM 
power peaks at 4 Hz in both groups (F). Error bars represent SEM. (B, E, H) Unpaired 
student t-test, p>0.05. (C, F, I) Two-way ANOVA and post hoc Bonferroni, p>0.05. 
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Fig 4.20 Deletion of BMAL1 in locus coeruleus did not induce sleep fragmentation. (A, 
B) Episode numbers of control littermates and LC-Bmal1 mice during 24 hours natural 
sleep. LC-Bmal1 mice had the same NREM (A) and REM (B) episode numbers during light 
period or dark period. (C, D) Episode duration of control littermates and LC-Bmal1 mice 
during the 24 hours natural sleep. Control and LC-Bmal1 mice had the same NREM (C) or 
REM (D) episode duration during the entire 24 hours. (E, F) Episode number (E) and episode 
duration in light period, dark period or total 24 hours (F) showed no difference between two 
groups. Error bars represent SEM. (E, F) Unpaired student t-test, p>0.05. 
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4.17 Discussion 
 
4.17.1 Circadian clock protein BMAL1 and HDC expression 
 
Circadian clocks allow the organism to anticipate changes in environment. The 
SCN in the hypothalamus houses the master clock, but the proteins that 
contribute to core clock function are widely expressed in the body and in most 
cell types in the brain which I showed in Fig 4.2. It is mostly unclear what these 
local neuronal clocks are doing (Kyriacou and Hastings, 2010). We asked how 
such a local circadian clock in a key arousal centre of the brain, histaminergic 
neurons in the hypothalamic TMN area, regulates the sleep-wake cycle. We 
found histamiergic neurons are BMAL1-positive, in addition, circadian clock 
genes (Bmal1, per1, cry1) in TMN area show diurnal expressions. What’s more, 
the Hdc mRNA and protein levels show a diurnal expression as well. We deleted 
the “master clock” BMAL1 gene selectively from histaminergic cells and found 
that this causes a chronic upregulation of hdc gene expression and the circadian 
clock genes (Bmal1, per1, cry1) in TMN lost their circadian expressions.  
How does BMAL1 actually regulate the hdc gene? Generally, as determined 
from other cell types, there are two kinds of molecular consequences of deleting 
BMAL1 from cells.  First, the BMAL1-CLOCK complex influences the 
expression of the negative regulators of its own expression, PER and CRY 
(Kondratova and Kondratov, 2012). In the HDC-BMAL1 mice, both the per1 
and cry1 transcript rhythms in the light-dark cycle were flattened in the 
posterior hypothalamic area; in fact, transcript levels from both genes were 
higher. Similarly, CRY1 transcript levels were also elevated in the BMAL1 local 
knockouts in the retina (Storch et al., 2007), liver (Kondratov et al., 2006;), and 
immune cells (Nguyen et al., 2013), so our findings are consistent. Second, by 
binding to E box sites, the BMAL1/CLOCK dimer influences the expression of 
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effector genes (circadian regulated genes) in LD rhythms (Komhauser et al., 
1990). Many genes have BMAL1/CLOCK binding sites, including the HDC 
gene, which has three E boxes, one in the proximal promoter, and two in introns 
(Koike et al., 2012).  We test the E box in the promoter of hdc gene in vitro, and 
we found BMAL1-CLOCK can increase hdc promoter activity via the E box. 
Without BMAL1 hdc transcript levels are higher, suggesting a repressive 
mechanism for the BMAL1 complex at the hdc gene. Although BMAL1 is 
usually an activator of genes, there are several precedents for it functioning as a 
repressor (Rey et al., 2011): BMAL1 deletion from monocytes upregulates the 
expression of chemokine genes (Nguyen et al., 2013). In fact, BMAL/CLOCK 
functions as an activator, but if CRY joins the complex, it becomes repressive 
(Kondratov et al., 2006); this paradoxically may enable circadian modulation of 
highly expressed promoters, such as the hdc gene. Alternatively, the 
BMAL/CLOCK complex may recruit a repressor such as Polycomb Repressive 
Complex 2 (PRC2) onto the hdc gene, which is how BMAL suppresses cytokine 
genes in monocytes (Nguyen et al., 2013). We found also that CRY itself can 
induce HDC expression independently of the E box in the HDC promoter, so 
this could also be an in vivo mechanism explaining the elevated hdc expression, 
as CRY is itself elevated. Additionally, BMAL1 can dimerize with partners 
other than CLOCK (Schibler and Naef, 2005), and these could be involved. In 
any case, by diurnally down-regulating hdc transcription, BMAL1 helps 
produce rhythms in histidine decarboxylase gene expression, such that without 
BMAL the HDC expression is chronically higher.  BMAL1 is needed for this 
plasticity of hdc gene expression.   
 
 
 
114 
 
4.17.2 Circadian clock protein BMAL1 in histaminergic cells and sleep-
wake cycle 
 
When we abolish this mechanism, by deleting BMAL1 specifically from HDC 
neurons, the resulting chronic hdc gene de-repression overrides sleep 
homeostasis and interferes with sleep-wake architecture, but did not affect the 
circadian periods (Fig 4.6D, E) of the HDC-Bmal1 mice. The dynamism, or 
plasticity, in hdc gene expression in HDC-Bmal1 mice is lost.  During “lights 
off”, HDC-Bmal1 mice had more dark periods, with much higher theta power 
in the EEG. In the “lights on”/light period, mutant mice had significantly fewer 
dark periods, many more NREM episodes, but which were shorter than normal, 
and many more NREM to REM transitions. NREM episode duration was 
significantly shorter than that of littermate control mice throughout the 24 hour 
period. All the results reveal that sleep was fragmented in HDC-Bmal1 mice, 
especially, in the ‘‘light on’’ sleep phase, this might due to the disrupted and 
elevated hdc expression. 
 
In many ways, HDC-Bmal1 mice have the opposite phenotype to hdc total 
knockout mice; hdc knockout mice fall asleep more easily, have reduced quality 
of wake, and more delta in their EEG (Parmentier et al., 2002; Ancelet et al., 
2009). Another strong phenotypic feature of the HDC-Bmal1 knockout mice 
was their substantially decreased recovery sleep after sleep deprivation: the 
amount of time the HDC-Bmal1 mice spent in rebound sleep was 
approximately halved. Perhaps as a consequence of this impoverished recovery 
sleep, the HDC-Bmal1 mice performed significantly less well than littermate 
controls in a simple memory task (novel object recognition).  
 
Mice with no BMAL1 anywhere have no circadian rhythm, but also have 
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increased sleep times and a pronounced delta rhythm in their EEG (Laposky et 
al., 2005). Their sleep phenotype is, in fact, in the opposite direction to that of 
the HDC-Bmal1 mice studied here. BMAL1 protein seems to be in nearly 
every type of neurons in the brain (Ikeda & Nomura, 1997; Honma et al., 1998), 
and is also found in most peripheral organs and the immune system, where it 
helps link their metabolic functions to time of day (Nguyen et al., 2013). So it is 
not clear how to interpret the enhanced sleep of the total Bmal1 knockouts.  
There will be many physiological changes in these animals, some of which, 
such as blood metabolites, from e.g. changed liver function, might promote 
sleep. We found, however, that deleting BMAL1 from noradrenergic neurons 
and associated cells in the region did not influence the sleep-wake cycle at all. 
This is perhaps not surprising, because LC noradrenergic tone is associated with 
stimulating motor neurons and muscle activity, but LC neurons are silent in the 
state of cataplexy, whereas histamine neurons are still firing during cataplexy 
and thus seems more associated with cognitive arousal per se (John et al., 2004). 
Another possibility is that the expression of BMAL1 between TMN and LC is 
different.  I did Q-PCR and found that Bmal1 mRNA level did not differ any 
difference between TMN and LC (data not shown). 
 
In conclusion, our work reveals a new stratum of regulation in the sleep-wake 
cycle, the diurnal fluctuation in hdc gene expression, controlled by a local 
clock-like mechanism involving the BMAL1 protein. This regulation might be 
as important as the “flip-flop” mechanism itself, or it might supplement this 
mechanism to ensure stability of the sleep-wake system. During sleep 
deprivation we also found that hdc expression is strongly upregulated in 
littermate control mice, and that that the return to baseline levels also depends 
on BMAL1. Perhaps related findings are that hdc expression increases in 
hibernating animals (Panula et al., 2000), and it also strongly increases in 
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human and rodent narcolepsy (Valko et al., 2013), possibly as a compensation 
for loss of orexin neurons and the associated drowsiness (Mileykovskiy et al., 
2005). We predict these plastic changes in hdc expression will also involve 
BMAL1.  
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5 Investigating the role of GABA released from histaminergic neurons. 
5.1 Summary 
 
In the previous chapter, I described how the circadian clock gene Bmal1 in 
histaminergic neurons regulates the sleep-wake cycle, and sleep homeostasis 
and in this chapter I still focus on histaminergic neurons. Although some 
evidence showed that HDC-neurons are GABA-positive (Kukko-Lukjanov and 
Panula, 2003; Melander er al., 1986; Trottier et al., 2002), the role of GABA in 
HDC-neurons has never been fully investigated. Actually, before histamine was 
discovered in the brain, the TMN was originally described as a GABAerigc 
projection nucleus (Vincent et al., 1983). In this chapter, I will explore the role 
of GABA produced specifically from histaminergic neurons. I found that 
genetically blocking the GABA system in histamine neurons by knocking down 
the vesicular transporter vGAT substantially increased activity of the mice 
during the night (active phase). Using optogenetics, GABA release could be 
selectively stimulated from HDC fibers to evoke an increase in GABAA-tonic 
inhibition in neocortex and striatum.  
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5.2 The majority of HDC-neurons were positive for markers of GABAergic 
neurons  
 
To investigate the role of GABA released from HDC-neurons, first of all, I used 
some markers of GABA to identify GABAergic cells in the TMN area. Two 
forms of the enzyme, Gad65 (Gad2) and Gad67 (Gad1) are responsible for 
producing GABA; and the vesicular GABA transporter (vGAT) is responsible 
for transporting GABA into vesicles. Here, Gad65, Gad67 and vGAT antibodies 
were used to stain the HDC-positive cells. Before staining the TMN sections, I 
characterized the GABAergic antibodies in cerebellum and hippocampus. 
Purkinje cells were stained vGAT- and Gad67-positive (Fig 5.1A), consistent 
with previous reports (Wang et al., 2009). The pyramidal cell layer in CA1 and 
CA3 regions of the hippocampus was stained Gad67- and vGAT- positive for 
terminals (Fig 5.1B). The HDC-Cre/ROSA26-stop-YFP-mice, which show the 
YFP expression clearly in HDC-neurons, were used to examine Gad67 
expression in the TMN. Fig 5.2A shows that the YFP-positive cells (green) in 
TMN were Gad67-positive cells; moreover, most of the Gad67 staining was 
located in the cytoplasm of the cells; nevertheless, some terminals were stained 
Gad67-positive, but the Gad65 expression was different. I found there was no 
Gad65 expression in HDC cell bodies; instead Gad65 was on the terminals, 
suggesting those terminals contain Gad65 and are probably GABAergic 
afferents from other regions. Further experiments using vGAT and HDC 
antibodies revealed that HDC-neurons (red) were vGAT-positive (green) (Fig 
5.2C). Notably, vGAT not only can be seen in soma, but also in the cell 
membrane (shown as green dots), suggesting that vesicles in histaminergic cells 
contain vGAT which can possibly transport GABA, and HDC-neurons also 
receive GABA from other targets. Next, I mapped the whole brain sections 
using HDC and Gad67 antibodies (Fig 5.3).  Fig 5.3C, D show most of the 
HDC-neurons in the TMN were Gad67-positive in particular brain sections; 
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moreover, in the TMN (VTM and DTM) area, only HDC-neurons had Gad67-
positive signal in cell bodies; however, other TMN areas could be stained for 
Gad67 in terminals. 
 
 
 
Fig 5.1 Characterization of vGAT and Gad67 antibodies. (A, B) show vGAT and Gad67 
staining in cerebellum (A) and hippocampus (B). vGAT and Gad67 can be stained in the 
cytoplasm of cerebellar Purkinje cells (Pc) and cerebellar granule cells (gr) were stained 
vGAT-positive in terminals (A). Bottom panels of Fig 5.1A are magnifications of the boxed 
area in the upper panels. In the CA1 and CA3 region of the hippocampus, terminals in cell 
membrane were stained positive for vGAT and Gad67 (B). Scale bars: 0.2 mm (upper panel 
of A and B); 40 m (lower panel of A and B). Pc, Purkinje cells; gr, granule cells; mol, 
molecular layer. DG, dentate gyrus. 
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Fig 5.2 HDC-neurons were positive for Gad67 and vGAT. (A) Double-staining of GFP 
(green) and Gad67 (red) shows most of the HDC-neurons in the TMN were Gad67-positive 
(yellow) in the TMN.  (B) Double-staining of HDC (red) and vGAT (green) shows most of 
the HDC-neurons were vGAT-positive (yellow). (C) Double-staining of GFP (green) and 
Gad65 (red) shows Gad65 can be stained in the terminals on GFP cells. Scale bars, A, B, C, 
20 m. VTM, ventral tuberomammillary.  
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Fig 5.3 Mapping HDC- and Gad67- positive cells in the TMN. (A) shows one coronal 
section of the posterior hypothalamus stained with HDC (green) and Gad67 (red) antibodies. 
Most of the HDC-positive cells were co-localized with Gad67-positive cells. (B) illustrates 
the staining in Fig A, HDC-positive cells were shown in green, Gad67-positive cells were 
shown in red; however, all the HDC-cells are Gad67-positve, so HDC and Gad67 merged 
cells are shown in orange. (C) outlines all the brain sections that were positive for HDC and 
Gad67. The DAPI stain (blue) reveals all the cells in the section. (D) The pie chart shows 
that, in total, 89.5% of the HDC-neurons (n=760) were Gad67-positive (n=680). Green 
represents HDC-positive cells; orange represents HDC- and Gad67-postive cells. 3V, 3rd 
ventricle. VTM, ventral tuberomammillary; MTM, medial tuberomammillary; DTM, diffuse 
tuberomammillary; MM, medial mammillary. Scale bar: 40 m. 
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5.3 Generating shRNAs vectors to target vGAT, Gad67 and Gad65 
 
In principle, the best way to knock out vGAT in HDC-cells would be to cross 
vgat lox/lox mice with our HDC-Cre knock-in mice; however, the vGAT and 
HDC genes are located on the same chromosome2 (Chr2), so there is no 
possibility to obtain the homozygous of HDC-Cre and vgat lox/lox mice. 
Another way is to generate HDC-cell-specific Gad knock-out mice; however to 
generate Gad67 and Gad65 double floxed mice is time consuming and the 
Gad67 and Gad65 genes are located on Chr2 as well. So, there is no possibility 
to generate genetic knockout mice by crossing HDC-Cre and vgat lox/lox or 
Gad lox/lox mouse lines. So, in order to knock out vGAT, Gad65 or Gad67 
specifically in HDC-cells, a virus-mediated shRNA was introduced. The potent 
RNA interference using microRNA expression (pPRIME) system (Stegmeier et 
al., 2005), uses miR30-based shRNAs. This system, by mimicking the natural 
microRNA system, ensures correct processing of the pre-miRNA to the mature 
siRNA (Stegmeier et al., 2005); it also allows an shRNA to be produced from 
an RNA polII transcript, allowing expression of a protein such as dsRed or GFP 
from the same transcript. Using the Cold Spring Harbor database, three hairpin 
oligonucleotides against vGAT, three against Gad67 and three against Gad65 
mRNA were designed respectively 
(http://katahdin.cshl.org:9331/siRNA/RNAi.cgi?type=shRNA) (See Chapter 2 
section 2.6 for methods and sequences). A total of nine oligonucleotides were 
PCR amplified and cloned into the pPRIME vector to construct dsRed-shvGAT 
(oligo1, 2 or 3) (Fig 3.3.4A), GFP-shGad67 (oligo1, 2 or 3) (Fig 5.4B) and 
GFP-shGad65 (oligo1, 2 or 3) (Fig 5.4C).  
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Fig 5.4 The pPRIME-shRNA vectors to knock down GABAergic signaling. (A) 
Oligonucleotides for scramble shRNA or three sholigonucleotides against vGAT 3’-UTR 
were cloned into the pPRIME-dsRed plasmid to generate pPRIME-dsRed-shvGAT. (B, C) 
Oligonucleotides for scramble shRNA or three sh-oligonucleotides against Gad67 (B) or 
three sh-oligonucleotides against Gad65 (C) mRNA were cloned into pPRIME-GFP plasmid 
to generate pPRIME-GFP-shGad67 or pPRIME-GFP-shGad65 respectively. CMV, 
cytomegalovirus promoter; DsRed, discosoma red fluorescent protein; GFP, green fluorescent 
protein; miR30, mircoRNA30. 
 
 
5.4 Testing the knock-down efficiency of the ‘‘GABAergic’’ shRNAs 
 
To test the knock-down efficiency of all the sholigo sequences and choose the 
most efficient ones to package into the AAV vector, I conducted experiments 
using HEK293 cells to test those shRNAs. A vGAT expression vector was made 
containing the coding sequence and 3’UTR, by PCR amplifying from mouse 
brain cDNA and cloning into the pcDNA vector (see Chapter 2, section 2.8). 
Gad67 and Gad65 expression vectors were obtained commercially (see Chapter 
2). PRIME-dsRed-shvGAT (sholigo1, 2 or 3) were co-transfected into the 
HEK293 cells with pcDNA-vGAT, separately (Fig 5.5A). 48 hours after 
transfection, dsRed fluorescence could be seen in most of the HEK293 cells, 
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and I used a vGAT antibody to assess the vGAT expression. Fig 5.5B shows 
dsRed and vGAT expression, and that compared with shScr and sholigo2, 
sholigo1 and sholigo3 presented the efficient knock-down effect, as vGAT 
expression was the lowest when transfected with dsRed-shvGAT carrying 
oligo1 or oligo3.  
 
The same method was used to examine the shRNAs (oligos) for Gad67 and 
Gad65 (Fig 5.6A; Fig 5.7A). Because the shRNA vector for Gad67 and Gad65 
encodes GFP, not dsRed, a secondary antibody which shows red fluorescence 
was selected for Gad67 and Gad65 detection. In the pPRIME-GFP-shGad67 
and pPRIME-GFP-shGad65 knock-down experiments, the sholigo2 against 
Gad67 gave the highest knock-down efficiency: as shown in Fig 5.6B, C, the 
Gad67 fluorescent intensity was the lowest, while for Gad65, sholigo3 showed 
the best performance (Fig 5.7B, C). So, I selected sholigo2 for Gad67 and 
sholigo3 for Gad65 to do the in vivo experiments. Furthermore, I tested if 
sholigo2 against Gad67 can affect Gad65 expression and sholigo3 against 
Gad65 can affect Gad67 expression. Fig 5.8 shows there was no cross knock-
down effect of shGad67 (Fig 5.8A) and shGad65 (Fig 5.8A).  
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Fig 5.5 Examining shvGAT knock-down efficiency. (A) HEK293 cells were co-transfected 
with pcDNA-vGAT and pPRIME-dsRed-shvGAT (sholigo1, 2 or 3) or pPRIME-dsRed-shScr. 
(B) HEK293 cells showed primary fluorescence for dsRed (left) and vGAT staining (middle) 
and merged images are shown on the right. Compared with the shScr group, sholigo1 and 
sholigo3 presented high knock-down efficiency, as vGAT staining was remarkably reduced 
with sholigo1 and sholigo3.  Boxed contents are magnifications of individual cells. Scale bar, 
100 m. Number of transfections = 3. 
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Fig 5.6 Examining shGad67 knock-down efficiency. (A) HEK293 cells were co-transfected 
with CMV-Gad67 and pPRIME-GFP-shGad67 (sholigo1, 2 or 3) or pPRIME-GFP-shScr. (B) 
HEK293 cells show GFP primary fluorescence (left) and were stained with antibody for 
Gad67 (middle) and merged images are shown on the right. Compared with the shScr group, 
the sholigo1 and sholigo2 both had high knock-down efficiency, as Gad67 staining was 
reduced strongly with sholigo1 and sholigo2. Boxed contents are magnifications of individual 
cells. Scale bar, 100 m. Number of transfections = 2. 
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Fig 5.7 Examining shGad65 knock-down efficiency. (A) HEK293 cells were co-transfected 
with CMV-Gad65 and pPRIME-GFP-shGad65 (oligo1, 2 or 3) or pPRIME-GFP-shScr. (B) 
HEK293 cells showed GFP primary fluorescence (left) and were stained with antibody for 
Gad65 (middle) and merged images are shown on the right. Compared with the shScr group, 
sholigo3 had high knock-down efficiency, as Gad65 staining remarkably reduced in sholigo3. 
Boxed contents are magnifications of individual cells. Scale bar, 100 m. Number of 
transfections = 2. 
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Fig 5.8 Examining shGad65 and shGad67 ‘‘cross reactivity’’. (A) HEK293 cells were co-
transfected with CMV-Gad67 and pPRIME-GFP-shGad65 (sholigo3). ShGad65 showed no 
knock-down effect on Gad67. (B) HEK293 cells were co-transfected with CMV-Gad65 and 
pPRIME-GFP-shGad67 (sholigo2). ShGad67 had no knock-down effect on Gad65. Scale bar, 
100 m. Number of transfections = 2. 
 
 
 
 
 
 
5.5 Constructing AAV-shRNA and AAV-FLEX-shRNA vectors 
 
We decided to use AAV to deliver shRNA into mouse brains. To get virus 
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expression in brain regions, the dsRed-shvGAT, GFP-shGad67 and GFP-
shGad65 cassettes in pPRIME were inserted into an AAV vector with a human 
synapsinII promoter (Add gene plasmid #44362), so shRNAs can be expressed 
in any neuronal cells (Fig 5.9A). Moreover, to obtain specific expression in 
certain cell groups or brain sites, shRNAs were inserted into the AAV vectors 
carrying a FLEX switch (Atasoy et al., 2008) (Fig 3.4.9A). All AAV transgenes 
were then packaged into AAV plasmids with a ‘‘1/2’’ coat protein mixed 
serotype (The full details of how the constructs were made are given in Chapter 
2, section 2.11). The diagram (Fig 5.9A, B) describes all the AAV-shRNA 
vectors: AAV-dsRed-shvGAT, AAV-GFP-shGad67 and AAV-GFP-shGad67; 
theoretically, those AAV can express in any neuronal cells; and AAV-FLEX-
dsRed-vGAT, AAV-FLEX-GFP-shGad67 and AAV-FLEX-GFP-shGad67. The 
FLEX switch allows those viruses to express if Cre is present. The FLEX-
switch virus plasmids were examined in vitro in HEK cells using a Cre 
recombination strategy. The expression of dsRed or GFP were not detectable 
without Cre expression; nevertheless, by transfecting plasmid expressing Cre 
into the cells together with AAV-FLEX plasmids, dsRed or GFP was detectable 
(Fig 5.9C), which confirmed that Cre allowed AAV-FLEX plasmids to express 
in vitro.  
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Fig 5.9 Generation of AAV-shRNAs transgenes. (A) The dsRed-shvGAT, GFP-shGad65 
and GFP-shGad67 were cloned into an AAV vector to generate AAV-dsRed-shvGAT, AAV-
GFP-shGad67 and AAV-GFP-shGad65. (B) Design of AAV employing the FLEX Switch 
strategy (Atasoy et al., 2008), which uses 2 pairs of heterotypic, antiparallel loxP-type 
recombination sites to achieve Cre-mediated transgene inversion and expression. The dsRed-
shvGAT, GFP-shGad65 and GFP-shGad67 were cloned from pPRIME into the AAV-vector 
in a reverse direction, which Cre recombination can reversal activate shRNAs expression. (C) 
To test the AAV-FLEX-shRNAs, HEK-293 cells were co-transfected with CMV-Cre and 
AAV-FLEX-dsRed-shRNA or AAV-FLEX-GFP-shRNA. There was no expression of dsRed 
or GFP without Cre; however, Cre can activate dsRed or GFP expression. Scale bar, 40 m. 
L-ITR, left-inverted terminal repeat; R-ITR, right-inverted terminal repeat; WPRE, 
woodchuck hepatitis posttranscriptional regulatory element. hSyn: human synapsin II 
promoter. 
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5.6 Positive control pilot experiment: Knocking down vGAT expression in 
caudate putamen (striatum) caused motor defects in mice 
 
As a positive control, to check if knocking down vGAT or Gad67/65 in certain 
brain areas would produce a behavioural phenotype, a brain area composed 
largely of GABAergic neurons, which closely relates to animal motor activity 
was choosen to examine shRNA effectiveness. I unilaterally injected AAV-
dsRed-shvGAT into the caudate putamen of adult mice (Fig 5.10A). Four weeks 
after injection dsRed expression was visible at the injection site (Fig 5.10B). 
After I checked the expression of dsRed, I performed turning behaviour 
experiments with a separate cohort of injected mice. Knocking down vGAT by 
injecting AAV-dsRed-shvGAT into the one side of the caudate putamen caused 
ipsilateral bias of turning in those animals, as shown in Fig 5.10C; the mice with 
shvGAT injection in one side turned one direction more than the other, by 
contrast; the shScr injected control mice turned both directions equally.  
 
 
 
Fig 5.10 Injection of AAV-dsRed-shvGAT into the striatum caused motor deficits. (A) 
AAV-dsRed-shScr (n=5) or AAV-dsRed-shvGAT (n=5) was unilaterally injected into the 
striatum. (B) Coronal section from a mouse brain injected with AAV-dsRed-shvGAT, 
showing signal for dsRed. (C) AAV-dsRed-shvGAT injected mice also show a strong 
ipsilateral bias in turning. Scale bar, 60 m. Error bars represent SEM. Unpaired two-tailed t-
test, p<0.05.  
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5.7 Positive control pilot experiment: knocking out vGAT in caudate 
putamen (striatum) caused motor defect 
 
In the above experiments, I injected AAV-dsRed-shvGAT into the striatum to 
assess mouse behaviour as a positive control. Here, I used a mouse line that has 
exon 2 of the vgat gene flanked by loxP sites (Tong et al., 2008).  Exogenous 
Cre delivery should delete exon 2 of the vgat gene; thus the vGAT will be 
knocked out in Cre-expressing cells. First of all, to test this strategy, I delivered 
AAV-Cre-Venus into the vgat lox/lox mice striatum to knock-out vGAT in 
striatum (Fig 5.11A). Fig 5.11B shows AAV-Cre-Venus expression resulting 
from injection into one side of the striatum. Venus was expressed in the striatum 
as stained with GFP antibody. Next, I performed a behavioural experiment by 
examining turning. Knocking out vGAT by injecting AAV-Cre into one side of 
the caudate putamen caused ipsilateral bias of turning in those vgat lox/lox mice 
(Fig 5.11C). In these experiments, the control mice received a unilateral 
injection into the caudate putamen of an AAV expressing GFP only. AAV-GFP 
injected mice showed no bias in turning. 
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Fig 5.11 Injection of AAV-Cre into the vgat lox/lox mice striatum caused motor deficits. 
(A) AAV-GFP or AAV-Cre-Venus was unilaterally injected into the striatum of vgat lox/lox 
mice. Cre recombination deletes the exon II of vgat gene. (B) Coronal section from a mouse 
brain injected with AAV-Cre-Venus shows Venus expression. Scale bar, 30 m. (C) AAV-
Cre-Venus (n=4) injected mice displayed remarkable ipsilateral bias in turning compared with 
the AAV-GFP (n=4) injected mice. Error bars represent SEM. Unpaired two-tailed t-test, 
p<0.05. 
 
 
5.8 Knocking down vGAT expression selectively in HDC-neurons increased 
locomotor activity in mice 
 
My previous data confirmed the earlier literature that HDC-neurons are 
GABAergic cells (Fig 5.2). To investigate the role of GABA in HDC-neurons, I 
built different AAV-shRNAs to selectively target the GABA system in HDC-
neurons with FLEX-switches (Fig 5.9). AAV-FLEX-dsRed-shvGAT was 
bilaterally injected into the TMN area of HDC-Cre mice to knock down vGAT 
in specific HDC-neurons. AAV-FLEX-dsRed-Scr was injected as a control (Fig 
5.12A, B). To assess the behaviour, a locomotion experiment was performed 
first when mice were placed in a novel cage. Fig 5.13 shows that the AAV-
FLEX-shvGAT injected mice ran much further than the AAV-FLEX-shScr 
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injected control group. The distance was significantly increased after 10, 15, 20 
and 25 minutes, and the travelling speed was higher during the entire 30 
minutes (Fig 5.13A, B). Notably, in AAV-FLEX-shScr mice, the distance and 
speed gradually reduced during the 30 minutes; however, the shvGAT injected 
mice maintained a stable, but high activity during the 30 minutes (Fig 5.13A, 
B). Some mice were attached with Neurologgers to detect the ‘‘running theta’’ 
power in the locomotion experiment. Two pairs of mice were examined; in each 
pair, two mice (shScr injected and shvGAT injected) were attached with the 
same Neurologger; similar results could be observed in both pairs. FFT power 
spectra and Morlet wavelet analysis showed that total EEG theta power 
increased in the TMN-vGAT knock down mice (Fig 5.13C, D), although there 
appeared some individual differences; for example, in pair 1, theta frequency 
varied from 4 to 8 Hz in both control and shvGAT mice, while in pair 2, theta 
frequency showed an apparent single peak at 8 Hz (Fig 5.13C). This EEG power 
analysis further confirmed that mice are more active with shvGAT expressed in 
the HDC-neurons. 
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Fig 5.12 Delivering AAV-FLEX-dsRed-shvGAT into the TMN of the HDC-Cre mice. 
AAV-HDC-Cre-Venus was bilaterally injected into the TMN area of HDC-Cre mice. Cre 
activation in HDC-neurons could turn on the expression of dsRed and shvGAT in specific 
HDC-cells. (B) Immunostaining shows dsRed (red, primary fluorescence) was expressed 
specifically in HDC-neurons (green, anti-HDC). Scale bars: 20 m. 
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Fig 5.13 Knocking down vGAT in HDC-neurons increases mouse locomotion activity. 
(A, B) ShvGAT injected HDC-Cre mice (n=8) (red trace) travel further (A) and faster (B) 
than shScr control mice (n=7) in a 30 minute period when placed in the activity monitor. (C, 
D) EEG power spectra of two groups of mice that travelled in 30 minute period; ShvGAT 
injected HDC-Cre mice had higher theta power; (D) the 30 second Morlet wavelet power 
spectrum showed in shvGAT injected mice, there was a stronger theta power frequency at 
about 8 Hz compared with controls. Error bars represent SEM. Two-way ANOVA and post 
hoc Bonferroni, *p<0.05, **p<0.001. Coloured bar shows log10 power. 
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5.9 Knocking out the vgat gene from the TMN area of vgat lox/lox mice 
 
Besides using shRNAs to knock down vGAT or GAD in HDC-neurons, Cre can 
be delivered into the HDC-neurons to knock out vGAT using the vgat lox/lox 
mouse line (Tong et al., 2008). Thus, it is a good idea to do independent 
methods to see if these still give the same phenotype (Yang et al., 2013). 
Because mostly only HDC-neurons in TMN area were Gad67-positive (see Fig 
5.3), and actually, most of the vGAT-positive cells in TMN area were HDC-
neurons, I realized that if I injected the AAV-HDC-Cre-Venus into the TMN 
area, most of the vGAT knock out cells should be HDC-neurons, and so this 
would be an approximate ‘‘HDC-neuron-specific’’ vGAT knock-out. Fig 5.14 
shows AAV-HDC-Cre-Venus was bilaterally delivered into the TMN area. 
Venus (GFP) expression could be seen in the VTM and MTM. By staining with 
HDC antisera, most of the HDC-positive cells were GFP-positive.   
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Fig 5.14 Delivering AAV-HDC-Cre-Venus into the TMN. (A) AAV-HDC-Cre-Venus was 
bilaterally injected into the TMN area of vgat lox/lox mice. (B) shows staining of GFP and 
HDC in the coronal section of TMN area. GFP expression is present in the VTM and DTM. 
By staining with HDC antisera, most of the HDC-neurons were GFP-positive cells. In 
addition, there were some extra GFP-positive cells in the TMN. Scale bars: 20 m. 
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5.10 Deleting vGAT in the TMN area increases locomotion activity of mice 
 
To assess the behaviour, a locomotion experiment was performed as I did 
before: by putting mice into an open field for 30 minutes. A very similar 
locomotion phenotype was observed when removing vGAT from the general 
TMN area by Cre compared to down-regulating vGAT specifically in HDC-
neurons using AAV-FLEX-shvGAT. Fig 5.15 shows removing vGAT from the 
TMN area dramatically increases the activity of mice, compared to the AAV-
GFP injected control group. The distance travelled was significantly increased 
at the 10, 20, 25 and 30 minute time points in the AAV-Cre injected group and 
they travelled much faster than the AAV-GFP injected control mice during the 
entire 30 minutes (Fig 5.15B). Moreover, the AAV-Cre injected mice sustained 
a high activity during the whole 30 minutes (Fig 5.15A, B). Some mice were 
fitted with Neurologgers to detect the ‘‘running theta’’ power in the locomotion 
experiment. Two pairs of the mice were examined; in each pair, two mice (GFP 
injected and Cre injected) were attached with the same Neurologger. FFT power 
spectra and Morlet wavelet analysis show that total EEG theta power increased 
in the vGAT knocked out mouse in pair 2, but not in pair 1 (Fig 5.15C, D), 
suggesting there appeared to be some individual differences.  
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Fig 5.15 Knocking out vGAT in TMN area increased locomotion activity of vgat lox/lox 
mice. (A, B) AAV-Cre injected mice (n=4) (red trace) travel further (A) and faster (B) than 
AAV-GFP injected control mice (n=4) in a 30 minute period when placed in the activity 
monitor. (C, D) EEG power spectra of two groups of mice that travelled in a 30 minute 
period; AAV-Cre injected mice had the same theta power compared with AAV-GFP injected 
control mouse in pair 1; however, in pair 2, the AAV-Cre injected mouse had much higher 
theta power; (D) the 30 second Morlet wavelet power spectrum taking from 30 minutes 
travelling showed that in shvGAT injected mice, there was a stronger theta power frequency 
at about 8 Hz compared with controls in pair 2. Error bars represent SEM. Two-way ANOVA 
and post hoc Bonferroni, *p<0.05, **p<0.01, ***p<0.001. 
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5.11 Knocking down vGAT in HDC-neurons increased wakefulness over 
the 24 hour natural sleep-wake cycle 
 
Next, I assessed the 24 hour natural sleep-wake cycle of AAV-FLEX-shvGAT 
injected mice. Fig 5.16 shows the percentage of wake (A), NREM (C) and REM 
(E) 24 during the entire 24 hours. In the light period, both groups showed a 
normal sleep-wake pattern; however in the dark period, a more active phenotype 
was observed in the vGAT knock down group. At the start of the ‘‘lights off’’, 
and for the continuous first five hours of this period, AAV-FLEX-dsRed-
shvGAT injected mice were significantly more active than the AAV-dsRed-
FLEX-shScr injected controls, and as the dark period progressed, the activity of 
the mice was still higher than the controls, although this later difference was not 
significantly different. The total wake time of shvGAT injected mice averaged 
over 24 hours was increased (Fig 5.16B), but they spent the same time awake in 
the light period (Fig 5.16B). Over the 24 hour period the amount of NREM 
sleep was decreased in the vGAT knock down group (Fig 5.16D); AAV-FLEX-
shvGAT injected mice had the same amount of REM sleep compared with the 
controls in earlier sleep or dark periods (Fig 5.16F). 
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Fig 5.16 The 24 hour sleep-wake cycle of AAV-FLEX-dsRed-shScr control and AAV-
FLEX-dsRed-shvGAT injected into the TMN of HDC-Cre mice. (A, B, C, D) HDC-Cre 
mice with shvGAT injected (n=6) were more active than littermate controls (n=6) at the start 
of lights off (dark period), but showed no difference during lights on (light period). AAV-
FLEX-dsRed-shvGAT mice had a significant reduction of NREM sleep during the dark 
period (D). There was no difference in REM sleep between two groups (E, F). Error bars 
represent SEM. Unpaired two-tailed t-test, *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
143 
 
5.12 Knocking down vGAT expression in HDC-neurons increased EEG 
theta power 
 
AAV-FLEX-shvGAT injected mice had significantly increased wake as 
measured by EEG wake power during 24 hours (Fig 5.17A). There was an 
upward shift of maximum theta power frequency. In control AAV-FLEX-dsRed-
shScr injected mice, the peak theta power occurred at 7.8 Hz; however, in the 
vGAT knock down mice, the peak theta power was 8.4 Hz. The power was 
significantly higher at the rage of 8-12 Hz in the knock down group, whereas 
the lower frequency (4-6 Hz) was decreased in the knock down group compared 
with the controls (Fig 5.17A). No changes were found in NREM or REM power 
in the total 24 hours between the two groups (Fig 5.17B, C). Since the 
remarkable sleep-wake phenotype was only observed in the dark period, I split 
the 24 hours EEG power into a light period (0-12 hours) and a dark period (13-
24 hours) segments. As can be seen from Fig 5.17D, E, there were no 
differences of EEG wake and NREM power in the light period between AAV-
FLEX-shScr injected control and AAV-FLEX-shvGAT injected mice; however, 
in the light period, the wake power was slightly elevated in the shvGAT group at 
around 8 Hz. Strikingly, the EEG wake power was significantly increased in the 
dark period in the knock down mice, which was consistent with the sleep 
phenotype I observed before (Fig 5.16).  
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Fig 5.17 Knocking down vGAT specifically in HDC-neurons increased EEG theta 
power. (A, B, C) show EEG wake (A), NREM (B) and REM (C) power over the 24 hours. 
AAV-FLEX-shvGAT injected mice (n=6) had more theta power peaking at 8 Hz, but less 
delta power at about 4 Hz compared with the AAV-FLEX-dsRed-shScr injected controls 
(n=6). NREM and REM power appear the same between the two groups. (D, E) show the 
wake (D) and NREM (E) power during the 12 hour light period (lights on) or 12 hours dark 
period (lights off). AAV-FLEX-dsRed-shvGAT injected mice had a remarkable increase of 
wake theta power during the 12 hours dark period, whereas NREM power stays the same 
between two groups during the light period or dark period. Error bars represent SEM.  
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5.13 Deleting vGAT in the TMN area increased wakefulness in mice over 
the 24 hour sleep-wake cycle 
 
Next, I assessed the 24 hour natural sleep-wake cycle of mice with a vGAT 
disrupted gene in the TMN area (AAV-Cre-Venus injected vgat lox/lox mice). 
Fig 5.18 shows the percentage of wake (A), NREM (B) and REM (C) 24 during 
the entire 24 hours. In the ‘‘lights on’’ light period, both groups showed the 
same sleep-wake pattern; however, in the dark period, knocking out vGAT in 
the TMN area increased the wakefulness of the mice. At the start of the lights 
off, and for the continuous first five hours, Cre injected mice were significantly 
more active than GFP injected controls, and as the dark period progressed, the 
activity of the mice was still much higher than the controls. Cre injected mice 
had significantly intense wake as measured by EEG wake power during the 24 
hours (Fig 5.18A). There was a remarkable shift of maximum theta power 
frequency. In control mice, the peak theta power occurred at 8 Hz and 2 Hz; 
however, in knock-out mice, the peak theta power was shifted to 8.5 Hz. The 
power was much higher at the rage of 8-12 Hz in knock-out mice, while the 
lower frequencies (2-4 Hz) decreased in the knock-outs compared to the 
controls (Fig 5.18D). No changes were found in NREM or REM power in the 
total 24 hours between the two groups (Fig 5.18E, F).  
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Fig 5.18 24 hour sleep-wake cycle of TMN area AAV-GFP injected vgat lox/lox control 
mice and AAV-Cre injected vgat lox/lox mice. (A, B, C) Vgat lox/lox mice with Cre 
injection (n=4) were more active than littermate controls (n=4) at the start of lights off (dark 
period), but showed no difference during lights on (light period). AAV-Cre-injected mice had 
a significant reduction of NREM sleep during the dark period (B). There was no difference of 
REM sleep between two groups (C). (D, E, F) EEG power of wake, NREM and REM over 
the entire 24 hour. Cre injected mice had a much higher and shifted theta power. NREM and 
REM power appeared to be the same between the two groups (E, F).  
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5.14 Knocking down vGAT selectively in HDC-neurons reduced sleep 
rebound after sleep deprivation 
 
To assess the sleep homeostasis of mice with vGAT expression reduced in 
histamine neurons, mice were sleep deprived for 5 hours during the beginning 
of the light period, similar to the experiments I described in Chapter 4. After 
sleep deprivation, mice were left to sleep freely in their home cages. Both HDC-
vGAT scramble and HDC-vGAT KD mice slept substantially after sleep 
deprivation, but compared with the control mice, HDC-vGAT KD mice had a 
reduced rebound of NREM sleep after sleep deprivation (Fig 5.19A), especially 
in the first 5 hours of recovery sleep; however, the HDC-vGAT KD mice 
showed an increase of REM sleep at certain time points (ZT 10 and ZT 12); but 
the overall REM rebound appeared to be the same between two groups (Fig 
5.19B). Next, we analysed the accumulated NREM and REM changes 
compared with the 24 hour baseline sleep. The rate of NREM and REM loss 
during sleep deprivation was the same between the two groups (Fig 5.19C, D); 
but during recovery sleep, the accumulated NREM rebound time in HDC-vGAT 
KD mice was less than the control mice (Fig 5.19C). Nevertheless, the 
accumulated REM rebound appeared to be the same between the two groups 
(Fig 5.19D) 
 
 
 
 
148 
 
 
 
 
Fig 5.19 Knocking down vGAT in HDC-neurons reduced sleep rebound after sleep 
deprivation. Mice (HDC-vGAT scramble, n=4; HDC-vGAT KD, n=4) were sleep deprived 
(SD) for 5 hours, and then allowed to take a recovery sleep in their home cage. (A, B) After 5 
hours of SD during the lights on (natural light period), AAV-FLEX-shScr injected control 
mice had more sustained bouts of NREM recovery sleep than AAV-FLEX-shvGAT injected 
mice (A) and REM sleep showed a similar pattern between two groups, although the REM 
sleep increased at ZT10 and ZT12 (B). (C, D) Accumulated NREM and REM changes 
compared with the baseline sleep. The HDC-vGAT KD mice showed a trend of decrease of 
NREM rebound than the control mice (C); and the accumulated REM change showed no 
major difference between the two genotypes (D). Error bars represent SEM. Unpaired two-
tailed t-test, *p<0.05. 
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5.15 Positive control pilot experiment: Knocking down Gad67/65 
expression in caudate putamen (striatum).  
 
I am undertaking a final series of complimentary experiments: GAD knock 
down in HDC neurons. As a positive control for the shRNA, I have delivered 
AAV-dsRed-vGAT into the caudate putamen to knock down vGAT which 
caused a bias of turning (see 5.6). In addition, here, I conducted the same 
experiment using AAV-GFP-shGad65 and AAV-GFP-shGad67 (Fig 5.9A). 
AAV-GFP-shGad67 and AAV-GFP-shGad65 were mixed and injected 
unilaterally into the caudate putamen (Fig 5.20B). GFP was clearly expressed 
stains clear in the caudate putamen (Fig 5.20B). After injection of shGad67/65, 
there was a reduction of Gad67 and Gad65 expression compared with the AAV-
GFP-shScr injected group (Fig 5.20C). I am performing the behavioural 
experiments now. So far, they were not completed at the time of writing.  
 
 
 
Fig 5.20 Injection of AAV-GFP-shGad67 and AAV-GFP-shGad65 into the striatum 
decreased Gad67 and Gad65 expression. (A) AAV-GFP-shScr or AAV-GFP-shGad67/65 
was unilateral injected into the striatum. (B) Coronal sections from a mouse brain injected 
with virus were stained for GFP. (C) Injection of shGad67/65 down-regulated Gad67 and 
Gad65 expression in GFP-positive cells compared with the AAV-GFP-shScr injected 
controls. B, 30 m; C, 20 m. 
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5.16 Preliminary results: Knocking down Gad67/65 expression in HDC-
neurons  
 
I injected AAV-FLEX-GFP-shGad67 and AAV-FLEX-GFP-shGad65 into the 
HDC-Cre mice TMN region to knock down Gad67 and Gad65 expression in 
specific HDC-neurons (Fig 5.21A). Three weeks after injection, the expression 
of virus was assessed using immunohistochemistry. Fig B shows the GFP 
expression (green) from the AAV vector restricted to HDC-neurons (red) (Fig 
5.21B). To check the knock-down efficiency, both AAV-FLEX-shScr injected 
and AAV-FLEX-shGad67/65 injected groups were stained with Gad67 or 
Gad65 antibodies. As shown in Fig 5.21C, there was a reduced Gad67 signal 
following AAV-FLEX-shGad67/65 injection. Next, I assessed the behaviour of 
those mice. So far, I have done only two mice: the AAV-FLEX-GFP-
shGad67/shGad65 injected mouse travelled further than the AAV-FLEX-GFP-
shScr control mouse. However, I will increase the numbers in future 
experiments (Fig 5.21D).  
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Fig 5.21 Preliminary data: knocking-down Gad in specific HDC-neurons increased 
mouse locomotor activity. (A) AAV-FLEX-shGad67 and AAV-FLEX-shGad65 were mixed 
and injected into the TMN of HDC-Cre mice. (B) Staining of the TMN section with GFP and 
HDC antibodies. GFP was expressed in specific HDC-cells. (C) Brain sections were stained 
with GFP and Gad67 in both shScr and shGad-injected mice. AAV-shGad injection 
efficiently down-regulated Gad67 expression in HDC-neurons. (D) A locomotion experiment 
was conducted in an open field for 30 min, shGad-injected mouse (n=1) travelled further than 
the shScr-injected control mouse (n=1). Scale bars in A, B and C, 20 m. 
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5.17 Preliminary data: using optogenetics to manipulate histaminergic 
neurons. 
 
Having demonstrated that genetically knocking down components of the 
GABAergic machinery in histaminergic neurons produced profound changes in 
behaviour of the mice, namely enhanced waking activity during the night, the 
next question to tackle is: “is there any evidence for functional GABA release 
from histaminergic neurons”? In the last few months, we have started to address 
this question by using optogenetics to study GABA release from histaminergic 
neurons. I have been injecting AAV-EF1a-doublefloxed-hChR2(H134R)-EYFP-
WPRE-HGHpA (Deisseroth lab: humanized ChR2 gene with histidine 134 
changed to arginine, to achieve higher currents, and EYFP fused to the C-
terminus of ChR2, Addgene plasmid 20298, see Chapter 2, section 2.8), 
abbreviated to “AAV-ChR2-EYFP”,  into the TMN of HDC-Cre mice (Fig 
5.22A). Two weeks after injection, YFP was visible in specific HDC cells as 
assessed by double immunocytochemical staining with GFP and HDC antisera 
(Fig 5.22B).  Zhiwen Ye, Dr. Cat. Houston and Dr. Anna Zecharia in our lab and 
Dr. Stephen Brickley’s lab are doing the electrophysiology to patch neurons in 
different brain areas of these HDC-ChR2 mice, and analyse how these cells 
respond to selective light-stimulation of HDC fibres.  
 
So far, I have carried out a series of AAV-flex-ChR2-EYFP injections into the 
TMN area of HDC-Cre mice. Three to four weeks later, Dr. Zecharia then 
makes acute slices of the TMN area of these HDC-ChR2 mice for 
electrophysiological analysis.  For the successful injections, in the TMN of 
AAV-ChR2-EYFP injected mice, we have found a strong expression of primary 
YFP florescence in the TMN area (Fig 5.23A2, A3), but not in control mice (Fig 
5.23A1, A2). During wake, histaminergic neurons normally fire in the range 1 
to 5 Hz (Parmentier et al., 2009). Shining blue light at 5 Hz pulses triggered 
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histaminergic neuronal firing (Fig 5.23C, D, E). 
 
Because histaminergic neurons project to the entire brain (Fig 5.23B), for 
example neocortex and caudate-putamen (striatum) (see chapter 3), to study if 
the histaminergic neurons affect activity in these area, my colleagues (Zhiwen 
Ye, and Dr. Cat. Houston) have been doing patch-clamp recordings from 
neurons in acute slices of neocortex (Layer IV and V of the visual cortex) and 
striatum (caudate-putamen) prepared from HDC-ChR2 by photostimulating  
terminals and fibres with blue LED-generated light. A layer of the neocortex 
from HDC-Cre x lox-stop-loxROSA mice (see Chapter 3) which showed 
particularly dense fibres was layer IV (see Fig 3.11). Thus we decided to focus 
on responses of layer IV cortical neurons in response to blue light. Fig 5.24A 
shows a recorded biotin-filled cell from neocortex (layer IV of the visual 
cortex). Photostimualtion at 5 Hz of HDC-ChR2-EYFP fibers for 1 ms in 
neocortex triggered a slow increase of tonic inhibitory current in layer IV (8 
neurons were recorded, 5 out of 8 cells increase in current, 125±54 pA), which 
only started after the 5 Hz light stimulation ended (Fig 5.23B), while application 
of gabazine (a GABA-A receptor antagonist) abolished this increase in tonic 
current  (Fig 5.23C), suggesting that light-stimulation of HDC fibres had 
triggered an increase in in GABA-A receptor mediated tonic (non-synaptic) 
inhibition. There was no change in the frequency of IPSCs recorded from 
principal neurons. To know whether this increase in tonic inhibitory GABA-A  
was due to direct GABA release from histaminergic terminals/varicosities or 
histamine excitation of  GABA interneurons, we applied H1 and H2 antagonists 
(Pyrilamine and Ranitidine)  into the slices to block the effects of histamine. 
Examples of two cells recorded in neocortex (layer IV of the cortex) still 
showed an increase of GABA-A receptor mediated tonic current in the presence 
of histamine antagonists (Fig 5.23D), possibly suggesting direct GABA release 
from HDC terminals. Similar results could be seen in the caudate-putamen 
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experiments. Primary flourescence from ChR2-YFP fibers was particularly clear 
in the caudate-putamen (Fig 5.25A), and Dr. Houston recorded fromneurons 
fibers (Fig 5.25A). Photostimulation (5 Hz, blue light) of TMN fibers also 
increased tonic current in the caudate-putamen, but had no effect on IPSC 
frequency (Fig 5.25B, C). In control experiments, by directly adding histamine 
(10 M) into the caudate-putamen slices of wild-type mice, there were no 
changes of tonic current or IPSC frequency during the recording time (0-15min) 
(Fig 5.25D), suggesting that bath-applied histamine had no effect on tonic 
current or IPSC frequency. 
 
 
 
 
Fig 5.22 ChR2 was expressed in specific HDC-neurons. (A) AAV-FLEX-ChR2-EYFP was 
bilaterally injected into the TMN of HDC-Cre mice. (B) Three weeks after injection, as seen 
by staining with YFP and HDC antisera, YFP expression was restricted to histaminergic 
neurons. 
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Fig 5.23 Photostimulated histaminergic neuronal firing. (A) Acute coronal brain slices 
that used to patch the TMN neurons showed ChR2-YFP expression in TMN (A3, A4), but not 
in control slices (A1, A2). (B) Schematic of light stimulates TMN to release histamine or 
(and) GABA onto the whole brain, including neocortex and striatum. (C) Photostimulation of 
a ChR2-YFP-positive TMN neuron at 5Hz for 2 seconds triggered membrane depolarisation 
with action potential at low LED intensity. (D) Photostimulation of a ChR2-YFP-positive 
TMN neuron at 5Hz with higher LED intensity for 2 seconds duration triggered membrane 
depolarisation but with many more action potentials. (E) Photostimulation of a ChR2-YFP-
positive TMN neuron at 5 Hz with 2 ms duration triggered membrane depolarisation with 
action potential. Recordings made by Dr. A. Zecharia. 
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Fig 5.24 Optogenetic release of GABA in neocortex.  (A) ChR2-YFP histaminergic fibers 
were seen in the neocortex of acute slices. A recorded biotin-filled cortical neuron in the YFP 
fiber area. (B, C) Photostimulation of ChR2-YFP TMN fibers at 5 Hz in neocortex increased 
tonic inhibitory current in cortical neurons. Here shows two examples of patched cells. (C) 
Gabazine administration blocked this tonic induction. (D) H1 and H2 antagonists (Pyrilamine 
and Ranitidine) did not affect the light-stimulated tonic GABAA induction. Recordings 
provided by Zhiwen Ye. 
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Fig 5.25 Optogenetic release of GABA in striatum. (A) ChR2-YFP fibers in striatum of a 
ChR2-injected HDC-Cre mouse. (B) Photostimulation of ChR2-YFP TMN fibers in striatum 
increased tonic current in striatal neuron, but had no effect on control mouse (without YFP 
expression in TMN). (C) shows light-stimulating ChR2-YFP fibers in striatum triggered 
induction of tonic current in striatal neurons, but did not affect IPSC frequency. (D) Direct 
application of histamine in acute slices of the wild mice did not affect tonic current and IPSC 
frequency in striatal neurons. Recordings provided by Dr. Cat. Houston. 
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5.18 Discussion  
 
To investigate if GABA is released from HDC neurons, in this chapter I 
described the genetic approaches that I used to inhibit the GABAergic system 
specifically in HDC neurons and further examined the behavioural role of 
GABA produced from HDC neurons. Finally, we have started to gather 
functional (optogenetic) evidence for the release of GABA from HDC fibres. 
First of all, by using classical immunohistochemistry, GAD67 and vGAT 
antisera were used to stain the TMN region, and in addition, to identify the 
HDC neurons, I used a genetic method by crossing HDC-Cre mice with Rosa 
reporter mice (chapter 3); consequently, HDC neurons were labelled with YFP, 
by double staining with YFP and GAD67 or vGAT, most of the HDC neurons 
were confirmed to be GAD67 and vGAT positive. This confirms the original 
studies that TMN neurons are GABAergic (Kukko-Lukjanov and Panula, 2003; 
Haas et al., 2008). The advantages of using the reporter mouse are that HDC 
neurons can be clearly labelled, especially in terminals; and the projections are 
easy to identify in different brain regions. To target the GABA system in HDC 
neurons, the first idea that came to our mind was to block GABA transport by 
crossing HDC-Cre mice with a floxed vgat mouse line; however, the hdc gene 
and vgat gene are located on the same chromosome (Chr2), so this method will 
not provide an effective way to remove GABA transporter in HDC neurons, as 
maximally only heterozygote HDC-vGAT mice could be obtained. So instead, 
we chose to use AAV-mediated shRNAs to target GABA in HDC neurons. I 
generated a Cre-dependent AAV-shRNA to target vGAT in histaminergic cells. 
After I delivered shvGAT into the HDC-Cre mice, behavioural experiments 
were carried out. I observed a strong phenotype in HDC-vGAT KD mice: they 
were much more active in a novel environment; they had increased wakefulness 
in the night; and they had reduced sleep rebound after sleep deprivation. It has 
also become apparent that chronic Cre-dependent knockout of genes, even if 
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cell-type selective, can give different results from acute shRNA mediated knock 
down of the same gene. For example, this was compared recently for the same 
gene side by side. Additionally, I also delivered AAV carrying a HDC-promoter-
Cre-2A-Venus transgene into the TMN area of vgat lox/lox mice to knock out 
vgat (TMN-vGAT mice). The same behavioural results were observed as with 
the HDC-vGAT-KD mice. All of these results suggest GABA produced in 
histaminergic neurons inhibits activity in mice during the night; GABA seems to 
balance the excitatory effect of histamine. The histaminergic cells fire most 
during the dark period, and start firing shortly after mice wake up (Saper et al., 
2010), i.e. for mice the “lights off”/night period. This fits our results: the active 
phenotype of HDC-vGAT-KD mice was observed only during the night; during 
this period, less GABA would be released from TMN cells, which would cause 
less inhibition onto other targeted regions; consequently, mice were more active. 
Moreover, I also generated shRNAs targeting GAD67 and GAD65 transcripts in 
histaminergic cells; and behavioural experiments are being performing at the 
moment on HDC-GAD65/75-KD mice.  
 
It is interesting that reduction or removal of GABA release in histaminergic 
neurons caused such a phenotype (enhanced wake). To understand the 
mechanism more directly, I delivered a Cre-activateble ChR2-EYFP transgene 
into the TMN of HDC-Cre mice to give HDC-ChR2-EYFP mice. Although 
histaminergic neurons project to the whole brain (Panula et al., 1984; Panula et 
al., 1989; Inagaki et al., 1988), we chose some particular brain regions to study: 
neocortex and striatum (caudate-putamen), because those regions contained 
significant numbers of YFP fibers according to our mapping results with the 
HDC-Cre x lox-stop-lox ROSA mice (Chapter 3). Photostimulating TMN fibers 
in acute slices prepared from the neocortex and caudate-putamen of HDC-
ChR2-EYFP mice triggered a slow increase of tonic GABAergic current in 
neurons, suggesting there was an increased ambient GABA release (i.e. volume 
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transmission or extrasynaptic transmission).  However, IPSC frequency in those 
cells did not change after light stimulation, which indicates histaminergic cells 
did not send GABA onto those cells via direct synaptic transmission. This slow 
increase of tonic GABA-A receptor current could be caused by more GABA 
that has been released from TMN fibers or by histamine stimulating local 
GABAergic interneurons. So, to test this latter possibility, we added histamine 
receptor antagonists H1 and H2 to the acute cortical and striatal slices from 
HDC-ChR-YFP mice, and then photostimulated TMN fibres; however, H1 and 
H2 antagonists did not abolish the increase of tonic current, suggesting GABA 
has been released directly from TMN fibers, increasing the ambient GABA by 
volume transmission. Nevertheless, and strangely, photostimulating HDC-
ChR2-EYFP fibres should also cause excitatory histamine to be released into 
the slices; but in our optogentic experiments, we did not yet find the evidence 
for an excitatory histamine response on any cell type in the neocortex or 
striatum; on the other hand, Dr Houston found that even adding histamine into 
the bath to a concentration of 20 M produced only a mild depolarization which 
took over fifteen minutes to develop (personal communication). Indeed, similar 
results were obtained by Ellender and his colleagues (Ellender et al., 2011) in 
slices from caudate-putamen; Yet clearly, blocking the histamine system by 
taking a histamine receptor H1 antagonist during wake produces sedation in 
intact animal (Haas and Panula, 2003), so there must be an ongoing 
histaminergic tone. Recently another group has also used ChR expressed 
selectively in HDC cells to look for GABA and histamine release from these 
cells (Williams et al., 2014). Almost the exact opposite to us, they found that 
blue light evoked stimulation of HDC neurons caused excitatory histamine 
release onto GABAergic interneurons in the VLPO area, which in turn inhibited 
the putative sleep-active GABA neurons posited for the flip-flop mechanism 
(Williams et al., 2014). They did not find any evidence of GABA release from 
histamine neurons; however, they did not examine the neocortex or caudate-
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putamen. 
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6 Reducing GABA release from anterior hypothalamus increases mouse 
activity and wakefulness  
 
6.1 Summary 
The anterior hypothalamus has been reported to contain many GABAergic 
neurons, including, in the VLPO and extended VLPO area (Saito et al., 2013). 
GABAergic neurons in the anterior hypothalamus have been hypothesized to 
regulate the sleep-wake cycle as many of these neurons are sleep active (Lu et 
al., 2000). As we discussed before, the approaches to study the anterior 
hypothalamus have been restricted to lesioning. In the last chapter, I reported 
various AAV-shRNAs targeting the GABA system, so in this chapter, I intend to 
investigate the role of GABA released from VLPO and the extended VLPO 
area. And also, I will deliver Cre into the anterior hypothalamus of vgat lox/lox 
mice to delete GABA transport into vesicles, and hence remove the GABA 
output from VLPO and associated preoptic hypothalamic areas. 
 
 
6.2 Knocking down vGAT in anterior hypothalamus increases mouse 
locomotor activity  
 
I injected AAV-dsRed-shvGAT (see Chapter 2, section 2.6) bilaterally into the 
anterior hypothalamus: including the VLPO and the extended VLPO areas. I 
termed these animals “VLPO-vGAT KD” mice.  DsRed-positive cells could be 
seen in VLPO and extended VLPO three weeks after injection (Fig 6.1A, B). 
Locomotion experiments were conducted for consecutive 3 days, each day for 5 
minutes by putting the mice in an open field. Reducing vGAT in anterior 
hypothalamus increased locomotion activity. The graph in Fig 6.1C shows the 
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trace of the distance that mice travelled in 5 minutes. The upper panel of the 
graph displays the paths of control mice, injected with AAV-dsRed-scramble, in 
consecutive 3 days. These control mice tended to stay round the edges of the 
area; by contrast, VLPO-vGAT KD mice crossed all areas of the cage. The 
control (scramble) mice travelled much less in the following two days. 
However, the VLPO-vGAT KD mice travelled further in the first day compared 
to the controls, as shown in the bottom panel of Fig 6.1C, D; notably, they kept 
a consistent distance in the following two days, which was significantly further 
than the control group. 
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Fig 6.1 Injection of AAV-dsRed-shvGAT into the anterior hypothalamus increased 
mouse locomotion activity.  (A) illustrates the dsRed expression area (injection sites) in the 
mouse brain coronal sections. (B) Coronal sections from a mouse brain injected with AAV-
dsRed-shvGAT show dsRed expression in the VLPO and extended VLPO areas but not 
VMPO. (C) Motor activity in a novel cage was assayed in three successive days for 5 minutes 
each time. Trace of the mice that travelled in an open field. (D) AAV-dsRed-shvGAT (n=5) 
injected mice display increased motor activity in the open field for successive 3 days 
compared to the controls (n=5). Bars represent SEM. 
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6.3 Preliminery data: Knocking out vGAT by delivering AAV-Cre into the 
vgat lox/lox mice in anterior hypothalamus increases mouse locomotor 
activity  
 
As a parallel method to knocking down vGAT expression with shRNA, I 
injected AAV-Cre-Venus into the anterior hypothalamus of vgat lox/lox mice: 
including the VLPO and extended VLPO areas. Three weeks after injection, 
GFP-positive cells could be seen mostly in VLPO and GFP-positive cells were 
also in the extended VLPO (Fig 6.2A, B). Additionally, to check if GABAergic 
neurons in VLPO were transduced by virus, a Gad67 antibody was used to label 
the GABAergic cells. Fig 6.2B shows some GABAergic cells (Gad67-positive) 
in VLPO were GFP-positive (yellow cells in Fig 6.2B), which confirmed that 
the virus was expressed GABA cells in the VLPO area. A locomotion 
experiment was conducted in an open field. Fig 6.2C, D shows the Cre-injected 
mouse travelled further compared with the control mouse; however, I will 
increase the numbers of the mice in future experiments.  
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Fig 6.2 Pilot data: injection of AAV-Cre into the vgat lox/lox mice anterior 
hypothalamus increased mouse locomotion activity. (A) shows GFP expression brain area: 
VMPO, VLPO and extended VLPO. (B) Coronal section from a mouse brain injected with 
AAV-Cre-Venus shows Gad67-positive (red) cells were transduced by virus (green). (C, D) 
Motor activity was assayed for 30 minutes. AAV-Cre-Venus injected mouse (n=1) displayed 
increased motor activity in the open field with further distance travelled (C) and higher speed 
(D) compared with AAV-GFP injected mouse (n=1).  
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6.4 Reducing vGAT expression in preoptic hypothalamus disrupted 24 hour 
natural sleep-wake cycle. 
 
It has been reported that preoptic hypothalamic lesions in general, and more 
specifically lesioning VLPO or the extended VLPO, increases wakefulness 
(Nauta, 1946; McGinty and Sterman, 1968; Lu et al., 2000; Szymusiak et al., 
2007), so I intended to study if VLPO or the extended VLPO area can regulate 
the sleep-wake cycle by using our AAV-shRNAs that target the GABAergic 
system. AAV-dsRed-shvGAT or AAV-dsRed-shscramble was injected 
bilaterally into the anterior hypothalamus to target most of the VLPO and 
extended VLPO neurons. Three weeks after injection, mice were attached with 
Neurologgers to assess the 24 hour natural sleep-wake cycle. Fig 6.3A, D, G 
shows the percentage of wake, NREM and REM sleep during the 24 hours. 
ShvGAT injected mice presented a different sleep-wake pattern than the control 
group: shvGAT injected mice were much more active than the control mice. The 
percentage of wake was dramatically higher after “lights on” and lasted about 
10 hours, and at the end of the sleep phase, 2 hours before lights off, the 
shvGAT injected mice started to become active. NREM sleep of shvGAT 
relative to scramble-injected mice was significantly decreased in both sleep and 
dark periods, but especially in the dark period. In contrast to the NREM sleep 
pattern, there was a slight increase of REM sleep in the shvGAT injected mice. 
Further analysis of the amount of time in wake, NREM and REM showed there 
was a significant reduction of NREM in the sleep and dark periods, and that the 
total amount of NREM sleep time dropped to half of the control levels (Fig 
6.3B, E, H).  Thus decreasing vGAT expression in the preoptic hypothalamus 
increased mouse EEG theta power in the wake state. The total wake power of 
AAV-dsRed-shvGAT-injected mice during the entire 24 hours was significantly 
higher than the control mice, but both groups reached the maximum power at 
8Hz (Fig 6.3C). However, no differences were observed in EEG NREM and 
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REM power over the 24 hours between the two groups (Fig 6.3F, I).  
 
 
 
 
Fig 6.3 The 24 hour sleep-wake cycle of shScr injected control and shvGAT injected 
mice in preoptic hypothalamus. (A, D, G) show the percentages of wake (A), NREM (D) or 
REM (G) during the 24 hours. (B, E, H) illustrate the time of wake (B), NREM (E) or REM 
(H) at light period, dark period or total 24 hours. (C, F, I) show the EEG wake (C), NREM 
(F) or REM (I) power across the entire 24 hours. ShvGAT injected mice were much more 
active than controls (A, B, D, E). ShvGAT injected mice spent much less time in NREM 
sleep during light period and dark period (A, D, B, E).  (C) EEG wake power during the 24 
hours. ShvGAT injected mice had significant more theta power peaking at 8 Hz compared 
with the AAV scramble injected control littermates. (F, I) NREM power and REM power 
during the 24 hours showed no difference between shScr (n=5) and shvGAT (n=5) injected 
groups. Bars represent SEM. Unpaired two-tailed t-test, *p<0.05, **P<0.01, ***P<0.001. 
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6.5 Discussion  
 
In this chapter, I have started to explore how GABA in the preoptic 
hypothalamus by contributes to the control of activity and the sleep-wake cycle 
in mice. I delivered AAV-dsRed-shvGAT into the anterior hypothalamus 
targeting the VLPO and extended VLPO to knock down the vesicular GABA 
transporter, and I found there was an increased activity and wakefulness in 
mice. In addition, I also delivered AAV-Cre into the preoptic hypothalamus of 
vgat lox/lox mice to knock out vGAT, similar results could be observed: an 
increased activity in mice.  
 
A bedrock of the sleep field is that certain hypothalamic nuclei in the preoptic 
area, when activated, promote sleep. The preoptic region is a complex mixture 
of sleep-active, wake-active and state-indifferent neurons. At sleep onset, a 
subset of GABAergic neurons in VLPO and MnPO, increase their firing rate 
and are believed to inhibit, by long range projections, wake-promoting 
aminergic-type neurons, such as those in the TMN (histamine), LC 
(noradrenaline), and the orexinergic neurons in the Pef area (Sakurai et al., 
2005). Thus the results I have obtained support the earlier literature on 
lesioning, and the importance of GABAergic neurons supressing arousal 
neuorns, and so would seem to be expected. One interesting difference between 
my data and the Lu et al 2000 lesion paper of VLPO is that the vGAT KD mice 
were more active during the night (“lights off”) but had unchanged wake during 
the day (“lights on”) (see Fig. 6.3), whereas in the Lu et al study, the rats had 
substantially more wake throughout the 24 hours. I found that during the day, 
mice had less NREM and more REM. On the other hand, selective 
pharmacogenetic stimulation of GABAergic neurons with the CNO-DREADD 
system in the preoptic area produced only small increases in NREM sleep (Saito 
et al., 2013). Futhermore, we showed previously that selectively genetically 
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removing either synaptic GABA-A or metabotropic GABA-B receptors from 
histaminergic neurons did not change the basic sleep-wake cycle (Zecharia et 
al., 2012). Yet clearly GABAergic neurons in the preoptic area are playing a role 
in supressing wake. Recently, Saito and his colleagues delivered AAV-flex-
ChR2 into the VLPO regions of a GAD67-Cre mouse line and mapped the 
GABA projections from the VLPO region. The targeted areas include Pef 
(orexin neurons), TMN (histamine neurons), PPT (cholinergic neurons), DR 
(serotonergic neurons), and LC (noradrenergic neurons), Saito et al., 2013); So, 
not only the histaminergic neurons in the TMN receives VLPO projections, but 
other arousal neurotransmitter systems seem to do so as well. So even if we 
remove GABA input onto histaminergic neurons, the other arousal systems can 
still receive GABA input, so there might be compensation effects. Moreover, 
other factors, in addition to GABA input, can regulate the activity of HDC-
neurons. In chapter 3, I identified that the circadian clock in specific HDC-
neurons maintains rhythmic hdc gene expression, and thus this might stabilize 
sleep-wake architecture.  
Future work: I am preforming more experiments to increase the number now, 
and better characterize the injection site. In future experiments, I will use cell-
type selective methods to manipulate particular groups of neuronal cells in the 
preoptic hypothalamus.  
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7 Closing Discussion and Future Work 
 
7.1 Mapping histaminergic neurons (Chapter 3) 
 
Previously mapping of the histaminergic neurons and their projections was 
restricted to immunohistochemistry approaches (Airaksinen and Panula, 1988; 
Panula et al., 1989; Panula et al., 1984). In my studies (chapter 3), we developed 
two genetic approaches to label our targeted neurons. One was to generate a 
fluorescent tag knock-in mouse line (HDC-GFP); another was to cross the 
HDC-Cre mouse line which expresses Cre recombinase in histaminergic 
neurons with a reporter mouse line, the Rosa26-loxP-stop-loxP-YFP mouse. 
Although those two methods successfully labelled the histaminergic neurons, 
the expressions of tag protein in HDC-neurons were different. For our purpose, 
we need to visualize the cells in ex vivo experiments; for example, it would be 
easy to patch a specific histaminergic cell for electrophysiology if that cell is 
labelled with a fluorescent protein. Another purpose is to detect the terminals in 
other brain regions, and which are necessary for mapping the projections in the 
whole brain. Compared with the two methods that we used, the Rosa reporter 
mice provided much stronger primary fluorescence in cells. This Rosa reporter 
mouse line has been used in various biologic fields, including developmental 
biology, stem cell biology, cancer biology, and especially neuroscience. The first 
purpose is to report the Cre activity (Hadjab et al., 2013) and label a group of 
cells (Zhuang et al., 2005; Rivers et al., 2008). Furthermore, the reporter mice 
are useful as lineage markers (Shan et al., 2010). In our HDC-Cre/Rosa-lox-
stop-lox-YFP experiment, we found not only HDC-neurons were labelled with 
YFP, but also other brain regions, like the DLG in the thalamus, cerebellar 
Purkinje cells, and the SCN. All of these areas might synthesize histamine 
transiently during development, as HDC-Cre was transiently expressed in those 
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cell groups. However, the exact time course of the development process is not 
clear, and it would be interesting to examine the YFP expression at different 
developmental stages. At the same time, this could be a disadvantage to map the 
projection of a specific group of cells. To avoid the unspecific projections, 
another method using Cre-dependent AAV could be introduced (Atasoy et al., 
2008). However, this method depends on the titer of the virus; higher titers give 
more efficient infections. Nevertheless, virus injections can’t cover the entire 
group of cells, resulting in losing some information about projections. In our 
future experiments, first of all, I will reconstruct the 3-dimensional projections 
of histaminergic cells using HDC-Cre/Rosa reporter mice. Combined with 
another novel method, for example, to make transparent brains (Hama et al., 
2011; Dodt et al., 2007), I could image the reporter mice with better resolution. 
To avoid the expression of YFP in other brain regions during early development, 
we will combine reporter mouse and virus-delivery to map our target area or 
generate a mouse line that carries an inducible Cre to breed with the reporter 
mouse.   
 
7.2 Circadian clock in histamergic neurons and sleep (Chapter 4) 
 
A striking phenomenon of the sleep-wake cycle is that groups of aminergic 
neurons in the hypothalamus and brainstem are active during wake and less 
active during sleep (Saper et al; 2010).  Such neurons include the histaminergic 
cells (Haas and Pannula, 2003). Histamine, which promotes desynchronized 
cortical EEGs and associated arousal (Monnier and Hatt, 1969; John et al., 
2004), intensifies the cognitive aspects of wakefulness (John et al., 2004).  The 
neurons fire at between 1-5 Hz during quiet and active waking, are silent during 
NREM and REM sleep, and start to fire just after animals wake up. A prominent 
and experimentally supported model to explain this state-dependent firing, the 
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“flip-flop” hypothesis (Saper et al., 2010), proposes that sustained GABAergic 
and galinergic inhibition during sleep from the ventral lateral preoptic and 
median proptic nuclei in the anterior hypothalamus onto histaminergic neurons 
keeps them from firing (Saper et al., 2010). Nevertheless, we discovered 
previously that neither synaptic ionotropic GABAA or extrasynaptic 
metabotropic GABAB receptors on histaminergic cells were needed for 
regulation of the normal sleep-wake cycle (Zecharia et al., 2012). Mice with 
specific deletions of these receptors from HDC-positive cells had unchanged 
EEG and sleep parameters (Zecharia et al., 2012). There are lots of 
explanations: other neuronal populations are likely to control the switch; other 
factors acting on histaminergic neurons, such as galanin coreleased with GABA 
from preoptic nuclei; or compensation effects during development. 
 
Thus even if we argue that the flip-flop mechanism is so central that there has 
been a homeostatic compensation, such that the sleep-wake ratio is perfectly 
preserved, our negative finding did set us to investigate if there could be other 
factors regulating the effectiveness of histaminergic neurons to promote 
wakefulness. In fact, initially by chance, I found that there is a rhythm to HDC 
expression in TMN neurons; hdc gene expression is higher at ‘‘lights off’’ when 
the mice are most active (Chapter 4); this rhythm in histamine synthesis 
presumably interacts with the other factors regulating sleep-wake to ensure the 
mouse is most active at the right time. Our findings agree with earlier work: in 
particular, HDC enzyme activity in rat brain hypothalamic extracts varies with 
time of day (Orr and Quay, 1975; Rozov et al., 2014); and hdc mRNA levels in 
post-mortem human hypothalamus are 2-fold higher if death occurs during the 
day (Shan et al., 2012). We have shown that this rhythm in hdc expression is 
controlled by the BMAL clock system intrinsic to histamine neurons (Chapter 
4).  
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In the SCN, heart and inner retina, BMAL1 directly and indirectly regulates 
genes which code for proteins influencing electrical activity (Colwell, 2011; 
Storch et al., 2007; Jeyaraj et al., 2012; Belle, 2009).  However, the electrical 
properties e.g. membrane potential of HDC neurons in acute hypothalamic 
slices from HDC-Bmal1 mice taken from either the “lights on” or “lights off” 
period were unchanged compared with littermate controls. So BMAL1 probably 
does not regulate ion channels or transporters in these neurons. The phenotype 
of HDC-Bmal1 mice is most likely explained by increased HDC expression, 
and would not necessarily need to rely on changed neuronal firing properties. 
The HDC enzyme is transported into all the far reaching processes of these 
neurons (Haas and Panula, 2003; Wada et al., 2001). It could well be that there 
is local servicing of histamine production and release in far removed axonal 
varicosities, analogous to that recently discovered for dopamine fibres (Threlfell 
et al., 2012), independent of action potential firing in the cell soma. For 
dopamine neurons, local interneurons can trigger the release of dopamine from 
nearby varicosities, even if the dopamine neuron is not firing an action potential 
(Threlfell et al., 2012). In this sense, one might think of the histamine or 
dopamine fibres as like supply lines, making their transmitters available in 
response to local demand.  
 
In future experiments, the main work will involve understanding the mechanism 
of how hdc gene is regulated by circadian clock factors. My previous 
experiments revealed that BMAL1/CLOCK positively regulated HDC-promoter 
activity via an E box, but surprisingly, CRY1 alone can remarkably activate the 
hdc gene promoter. How CRY1 regulates the hdc gene promoter remains 
unknown. Since the hdc gene was up-regulated in the HDC-Bmal1 mice, yet 
we do not know if histamine released has been changed, we are currently 
measuring the histamine content in the brain. Although deleting BMAL1 in 
histaminergic cells affects the sleep-wake cycle and sleep rebound after sleep 
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deprivation, removing BMAL1 in locus coeruleus had no effect on any sleep 
parameters (Chapter 4). But it would be interesting to explore the role of 
BMAL1 in other arousal or sleep nuclei in future.   
 
7.3 GABA release from histaminergic neurons (Chapter 5) 
 
Although, classically, Dale’s principle states that the same neurotransmitter is 
released from all terminals of a neuron (Eccles et al., 1954; Strata et al., 1999), a 
significant growing number of studies have proved that different 
neurotransmitters can be released within one type of neuron (Docherty et al., 
1987; Campbell et al., 1991). It has been reported some neurons release both 
inhibitory and excitatory neurotransmitters, though it has been assumed that 
neurons release only one classical neurotransmitter. Vesicular monoamine 
transporter VMAT2 is expressed in nearly all monoamine neurons and 
recognizes serotonin, histamine and catecholamines (Verney et al., 2002). 
VMAT2 has been recently reported to transport GABA into vesicles in 
dopamine-releasing neurons projecting from the substantia nigra (Tritsch et al., 
2012). The vesicular GABA transporter can transport GABA as well as glycine 
(Chaudhry et al., 1998). Indeed, spinal interneurons co-release GABA and 
glycine (Jonas et al., 1998). There are several other neurotransmitter co-release 
systems in the brain: GABA and glutamate corelease from hippocampal mossy 
fibers and medial nucleus of the trapezoid body (Sandler and Smith, 1991); 
monoamine and glutamate corelease from VTA neurons (Hnasko et al., 2010).  
 
TMN cells actually had been found to contain GABA before they were 
identified as histaminergic cells (Vincent et al., 1983); later studies also 
confirmed that histaminergic cells were positive for glutamate decarboxylase 
(Senba et al., 1985). However, the rest of the questions remain unknown: even if 
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hisminergic cells contain GABA, can GABA be released? What brain regions 
do those GABA axons project to? Does GABA released from histamine fibers 
have any functions in the brain? One of the aims of my studies is to answer 
these questions. First, I found histaminergic cells stained strongly for Gad67. 
Histaminergic cells contain VMAT2, which has been recently reported to 
transport GABA into vesicles (Tritsch et al., 2012); however, in cultured 
histaminergic cells, GABA and VMAT2 do not co-localized (Kukko-Lukjanov 
and Panula, 2003), suggesting that VMAT2 is not responsible for delivering 
GABA, but this issue remains be resolved. My further studies reveal that 
histaminergic cells were stained positive for vGAT, which might be the relevant 
vesicular transporter. To explore the function of GABA produced in HDC-cells, 
I used AAV-based shRNA to knock down vGAT or GAD67/65 in specific HDC-
cells. Before we delivered the shRNAs into our target neurons, I injected AAV-
shRNAs into other brain regions, for example, VLPO and the extended VLPO 
(Chapter 6), which contain sleep-promoting GABAergic neurons. Reducing 
GABA release from the VLPO region remarkably decreased NREM sleep 
(Chapter 6). Those AAV-shRNAs are a useful tool to target GABAergic cells in 
other brain regions. Additionally, to target a specific group of cells, we firstly 
combined FELX-switch and shRNA in an AAV vector; subsequently, I delivered 
those FLEX-shRNAs into the TMN area of HDC-Cre mice. Interestingly, 
removing GABA release from TMN neurons increases the general activity of 
the mice, however, the reasons could be diverse: histaminergic cells release 
GABA to neocortex; when less GABA projects to the neocortex, there would be 
less inhibition directly into the neocortex; histaminergic cells could release 
GABA to the excitatory neurotransmitter systems, like histaminergic cells onto 
each side, dopaminergic cells, and noradrenergic neurons. Reduced GABA input 
to those cells would increase the excitability of those cells, and as a 
consequence, excitatory neurotransmitters would be released more; so in our 
future experiments, it would be important to measure the excitability of those 
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cells, as well as the content of neurotransmitters. The big question of our study 
remains to be solved: why do histaminergic cells release an excitatory 
neurotransmitter, histamine and also an inhibitory neurotransmitter GABA? I 
think this question can’t be simply understood now; nevertheless, according to 
our discovery at the moment, mice without the inhibitory neurotransmitter side 
in HDC cells were much more active, and a previous report revealed that mice 
without histamine show decreased activity (Parmentier et al., 2002), so this 
inhibitory and excitatory balances keep the animals in a ‘‘comfortable situation’’ 
and makes them adapt to the environment changes, and importantly, this balance 
can be achieved within one group of neurons. We have started investigating the 
possible mechanism by introducing optogenetics. Theoretically, opto-
stimulation of TMN neurons using channelrhodopsin induces histamine as well 
as GABA release. To find the brain region(s) that receive GABA is of great 
importance. The experiments that we are doing now involve finding the GABA 
targeted brain regions which had highly densities of histaminergic firbes, for 
example neocortex and striatum.   
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